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Abstract 
Insulin resistance is a central feature of the 1netabolic syndrome and strongly 
associated with diabetes and cardiovascular disease. The frequently sampled 
intravenous glucose tolerance test (FSIVGTT) is an alternative tnethod to the 
euglycaetnic hyperinsulinaetnic clamp technique for quantitation of insulin 
resistance. Other sitnple indices can also be derived frmn single titne point fasting 
sample (e.g. hmneostasis tnodel assessment). The sennn protein insulin-like growth 
factor binding protein 1 (IGFBP-1) is an etnerging 1narker and 1nay be useful in the 
assesstnent of insulin resistance. Few ethnic studies have been undertaken and to 
date, neither insulin resistance nor IGFBP-1 have been compared between Caucasian 
and Saudi population. The n1ain aims of the project were therefore to directly 
compare insulin resistance between these two poulations and to investigate IGFBP-1 
as a marker of insulin resistance and cardiovascular risk. In addition the project 
aimed to investigate variations of different methods of insulin resistance over 
different time-intervals. 
After establishing the analytical criteria of an ELISA technique, sermn IGFBP-1 was 
observed to be highly associated with the insulin sensitivity (Si) parameter derived 
from FSIVGTT (r = 0.79, p < 0.0001) in normal subjects (n = 22) and could 
therefore be used as a reliable marker of insulin resistance in these subjects. 
Total variation (reproducibility) was detennined for serum IGFBP-1 in subjects with 
nonnal glucose tolerance (NOT = 15), itnpaired fasting glucose (IFG = 9), itnpaired 
glucose tolerance (lOT = 9) and type 2 diabetics (DM = 9). Reproducibility was 
iv 
20.9%, 29.5%, 33.1% and 48.0% for subjects with NGT, IFG, IGT and DM 
respectively. IGFBP-1 1neasuren1ent was least variable in NGT individuals and 
variability increased with deteriorating glucose tolerance. 
Insulin resistance was cotnpared in subjects from two populations (33 Saudis and 28 
Caucasians tnatched for adiposity) using FSIVGTT and several simple surrogate 
indices of insulin resistance. These subjects were frmn different categories of glucose 
tolerance. Saudis in the NGT category had a significantly lower tnean Si (p < 0.01) 
and fasting IGFBP-1 (p < 0.05) cmnpared to Caucasians. The data suggest that 
Saudis with NGT are tnore insulin resistant than tnatched Caucasians. 
In addition to this the phosphorylation status of serum IGFBP-1 was investigated in 
individuals with (n = 36) and without (n = 39) cardiovascular disease. Significant 
differences were found between the two groups in less-phosphorylated IGFBP-1 (p < 
0.001), phosphorylated IGFBP-1 (p < 0.01) and their ratio (p < 0.01). IGF-I was 
negatively associated with the ratio (r =- 0.45, p < 0.0001). It therefore appears that 
low serum levels of different fonns of IGFBP-1 could be used as a potential n1arker 
of coronary risk, and the ratio tnay be an index of biologically active IGF-I. 
v 
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1. General Introduction 
1.1 Metabolic syndrome 
The tnetabolic syndrmne is a cluster of risk factors associated with an increased risk 
of developing diabetes and cardiovascular disease (CVD) (Figure 1.1) (Stern eta!., 
2004). Reaven was the first to use the tenn syndrmne X (Reaven, 1988), although the 
clustering was noted previously approximately 90 years by two Austrian physicians, 
Karl Hitzenberger and Martin Richter-Quittner as they discussed the relationship 
between hypertension and diabetes 1nellitus (Hitzenberger K, 1921 ). 
Several definitions of the syndrmne have been advocated, including those proposed 
by the World Health Organization, WHO (Alberti and Zimtnet, 1998); the Third 
Report of the National Cholesterol Education Program's Adult Treatment Panel, 
ATPIII (NCEP, 2001); International Diabetes Federation, IDF (Alberti et al., 2005); 
European Group for the Study of Insulin Resistance EGIR (Balkau and Charles, 
1999) and the Atnerican College of Endocrinology AACE (Einhorn et a!., 2003). 
Criteria for the tnost cotnmonly used definitions are summarised in Table 1.1 
1.2 Major features of n1etabolic syndrome 
The two principal underlying feati.tres of the metabolic syndrmne are visceral 
adiposity and insulin resistance. The susceptibility to tnetabolic syndrome can be 
enhanced by several factors including physical inactivity, honnonal hnbalance, 
genetic aberrations, advancing age and fetal malnutrition (Eckel eta!., 2005; Grundy 
et al., 2004; Safar et al., 2006; Yajnik eta!., 2003). 
L__ ________________________________ ___ ___________ --
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Metabolic syndrmne is characterised by low serum levels of high density lipoprotein 
cholesterol (HDL-C), high fasting serum triglyceride and relative nonnal or slightly 
increased concentrations of low density lipoprotein cholesterol (LDL-C) (Wyszynski 
eta!., 2005), elevated blood pressure (lshizaka eta!., 2005), and prothrmnbotic and 
pro-inflan11natory states (Marckmann, 2000; Pannacciulli et al., 2002; Ridker et al., 
2004; Wannamethee eta!., 2005). These conditions are all known cardiovascular risk 
factors. 
1.2.1 Abdontinal obesity 
Adipose tissue is not sitnply an inert store of fat, but is increasingly being recognised 
to be a honnonal tissue. It secretes leptin and other horn1ones and is an important 
source of inflatnmatory adipocytokines. The latter have the potential to exacerbate 
the tnetabolic syndrmne (Berg and Scherer, 2005). For example excess non-esterified 
fatty acids (NEF A) released after triglyceride lipolysis will accumulate in tnuscle, 
liver and pancreatic ｾＭ｣･ｬｬｳＮ＠ This is thought to worsen insulin resistance, 
hyperinsulinaemia and atherogenic dyslipidaetnia. Other abnonnal products of 
adipose tissue produced in excess in obesity, include plasminogen-activator inhibitor 
1 (PAI-l), tumour-necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and resistin. 
Excessive amounts of these adipocytokines can prmnote vascular dysfunction and 
atherogenesis either by direct effects on the artery wall or indirectly through other 
tnetabolic risk factors. 
.-----+1 Cardiovascular disease I 
2x 
3x 
5x Type 2 diabetes 
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Figure 1.1: The risk of developing cardiovascular disease (CVD) is increased 
twofold in individuals with the 1netabolic syndrome compared to those without 
(Turban et a!., 2005). The risk of developing type 2 diabetes in the smne individuals 
is increased fivefold (Stern eta!., 2004). Type 2 diabetics have a threefold increase 
on the risk of developing CVD cmnpared to those without diabetes. 
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Table 1.1: Diagnostic Criteria for Metabolic Syndrome According to the WHO, 
EGIR A TP III and the ID F. 
WHO 1999 EGIR 1999 
(Diabetes or impaired glucose tolerance or insulin (Presence of fasting hyperinsulinemai plus 
resistance plus 2 of the following) any 2 of the following) 
1. Obesity: BMI > 30 kg/m2 or WHR > 0.9 (M) 1. Waist circumference: 2: 94 em (M) 
> 0.85 (F) 2: 80 em (F) 
2. Dyslipidaemia: triglycerides 2: 1.7 mmol!L or 2. Hypertriglyceridaemia: 2: 1.0 mmol!L 
HDL-C < 0.9 mmol!L (M), < 1.0 mmol!L (F) and or HDL-C ｾ＠ 1.0 mmol!L 
3. High blood pressure: 2: 140/90 mmHg or 3. High blood pressure: 2: 140/90 mmHg 
documented medication 
or medication 
4. Microalbuminuria rate > 20 JJ.g/min or 4. Fasting plasma glucose: 2: 6.1 mmol/L 
albumin: creatinine ratio > 30 mg/g or IGT (but not diabetes) 
ATPDI2001 IDF 2005 
(3 or more of the following) (Central obesity, waist circumference+ 
any 2 of the following) 
I. Waist circumference: 2: 102 em (M), 1. Raised Triglycerides: 2: 1.7 mmol!L 
2: 88 em (F) or treatment 
2. Hypertriglyceridaemia: 2: 1.7 mmol/L 2. Reduced HDL-C < 1.0 mmol/L (M), 
< 1.3 mmol!L (F) or treatment 
3. Low HDL-C: < 1.0 mmol!L (M), 
< 1.3 mmol/L (F) 3. High blood pressure: 2: 130/85 mmHg 
or medication 
4. High blood pressure: 2: 130/85 mmHg or 
medication 4. Fasting plasma glucose 2: 5.6 mmol/L 
or previous diagnosis of type 2 
5. Fasting plasma glucose: 2: 6.1mmol!L diabetes 
Key: ATPIII, National Cholesterol Education Program Expert Panel on Detection, 
Evaluation and Treatment of high blood cholesterol in adults (adult treatment panel 
III); EGIR, European Group for study of Insulin Resistance; IDF, International 
Diabetes Federation; WHO, World Health Organisation; M, male; F female; WHR, 
waist hip ratio; BMI, body mass index; HDL-C, high density lipoprotein cholesterol. 
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1.2.2 Insulin resistance 
Insulin resistance is a central cotnponent of tnetabolic syndrmne. It is associated with 
a significant increase in the risk of cardiovascular mortality and tnorbidity (Reaven, 
2002). Insulin resistance is considered to exist when an abnonnally high amount of 
insulin (endogenous or exogenous) is required for a normal biologic response 
(Wallace and Matthews, 2002). It is characterised by a decrease in the ability of 
insulin to stinullate glucose uptake by 1nuscle and adipose tissue and to suppress 
hepatic glucose output (Matthaei et al., 2000). Prospective studies show that insulin 
resistance is a powerful predictor of whether or not an individual will later develop 
diabetes or CVD (Lillioja et al., 1988; Warrmn et al., 1990). The aetiology of insulin 
resistance is believed to have both genetic and enviromnental cmnponents (Table 
1.2). Many studies have shown that insulin resistance may predate the onset of the 
diabetes by 10-20 years (Lillioja et al., 1988; Warram et al., 1990). Insulin resistance 
appears to be consistent finding in patients with type 2 diabetes (DeFronzo, 1988; 
Haffner et al., 1990; Reaven et al., 1976). Therefore in non-diabetic subjects it is 
considered to be a strong predictor for diabetes (Lillioja et al., 1988; Wan·am et al., 
1990). 
1.2.2.1 Insulin resistance and cardiovascular disease 
Insulin has a wide range of biological effects. It is not just the traditional insulin 
target tissues viz skeletal muscle and adipose tissue which are affected. All cells in 
the body represent a target for insulin and as such tnay be affected by increased 
insulin resistance. Moreover, recent studies have shown a relationship between 
carotid wall atherosclerotic lesions and levels of insulin resistance (Salomaa et a!., 
199 5; Suzuki et a!., 1996). Platelet aggregation and fibrinogen synthesis can be 
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increased by insulin resistance (Festa et al., 2000; Taniguchi et al., 2003) and the 
physiology of the vascular endothelial wall also be affected by insulin (Bonora et al., 
2004; Kahn and Flier, 2000). The evidence for the direct role of insulin resistance as 
a cardiovascular risk factor is lacking but it n1ay contribute to CVD independently of 
classic risk factors (hypertension, obesity and dyslipidaen1ia) (Bonora et al., 2003; 
Hills eta/., 2004). 
People with insulin resistance have higher circulating levels of endothelial adhesion 
tnolecules e.g. intercellular adhesion tnolecules-1 (ICAM-1) (Fu-zai et al., 2009). 
These 1nolecules reflect a state of vascular endothelial dysfunction. Other markers 
such as increased free fatty acid (FFA), C-reactive protein (CRP), and oxidized LDL 
indicate a chronic inflamtnatory state (Laakso et al., 1991). Also patients with insulin 
resistance have abnonnally high levels of fibrinolytic factors such as plasminogen 
activator inhibitor 1 (PAI-l), coagulation factor VII, white blood cell count, TNF-a., 
and IL-6 (Hak et a/., 2001). All these atherogenic risk factors including insulin 
resistance are tnodifiable by weight reduction (Sowers and Lester, 1999) as adipose 
tissue also produces TNF -a. and IL-6 which can alter insulin action at different 
levels in the intracellular pathway (Matsuzawa, 2005). In addition to this, resistance 
to insulin causes physiological abnormalities which ultimately impact on glucose 
transport. An increased accumulation of lipids in 1nuscle and liver tissue tnay lead to 
intracellular concentrations of fatty acid n1etabolites within endothelial cells 
including those of the arterial wall (Lusis, 2000). In association with genetic 
influences (predisposition to high blood pressure, dyslipidaetnia, etc.), insulin 
resistance and diabetes can accelerate the development of CVD. 
Table 1.2: Main causes of insulin resistance. 
Causes Conditions 
Congenital factors Fetal undernutrition 
Ethnic differences 
References 
(Wills et al. , 1996) 
(McKeigue et al. , 1993) 
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Molecular defects Insulin receptor mutations (Type-A insulin (Haring et al. , 1987) 
(genetics) 
Acquired factors 
Hormonal 
Others 
resistance) 
Post-receptor binding signalling mutations (Truglia et al., 1985) 
(Type-C insulin resistance) 
Physiological pregnancy 
Puberty 
High fat diet, 
Physical inactivity 
Aging 
Corticosteroids 
Acromegaly 
Phaeochromocytoma 
Polycystic ovary syndrome 
Hypertension 
Liver cirrhosis 
Sepsis 
Surgery 
Burns and trauma 
Autoantibodies to insulin receptor 
(Innes and Wimsatt, 
1999) 
(Moran et al., 2002) 
(Maron et al., 1991) 
(Gustat et al. , 2002) 
(Rodriguez et al. , 2005) 
(Karnieli et al., 1985) 
(Wasada et al. , 1997) 
(Raza et al. , 2004) 
(Apridonidze et al. , 2005) 
(Ferrannini et al., 1987) 
(Lin et al. , 2004) 
(Carlson, 2004) 
(Thorell et al., 1994) 
(Carter 1998), 
(Braund et al. , 1987) 
---------------------------- --------
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1.3 The epide1niology of Inetabolic syndro1ne 
Using ATP III criteria a study based on 8814 American tnen and wmnen of20 years 
of age and older Ford at el., have reported that the prevalence of tnetabolic syndrmne 
seems to be shnilar, in both genders at about 24%, (Ford et al., 2002). Its prevalence 
increases sharply with age (Ford et al., 2002). Unfavourable social and econmnic 
enviromnents (e.g. educational level, occupational category, and working status) are 
associated with the tnetabolic syndrmne (Dallongeville et al., 2005). Investigation of 
the prevalence of tnetabolic syndrome across populations in different countries is 
difficult as populations may have different age profiles and the sample surveyed tnay 
not be representative of a population. Examples for the prevalence of metabolic 
syndrmne in different populations are shown in Table 1.3. 
The prevalence of tnetabolic syndrmne will also be affected by the definition being 
applied (Ford, 2005). For exatnple tnicroalbmninuria is included in WHO definition 
but not in the A TP Ill definition. Another problem with using the current A TP III 
and WHO definitions has been their applicability to different ethnic groups, this 
particularly applies to the cut-off values defining obesity. For example, it is apparent 
that the risk of developing type 2 diabetes occurs at tnuch lower levels of adiposity in 
the South Asian population than in Europeans. Application of the current A TP III 
definition to Asians underestitnates the prevalence of tnetabolic syndrmne at least 
regarding the obesity criteria (Tan et al., 2004). Therefore, reducing the cut off 
values for waist circumference increased the crude prevalence of the tnetabolic 
syndrmne in Asians frmn 12.2% to 17.9%. This suggests the importance of ethnic-
specific cut-off levels for some specific tnetabolic risk factors. In general all the 
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available definitions help to identify people at high risk but further research m 
different populations will lead to new or more accurate predictive indices. 
Table 1.3: Prevalence of metabolic syndrome in different populations. 
Population Prevalence Criteria* Reference 
Indians 41.1% ATPIII (Ramachandran et al. 2003) 
Iranians 42% females & 24% males ATPIII (Azizi et al., 2003) 
Saudis 42% females & 3 7.2% males ATP III (Al-Nozha et al., 2005) 
Asians 15.5% females & 20.9% males ATP III (Tan et al., 2004) 
Americans 23.7% ATP III (Ford et al., 2002) 
Greeks 23.6% ATPIII (Athyros et al., 2004) 
Caucasians 16% EGIR (Beck-Nielsen, 1999) 
*Metabolic syndrome diagnostic criteria. ATPIII, National Cholesterol Education 
Program Expert Panel on Detection, Evaluation and Treatment of high blood 
cholesterol in adults (adult treatment panel Ill); EGIR. European Group for study of 
In sui in Resistance. 
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1.3.1 Metabolic syndro1ne, adiposity and CVD in Caucasians 
The prevalence of the tnetabolic syndrmne has been reported to be approxhnately 
16% mnong Caucasians using EGIR criteria (Beck-Nielsen, 1999). Approximately, a 
quarter of Caucasian obese children ( 6 - 16 years age range) have tnetabolic 
syndrome (Invitti et a!., 2006). In the United Kingdmn (UK) it has been suggested 
that 25% of the population have metabolic syndrmne (Tonkin, 2003). In 2003, the 
British Heart Foundation reported that one in five UI( adults is obese and 40% of 
death are caused by CVD. As rep01ted in the Health Survey for England, Prescott-
Clarke and Primatesta (1998) also estimated that n1ore than 4% of n1en and 3% of 
women have had diabetes diagnosed. The satne survey has also shown that the 
prevalence of obesity reached 17% in tnen and 20% in women (Prescott-Clarke and 
Prin1atesta, 1998). Compared to other ethnic groups Caucasians generally have a 
lower reported prevalence oftnetabolic syndrmne (Hoang eta!., 2007). 
1.3.2 Metabolic syndrome, adiposity and CVD in Saudi Arabians 
In a study carried out in Saudi Arabia based on 17,293 Saudi subjects and using the 
A TP III criteria, the total prevalence of the tnetabolic syndrmne was reported at 
39.3o/o. The prevalence in tnales was 37.2%, while it was higher in females at 42%. 
In addition to this, the prevalence was higher in urban areas ( 44.1%) than in rural 
areas (35.6%) (Al-Nozha et a!., 2005). In the same population within the same 
survey, the total prevalence of coronary artery disease (CAD) in Saudi Arabia was 
5.5% and the prevalence in tnales and fetnales were 6.6% and 4.4% respectively (Al-
Nozha et al., 2004). In a retrospective cross-sectional study of subjects age 35 years 
and above the prevalence of type 2 diabetes in males was 8.5% and in females 19.5% 
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(Karhn et al., 2000). The prevalence of overweight in Saudi children aged 1-18 years 
was 10.7% and 12.7% in boys and girls respectively and prevalence of obesity was 
6.0% and 6.7% respectively (El-Hazmi and Warsy, 2002). The prevalence of 
physical inactivity among a Saudi population ranged between 43.3% and 99.5% (Al-
Hazzaa, 2004). 
Dramatic changes in n1odern lifestyle and dietary habits in Saudi Arabia compared to 
other countries could be the n1ain reason leading to physical inactivity, weight gain 
and ultimately to the metabolic syndrmne. 
1.4 Managentent of metabolic syndrome 
Currently, no trials specifically exmnining the overall management of tnetabolic 
syndrmne have been undertaken. However, controlling the individual components of 
tnetabolic syndrome has been observed to delay or even to prevent the onset of 
hypettension, CVD and diabetes tnellitus (Chobanian et al., 2003; Knowler et al., 
2002). This tnanagetnent prhnarly depends on weight reduction and consequent 
hnprovement in insulin sensitivity (Riccardi et al., 2004). The clinical tnanagement 
of tnetabolic syndrome includes lifestyle tnodification (Tumnilehto et al., 2001) and 
the achievetnent of weight reduction by tneans of increased physical activity and 
drug therapy (Duncan et al., 2003; Ginsberg, 2003; Gregg et al., 2003). 
1.5 Insulin resistance assessment techniques 
A variety of tnethods are available for assessing insulin sensitivity, the choice of test 
depending on the purpose of the research, available resources (staff, expertise, 
equiptnents) and the information required (insulin sensitivity, ｾＭ｣･ｬｬ＠ function or 
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others). Whichever test is chosen, a careful pre-clinical investigation of the subject 
should be carried out. Subjects should undergo careful preparation in order to avoid 
acute perturbations in insulin and to obtain reliable results. For smne techniques a 
software progratn tnust be used for calculation of the parameters (Bergman et a!., 
1981). Subjects should avoid excessive physical activity which could increase 
peripheral glucose disposal independently of insulin action (Goodyear and Kahn, 
1998). Coffee and tea should be avoided on the tnorning of the test as they tnight 
increase catecholatnine levels (Arnlov et al., 2004; Mazurek and Negrusz-Kawecka, 
1999). Stnoking and alcohol 24 hr preceding the test tnust be avoided as smoking can 
decrease insulin sensitivity and alcohol consmnption can impairs gluconeogenesis 
(Facchini et al., 1992; Flanagan et al., 2000). During testing subject needs to avoid 
stress, discmnfort and excessive noise. The available tnethods to estimate insulin 
resistance can be divided into three tnain categories (Figure 1.2). 
r 
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ｾ＠
' 
.I 
Figure 1.2: Diagram showing different types of insulin resistance assessment 
techniques. 
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1.5.1 Dynamic tests 
In these techniques for assessing insulin resistance, the kinetics of non11al glucose 
111etabolist11 is perturbed, by endogenous or exogenous insulin stimulation. They 
require 111ultiple blood samples to be collected. Although there are several dynatnic 
tests which 111ay help to assess insulin resistance, selection of the 111ost appropriate 
one depends on tnany factors which 111ust be taken into account. So far none is 
suitable for routine clinical use. 
1.5.1.1 Hyperinsulinaemic euglycae1nic and byperglycaemic cla1nps 
The hyperinsulinaemic euglycaen1ic clmnp is used n1ainly for 111edical research 
purposes principally to assess the efficacy of new n1edications. First described by De 
Fronzo (DeFronzo et al., 1979), it remains the gold standard for investigating and 
quantifying insulin sensitivity. It involves infusing exogenous insulin at a constant 
rate of 6 mU/kgllninute. This is given along with 20% glucose at a variable rate 
sufficient to maintain blood glucose levels between 5 and 5.5 111111ol/L. The glucose 
infusion is adjusted according to plas111a glucose levels collected frmn the arterialized 
venous blood sm11ple at five 111inute intervals throughout the period of the clat11p 
being applied. The infused exogenous insulin suppresses hepatic glucose output 
(HGO). This 111eans that once a steady state is reached (within the last 30-60 111inutes 
of the test) the rate of glucose infusion equals the rate of peripheral glucose disposal. 
Individuals who are highly insulin sensitive require 1nore exogenous glucose to 
1naintain euglycaen1ia whereas those who have insulin resistance require less 
exogenous glucose. 
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The hyperglycaetnic clatnp is another related dynamic technique used as a 
quantitative procedure of ｾＭ｣･ｬｬ＠ sensitivity to glucose (Elahi, 1996). It is described as 
follows. By means of glucose infusion, the plasma glucose concentration is acutely 
raised to 6.9 mtnol/L above basal levels and then kept at that level for 2 hours. The 
intravenous glucose infusion consists of two doses. The first dose (the priining dose) 
is required to elevate the glucose concentration in plasma and in extravascular 
cmnpartments. The second dose (tnaintenance dose) is required every five minutes 
up to the end of the study. The volume of the second dose is based on the principle of 
insulin-glucose feedback action. The induced hyperglycaemia stimulates ｾＭ｣･ｬｬ＠
insulin secretion. As the glucose concentration in plasma is held constant, its infusion 
rate provides an index of glucose tnetabolistn. 
1.5.1.2 Frequently satnpled intravenous glucose tolerance test (FSIVGTT) 
with its limitations and advantages 
The frequently sampled intravenous glucose tolerance test (FSIVGTT) represents a 
relatively silnple alternative technique cmnpared to the clatnp procedure. The 
paratneters are calculated by a tnathetnatical representation of the glucose kinetics 
during the test. By estimating these parameters we can calculate both insulin 
sensitivity and glucose effectiveness indices. Plasn1a glucose and insulin levels 
measured during the test are subjected to tninimal model analysis. This is a 
tnathetnatical representation of glucose kinetics during the FSIVGTT. The 1nodel 
describes glucose disposal using two differential equations, one representing glucose 
kinetics and assuming a single cmnpartment and the second describing the effect of 
insulin assmned to take place in a cmnparttnent outside plasma. It predicts plasma 
glucose values at different thnes frmn the tneasured insulin values according to 
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preset paratneters. The tninitnum difference between the tneasured glucose and the 
paratneters represents the predicted values. Cmnputer software is available for the 
analysis (e.g. Mimnod) frmn which both insulin sensitivity (Si) and glucose 
effectiveness (Sg) indices can be detennined (Bergman et al., I 979). Si reflects the 
ability of insulin to prmnote peripheral glucose uptake and suppress hepatic glucose 
output whereas Sg is a tneasure of the effect of glucose to enhance its own disposal 
under basal insulin levels. A number of other paratneters can be derived including 
the acute insulin response (AIR). 
The standard technique for the FSIVGTT will be discussed in detail in the next 
chapter. Briefly, with the subject in the supine position baseline blood samples for 
insulin and glucose are taken following placetnent of an intravenous cannula. 
Glucose is then injected as a bolus over one minute. Multiple blood samples for 
glucose and insulin tneasurement are drawn at specific titne points after the start of 
the glucose injection (Bergman et al., 1979; Bergman et al., 1987). After the san1ples 
have been analysed for glucose and insulin, the results are then entered into the 
Mimnod software to calculate Si and other paratneters autotnaticaly. Although these 
parameters are derived frmn minimal model analysis they correlate well with those 
frotn clatnp studies. Usually patients with diabetes have poorer insulin responses. To 
overcmne this probletn, the test has been tnodified to enhance the insulin response. 
Approaches that have been taken are the adtninistration of an exogenous dose of 
tolbutamide or insulin to ensure that subjects with type 2 diabetes have an adequate 
second phase insulin response (Finegood et al., 1990; Yang et al., 1987). 
A study cotnparing insulin sensitivity parameters calculated frmn the FSIVGTT and 
the hyperinsulinaemic euglycaetnic clatnp showed the values to be significantly 
-----------------------------------···-. --· ....... . 
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correlated in subjects frmn different glycaetnic categories (r = 0.62, p < 0.001) (Saad 
et al., 1994). It has been shown that a reduced satnpling schedule yields sitnilar 
results to those obtained with the original protocol (Duysinx et a!., 1994). More 
details about this protocol will be described in Chapter 2. The insulin sensitivity (Si) 
parameters obtained frmn full and short satnpling protocols in subjects with normal 
glucose tolerance and in those with type 2 diabetes were r = 0.53, p = 0.046 and r = 
0.30, p = 0.085 respectively (Saad eta!., 1994). The lack of significance for those 
with type 2 diabetes suggests that the full sample protocol is preferable where 
subjects with diabetes are to be investigated. 
There are two tnain limitations of the FSIVGTT; a titne consuming and a software 
programme-dependent technique. In addition the software fitting procedure may fail 
in smne subjects due to an inadequate insulin response (Boston et al., 2003). 
One of the main advantages ofthe FSIVGTT is the tninimal invasiveness con1pared 
to the clamp technique. Due to the feedback loop between glucose and insulin, 
mathetnatical analysis of both insulin resistance and B-cell function can be calculated 
sitnultaneously by this technique. This tnethodology is less technically demanding 
and tnore cost .. effective cmnpared with equivalent clamps procedure particularly in 
large epidetniological studies. 
1.5.2 Indices using fasting and 2 hour post-glucose load samples 
1.5.2.1 Oral glucose tolerance test (OGTT) 
In order to sitnplify the tneasuretnent of insulin sensitivity, a nmnber of tnethods 
have been developed which involve deriving indices from data obtained during the 
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oral glucose tolerance test (OGTT). After taking a fasting blood sample the subject 
takes a 75g oral dose of glucose in water. Blood samples are then collected over the 
following 2 hours. The OGTT is commonly carried out in clinical practice for the 
purpose of classifying patients according to their glycaemic status i.e. normal glucose 
tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT) 
or diabetic (DM), the glucose results in each collected sample being interpreted 
according to WHO criteria (Table 1.4) (Alberti and Zimmet, 1998). 
Table 1.4: Classifications of subjects according to their glycaemic status based on 
fasting and 2 hours glucose results (venous plasma) of oral glucose tolerance test 
(75g). 
Fasting glucose 120 mins glucose 
(mmol/L) (mmol/L) 
Normal <6.1 <7.8 
Impaired fasting glucose ｾ＠ 6.1 and< 7.0 
Impaired glucose tolerance ｾ＠ 7.8 & < 11.1 
Diabetes Mellitus ?:_ 7.0 ｾ＠ 11.1 
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By tneasuring insulin and glucose levels together at tnultiple time points in a OGTT, 
insulin sensitivity can be calculated by developing specific indices derived frotn the 
OGTT. For exmnple, an index ofwhole-body insulin sensitivity, lSI (composite), has 
been observed to be well correlated with the hyperinsulinaetnic euglycaetnic clmnp (r 
= 0.73, p < 0.0001) (Matsuda and DeFronzo, 1999) and it can be calculated as 
follows: 
ＱＰＰＰＯｾｻ｛ｦ｡ｳｴｩｮｧ＠ glucose (tng/dL) x fasting insulin ＨｾｕＯｭｌＩ｝＠ x 
[mean glucose x tnean insulin]} 
This index has an advantage that it takes account of both hepatic and peripheral 
insulin sensitivity, providing a n1ore cotnprehensive assessment of the individual 
than fasting indices which can assess only one or the other as they do not take 
account of the observation that hepatic and peripheral insulin sensitivity tnay be 
affected to different extents in individuals owing to different tnetabolic 
abnonnalities. Hence the different responses that can be obtained during the OGTT 
i.e. elevated fasting plasma glucose level or elevated 2 hour plasma glucose level. A 
tneta-analysis of data frmn different studies showed a significant correlation between 
insulin sensitivity index glycaemia (ISI-gly) and tneasurements of insulin sensitivity 
tnade by the hyperinsulinaetnic euglycaetnic clamp (Belfiore et al., 2001 ). The index 
for fasting and 2 hours is calculated as follows: 
ISI-gly = 2/[(insulinp X glucosep) + 1] 
where insulinp and glucosep represent the smn of tneasuretnents of insulin (J..L U/mL) 
and glucose (tng/dL), taken before and 2 hours after a standard 75g oral glucose load, 
divided by the sutn of their respective normal values. The lower the ISI-gly value, 
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the lower is the insulin sensitivity. Nonnal subjects have a value around 1 with 0 and 
2 being the n1iniinum and tnaximutn possible values respectively. 
One of the tnain limitations of the oral glucose tolerance test is that the 
gastrointestinal delivery of the glucose load can be influenced by different rates of 
gastric etnptying as well as by post-absorptive glucose handling. Another limitation 
is the large intra-individual variation in the test, hence the WHO recommendation 
that before diagnosing diabetes, patients should be observed to have levels within the 
diagnostic range for diabetes on tnore thi:m one occasion. 
1.5.2.2 Homeostasis ntodel assessment (HOMA) 
HOMA is one of the earliest n1ethods used to quantitate insulin resistance, first 
described in 1985 (Matthews et al., 1985). This is based upon the principle that the 
degree of fasting hyperglycaemia is detern1ined by a cmnbination of ｾＭ｣･ｬｬ＠
deficiency and insulin resistance. The tenn HOMA-S is sometitnes used by 
researchers and represents the inverse of insulin resistance (HOMA-IR). ｈｏｍａＭｾＥ＠
is a parameter indicating the percentage of ｾＭ｣･ｬｬ＠ function. HOMA-IR and HOMA-
ｾＥ＠ values for a subject can be derived from fasting measurements as follows: 
HOMA-IR =fasting glucose (mtnol/L) x fasting insulin (tnU/L) /22.5 
ｈｏｍａＭｾＥ＠ = 20 x fasting insulin (tnU/L) I [fasting glucose (tnn1ol/L)- 3.5] 
HOMA-IR correlates well with estimates using the euglycemic clamp method (r = 
0.88, p < 0.0001) (Matthews et al., 1985). ｈｏｍａＭｾＥ＠ was reported to correlate with 
values derived from the hyperglycaetnic clamp (r = 0.61, p < 0.01). In norn1al-
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weight, healthy subject aged less than 35 years, P-cell function is assmned to be 
about 100% and insulin resistance 1. The increase in the value of HOMA-IR is 
correlated with an increase in insulin resistance. 
The updated version 2.2 of h01neostasis tnodel assessment (HOMA2) is a computer-
solved tnodel of insulin-glucose interactions which has been utilised to plot an array 
of fasting plasma insulin and glucose concentrations that are expected with varying 
degrees of insulin resistance and P-cell deficiency. It involves nonlinear solutions 
and is used to calculate insulin resistance (HOMA2-IR) and P-cell function 
(HOMA2-P) (Wallace et al., 2004). The insulin curve has been 1nodified to allow for 
an increased plasn1a insulin and glucose levels. The calculator of HOMA2 tnodel 
(version 2.2) is available online (www.dtu.ox.ac.uk). In the same calculator the 
option for insulin was selected rather than specific insulin. This was due to cross-
reactivity of our insulin assay with pro insulin. The units of pmol/L and m1nol/L were 
selected for both insulin and glucose respectively. 
The technique of HOMA has low precision for the estimates (31% CV for insulin 
resistance and 32% CV for P-cell deficient) which limits its use (Matthews et a/., 
1985). The post-load (2hr) insulin and glucose concentrations are not considered in 
calculating insulin sensitivity, thus constituting a less sensitive technique for 
screening and assessing 1netabolic abnonnalities. Another lhnitation is that HOMA is 
not linear over a wide range of insulin sensitivity because of the changes in the 
slopes of the linear regression lines for each class of patient but this has been 
hnproved by using the updated version ofHOMA2. 
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1.5.2.3 Quantitative insulin sensitivity check index (QUICKI) 
QUICKI is an index of insulin sensitivity described by Katz eta!., (Katz eta!., 2000) 
and calculated as follows from blood glucose and plasma insulin 1neasure1nents n1ade 
on a single blood specilnen frmn a fasting subject: 
QUICK!= 1/[log insulin (J.LU/mL) +log glucose (mg/dL)] 
The lower the QUICK! value, the lower the insulin sensitivity. This index is shnilar 
to HOMA, except that it is based on the data by taking both logarithms and the 
reciprocal of the fasting glucose-insulin product. Consequently, it is reported to be 
tnore accurate than HOMA in calculations over a broad range of insulin sensitivity 
and correlated more significantly with the insulin clamp technique (r = 0. 78, p < 2 x 
I o-12) (Katz et al., 2000). Due to the variability at low insulin secretion rates, 
QUICKI becmnes less-accurate when applied to subjects with dhninished insulin 
production. Another problem of QUICK! is its lhnited applicability to subjects 
lacking endogenous insulin secretion e.g. those with type I diabetes. 
1.5.2.4 Fasting glucose to insulin ratio (FGIR) 
The fasting glucose/insulin ratio (FGIR) has been compared with Si values 
detennined by the FSIVGTT and it has been suggested as a screening test for insulin 
resistance particularly in women with polycystic ovary syndrmne (PCOS) 
undergoing therapeutic interventions (Legro et a!., 1998). It can be calculated by 
dividing fasting glucose (mg/dL) by fasting insulin (tnU/L). 
The potential problems with using the fasting glucose/insulin ratio becmne apparent 
when fasting glucose levels are abnormal. FGIR is erroneously and paradoxically 
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increased in diabetic subjects where the level of insulinaemia IS unable to 
appropriately compensate for fasting hyperglycaetnia (Quon, 2001 ). 
1.5.2.5 Raynaud index 
The Raynaud index was calculated frmn the fasting insulin level using a simple 
equation (Raynaud eta!., 1999). It represents the simplest calculated index of insulin 
resistance. Raynaud index describes the best-fit relationship between fasting insulin 
and Si parmneter of FSIVGTT and it can be calculated as follow: 
Raynaud index= 40/ Fasting insulin (mUlL) 
1.5.3 Biochentical ntarkers 
1.5.3.1 Fasting insulin 
Fasting insulin levels correlate with the components of the insulin resistance 
syndrmne (Ferrannini eta!., 1991) and during the impaired insulin sensitivity the ｾﾭ
cells usually increase their insulin secretion. Thus, the cmnbination of 
normoglycemia and hyperinsulinaetnia provides evidence of insulin resistance. 
Insulin can be a Inisleading as a Inarker of insulin resistance, as its concentration 
depends on B-cell reserve and insulin degradation. Therefore insulin concentrations 
can overlap for those with normal and individuals with increased insulin resistance. 
Another liinitation is that several factors contribute to bias between different insulin 
assays i.e. values for serum insulin obtained using different insulin assay kits may 
differ significantly. These factors include calibration procedures, assay specificity, 
fonnat and conversion factors (Manley eta!., 2007). 
---------- - - ------- ----- - -- -
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1.5.3.2 Sex horntone-binding globulin (SHBG) 
SHBG is an insulin regulated, liver-derived protein that was proposed as being a 
promising measure for the identification of individuals with insulin resistance 
(Nestler, 1993). Low plasma SHBG concentrations have been correlated with several 
cotnponents of the metabolic syndrome and linked to cardiovascular risk (Goodman-
Gruen and Barrett-Connor, 1996; Tchernof et al., 1997; Tchernof et al., 1999). 
Serun1 SHBG concentrations have also been reported to be significantly correlated 
with insulin resistance values derived by the hyperinsulinaemic euglycaemic clamp 
technique (r = 0.74, p < 0.001) (Birkeland et al., 1993). Litnitations of SHBG will be 
discussed later in section 1.6.3. 
1.5.3.3 Other biochemical ntarkers of insulin resistance 
A variety of other serum levels of biochetnical tnarkers such as horn1ones, enzytnes, 
inflammatory tnarkers, coagulation factors, lipids and blood cell cmnponents have 
been noted to be associated with parameters of insulin resistance (Table 1.5). 
1.6 Insulin-lil{e growth factors and their binding proteins 
The family of insulin-like growth factors (IGF-1 and IGF-II) and related binding 
proteins (BPs) are secreted into extracellular fluids and act on cells in distal target 
organs, like other traditional honnones (endocrine function) (Guier et al., 1988). 
They can also act on the adjacent cells in addition to the original secretory cells 
(paracrine and autocrine function respectively) (McCarthy eta!., 1989) (Figure 1.3). 
These potential mechanistns of endocrine, paracrine and autocrine stin1ulation result 
in a cmnplex system of regulation of organ specific growth, maintenance and growth 
balance. 
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Table 1.5: Biochemical markers correlated with insulin resistance. Adapted from 
(Borai eta!. , 2007). 
Status in 
Correlation with the indices 
Marker insulin Reference 
of insulin resistance 
resistance 
Inflammatory markers 
CRP i FSIVGTT (tolbutamide); (Y e et at. , 2006) r =- 0.3, p < 0.0001 
WBC i FSIVGTT (tolbutamide); (Ye et a/., 2006) r = - 0.24, p < 0.0001 
Clotting factors 
Fibrinogen i FSIVGTT (tolbutamide); (Festa eta!. , 2000) r = - 0.18, p < 0.0001 
PAI-l i HOMA-IR; r = 0.35; p < 0.05 (Pannacciulli et a/., 2002) 
Platelets i HOMA-IR; r = 0.31 0, p < 0.001 (Taniguchi eta/., 2003) 
Enzymes 
GGT i HOMA-IR; r = 0.65 , p :S 0.001 (Ortega eta!. 2006) 
AST i HOMA-IR; r = 0.31 , p < 0.05 (Ortega eta!. , 2006) 
ALT i HOMA-IR; r = 0.41 , p < 0.01 (Ortega eta!. , 2006) 
Lipids 
Triglyceride i HOMA-IR; r = 0.277, p < 0.0005 (Taniguchi eta/., 2003) 
HDL cholesterol t HOMA-IR; r =-0.312, p < 0.0001 (Taniguchi eta/., 2003) 
Hormones 
Cortisol i HOMA-IR: r = 0.495 p < 0.02 (Bleicher eta!. , 2002) 
IGF-1 t HOMA-IR: r = 0.338, p < 0.03 (Bleicher eta/., 2002) 
IGFBP-3 t HOMA-%S: r = -0.357, p < 0.05 (Kocyigit et a!. , 2004) 
Adiponectin t HOMA-IR r = - 0.52, p < 0.05 (Lu et a!. , 2006) 
Resistin i HOMA-IR r = 0.27, p < 0.05 (Lu et a!. , 2006) 
IGFBP-2 t HOMA-%S rho = 0.26, p = 0.02 (Heald et a!. , 2006) 
Pro insulin i IGFBP-1 r = - 0.49, p < 0.001 (Kamoda et a!. , 2006) 
Key: CRP, C-reactive protein; WBC, white blood cell count; PAI-l , plasminogen 
activator inhibitor-! ; GGT, gamma glutamyl transferase; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; IGF-I, insulin-like growth factor-!; 
IGFBP, insulin-like growth factor binding protein; j , level increased, L level 
decreased. 
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Figure 1.3: Secretion of insulin-like growth factor I (IGF-I) by the liver. Growth 
hormone (GH) secreted from pituitary gland stimulates IGF-1 secretion. Other tissues 
(e.g. muscle) contribute in the IGF-I (autocrine) secretion locally. IGF-I can either 
bind to different binding proteins (BPs) or exist in an unbound 'free' state. 
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Both IGF-1 and IGF-II circulate bind to high-affinity binding proteins. These binding 
proteins have different regulatory effects on IGFs (Kostecka and Blahovec, 1999). 
1.6.1 ｉｮｳｵｬｩｮｾｉｩｫ･＠ growth factors I and II (IGFs) 
IGF-1 consists of 70 amino acids (Mw 7.646 kDa) and IGF-II 67 amino acids (Mw 
7.471 kDa) (Sara and Hall, 1990). Both IGFs are single-chain polypeptides with 
62% identical sequence homology. They circulate at 1nuch higher concentration than 
insulin and their structural homology is similar to insulin except that A and B 
dotnains remain attached to the C-peptide and also connected to another dmnain (D 
domain) at the carboxy tenninal extension. 
1.6.1.1 The biological properties of the IGFs 
Insulin-like activity of IGFs 
An intravenous dose of IGF-1 exceeding the binding protein capacity causes 
hypoglycaemia and suppresses sermn insulin, C-peptide, branched chain atnino 
acids, creatinine and urea concentrations in 1nan (Guier et a/., 1989). This acute 
response is si1nilar to the response to insulin in that both glucose lowering and 
anabolic affects can be observed. 
IGFs endocrine and paracrine activity 
IGFs have long been recognised to be the 1neans whereby growth honnone (GH) 
brings about its smnatic effects, hence their former name 'smnatmnedins'. GH 
administration to hypophysectmnized (pituitary removal by surgery) rats resulted in 
an increase in IGF-1 transcripts in skeletal tissues including cartilage, bone 
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(McCarthy et al., 1989), skin and in addition to other organs such as peripheral 
nerves (Hansson et al., 1986). Paracrine and autocrine production of IGF-1 can be 
regulated locally in tissues. IGF-1 production by tissues other than liver has other 
biological actions such as the effect of IGF-1 on cellular death (Muta and Krantz, 
1993) and differentiation (Mochizuki et al., 1992) in addition to the role of over 
expression ofiGF-1 receptors in the tumour propagation (Kaleko et al., 1990). 
1.6.2 The insulin-like growth factor binding proteins (IGFBPs) 
The IGFs circulate in blood cotnplexed to a fatnily of structurally related BPs called 
IGF-binding proteins (IGFBPs) (Figure 1.4, A and B). There are at least six binding 
proteins and they share ---35% sequence identity with each other. IGFBPs Inolecules 
contain 18 cysteine residues distributed on carboxy (six) and mnino (twelve) 
tenninus. Table 1.6 smn1narises the general characteristics of the IGFBPs. 
1.6.2.1 Binding and functions ofiGFs to IGFBPs 
IGFs and their BPs circulate in blood as different 1nacrmnolecular complexes 
(Gounnelen et al., 1994; Martin and Baxter, 1992). About 70-90% of total IGF-1 in 
the circulation exists as a ternary protein complex with a molecular weight 150 l<Da 
and half life of 12-16 hours. This ternmy complex consists of IGFBP-3 ＨｾＭｳｵ｢ｵｮｩｴＩＬ＠
acid labile subunit (a.-subunit) and IGF-I or IGF-II (y-subunit). There is also a binmy 
complex consisting ofiGF-1 or IGF-II bound to only one type ofiGFBP. It represents 
10-25% total IGFs in the circufation (28-35 Iilla and 30 minute half-life). This 
complex can transport IGFs to target cells by crossing the capillary barrier. Free IGF-
1 represents less than 1% of the total circulating IGF-1 (Blum et al., 1989). It has a 
half life of 10 n1inutes (McCusker RH, 1992). 
A 
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Figure 1.4: The interaction of IGF-I with binding proteins (BP's) residues: (A) 
Binding of IGF-I to BP's prevents its interaction with receptors (B) Three 
dimensional crystalography structure of insulin-like growth factor binding protein 4 
(BP-4) and its terminals interact with IGF-I; Adapted from (Sitar et al., 2006). 
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Table 1.6: Summary of general characteristics ofiGFBPs. Adapted from (Rajaram et 
a/., 1997). 
No. of Seine 
amino Mw Glycosy Regu- IGF Phospho Source in 
acids (kDa) -lation lation affinity -rylation biological fluids Sites 
Amniotic fluid, 
serum, placenta, 
Insulin, endometrium, milk IGFBP-1 234 25-28 Glucose I= II + urine, synovial fluid, interstitial 
fluid, and seminal 
fluid 
CSF, serum, milk, 
urine, synovial 
Insulin, fluid, interstitial IGFBP-2 289 31 - 34 II> I fluid, lymph Glucose follicular fluid, 
seminal fluid, and 
amniotic fluid 
Serum, follicular 
fluid, milk urine, 
Two GH, CSF, amniotic IGFBP-3 264 subunits + 
nutrition I= II + fluid, synovial, 29 & 53 fluid, interstitial 
fluid, and seminal 
fluid 
Serum follicular 
IGFBP-4 237 24-25 ? I= II fluid , seminal fluid, interstitial fluid and 
synovial fluid 
IGFBP-5 252 34 + ? II> I + Serum and CSF 
IGFBP-6 216 22 + ? Il>l CSF, serum and 
amniotic fluid 
The main functions of the IGFBPs smntnerised as follow: 
i) Transportation of IGFs within the vascular systetn. 
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ii) Prolongation of the half-lives IGFs and regulation of their metabolic clearance. 
iii) Control ofiGF access to the extravascular space. 
iv) Control oftissue distribution and localization ofiGFs. 
v) Control of access to IGF receptors (Figure 1.4, A) thereby regulating the 
biological effects of IGFs on cells growth and differentiation as binding of IGFs 
to IGFBPs prevents their interaction with receptors (Russell WE, 1995). The 
strength of this binding is tnodulated n1ostly by the degree of phosphorylation of 
the IGFBPs. Other factors influencing the degree of binding include, binding to 
cell surfaces, extracellular tnatrix association and proteolysis (Zapf, 1995). 
1.6.2.2 Putative roles of the IGF's and their BPs in cardiovascular disease 
The IGF family of peptides has been implicated in the developtnent of CVD. IGF-I 
stimulates proliferation of coronary vascular stnooth tnuscle cells (VSMCs), 
increases blood flow and production of nitric oxide frmn both the endothelimn and 
VSMC (Bayes-Genis et a/., 2000; Janssen and Lamberts, 2002). These biological 
effects are tnodulated by IGFBPs which control access of IGF-1 to its receptors. 
Because the prevalence of atherosclerosis is tnore predominant with increasing age, 
theoretically, the decreasing IGF-I levels observed with ageing could be involved in 
the development of atherosclerosis. In most cross-sectional studies, serum IGF-I 
levels have been observed to be low in subjects with CVD (Janssen et a/., 1998; Lee 
et a!., 1999). Therefore, serum concentrations of IGFBPs tnay confer differential 
biological effects of the IGFs including effects such as tnitogenesis that tnay have an 
impact on atherogenesis (Juul et al., 2002). Low baseline levels ofiGF-I and IGFBP-
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1 were found to increase the risk of ischaemic heart disease (IHD) independent of 
prevalent CVD risk factors (Laughlin et al., 2004). 
1.6.3 IIisulin-like growth factor binding protein! (IGFBP-1) 
IGFBP-1 is tnainly expressed in the liver, decidualized uterine endmnetrimn, ovarian 
granulosa cells and kidney, and it is abundant in blood (Lee eta!., 1993). Insulin 
regulates IGFBP-1 expression and inhibits its gene transcription in the liver. The 
serum IGFBP-1 concentration therefore varies reciprocally with the an1bient insulin 
concentration. The serum half-life of IGFBP-1 has been reported to be 89 tnin, 
considerably longer than that of insulin, which is only a few n1inutes. This tneans 
that serum IGFBP-1 concentrations lag behind insulin concentrations and may be 
useful to indirectly assess insulin secretion (Lee et al., 1993). Hence patients who 
have hyperinsulinaemia for any reason would be expected to have low serum 
IGFBP-1 concentrations. These observations have led to interest in IGFBP-1 as a 
possible tnarker of insulin resistance as it has the potential to identify patients with 
reduced insulin sensitivity by tneans of a sitnple fasting blood test. 
Low senun IGFBP-1concentrations have indeed been shown to correlate with 
hyperinsulinaetnia and to be associated with a variety of other cardiovascular risk 
factors (e.g. elevated BMI, elevated senun triglyceride and low HDL-C 
concentrations) which are all features of the metabolic syndrmne (Gibson et al., 
1996). As well as predicting cardiovascular risk, the sermn IGFBP-1 concentration 
was observed to increase in response to appropriate lifestyle interventions (Hellenius 
eta!., 1995). Following diet, exercise, or a combination of the two, fasting serum 
IGFBP-1 concentrations increased significantly. Serum IGFBP-1 concentrations 
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have also been observed to correlate strongly with the insulin sensitivity parameter 
(M values, insulin-mediated glucose disposal) obtained by the hyperinsulinaemic 
euglycaemic clamp (r = 0.73, p < 0.004), supporting the contention that it has a place 
in the clinical assessment of insulin sensitivity and assesstnent and tnonitoring of 
cardiovascular risk (Maddux et al., 2006). This study supports the contention that the 
fasting serum IGFBPw1 concentration tnay be useful as an early predictor of insulin 
resistance. In cmnparison with SHBG, IGFBP-1 is also regulated by insulin and is a 
tnore sensitive tnarker of insulin sensitivity, its serum concentrations having been 
observed to decrease tnore than those of SHBG during hyperinsulinaemic clatnps 
(Ebeling et al., 1995). In addition, IGFBP-1 has the advantage over SHBG of being 
free fron1 the effects of confounding factors that influence SHBG concentrations (i.e. 
oestrogens and testosterone) (I(ahne et al., 1999). 
1.6.3.1 IGFBP-1 gene expression and insulin regulation 
IGFBP-1 is encoded by a single copy gene on human chron1oson1e 7p14-pl2 
(Ekstrand et al., 1990). The gene spans 5.2 kb and consists of 4 exons. The isolated 
IGFBP-1 eDNA encodes 259 atnino acid precursor, 25 residue used as a signal 
peptide and 234 residue cmnpose the n1ature polypeptide. The approxitnate 
n1olecular tnass of IGFBP-1 is 25-28 Iilla. Its mRNA has an estimated half-life of 
two hours, (Lee et al., 1997a) this allows the concentration to be changed up to ten 
fold within a short thne (Lee et al., 1993). Transcription of IGFBP-1 is independent 
of growth honnone, but is suppressed by insulin (Powell et al., 1993). This leads to 
an inverse relationship between the levels of insulin and IGFBP-1 in blood plasma. 
Another effect of insulin is to regulate the tnovetnent of IGFBP-1 out of capillaries 
into adjacent tissues (Bar et a!., 1990). 
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1.6.3.2 IGFBP-1 phosphorylation 
When hmnan IGFBP-1 isolated from atnniotic fluid or HepG2 cell culture 
supernatants is analyzed by non-denaturing gel electrophoresis, one non-
phosphorylated and four to five serine phosphorylated fonns tnay be distinguished 
(Frost and Tseng, 1991 ). The separation of different forms of IGFBP-1 was based on 
the degree of charges of the phosphorylated sites. The terms of highly-
phosphorylated and lesser-phosphorylated IGFBP-1 are not very well defined. They 
have been used to describe the pattern of 1nigration seen when IGFBP-1 was 
analysed by n-octyl-glucoside polyacrylatnide gel electophoresis (Westwood eta/., 
1994). The proteins in this technique are separated on the basis of their charge rather 
than their mass, so the tnost phosphorylated forms ofiGFBP-1 will have the highest 
charge and willtnigrate the furthest down the gel which represent the bottmn band in 
a profile ofiGFBP-1 (e.g. pregnancy plastna or media conditioned by Hep G2 cells). 
Non-phosphorylated IGFBP-1 will have a lower charge and willtnigrate the least 
and is therefore represented by the top band of such a profile. The bands in between 
represent forms that have smne lesser degrees of phosphorylation cmnpared to the 
highly phosphorylated fonn, and these bands referred to as the less phosphorylated 
fonns. Three phosphorylation sites have been identified in human IGFBP-1 (Serine 
101, 119, and 169) (Jones et a/., 1993). Serine 101 is the tnost cmnmonly 
phoshorylated site. In hmnan heptoma cells, casein kinase II and another unknown 
kinase have been shown to be responsible for human IGFBP-1 phosphorylation 
(Ankrapp et al., 1996). Therefore depending on the degree of phosphorylation, 
circulating IGFBP-1 in different biological fluids is present as highly 
phosphorylated, less phosphorylated or non phosphorylated forms. For example in 
human amnioic fluid the degree of phsphorylation varies corresponding to the fetal 
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growth while highly phosphorylated forms of IGFBP-1 are predmninant in 
nonpregnant adult hmnan serum (!washita et al., 1998). Phosphorylation ofiGFBP-1 
alters its affinity for IGF-1. The hmnan phosphorylated forms ofiGFBP-1 have a 10-
fold higher affinity for IGF-1 than its non-phosphorylated forms (Jones et al., 1991). 
Differences in affinities have been shown to correlate with the ability of human 
IGFBP-1 to tnodify IGF-1 actions (Jones and Clemtnons, 1995). In pregnancy, 
changes in IGFBP-1 phosphorylation may influence IGF bioavailability and hence, 
fetaltnaturation (Westwood et al., 1994). The degree of phosphorylation ofiGFBP-1 
tnay protect against or aggravate the development of smne diseases e.g. 
cardiovascular disease and hypertension (Heald et al., 2002). More details about 
IGFBP-1 phosphorylation will be discussed in Chapter 8. 
1.6.3.3 IGFBP-1 proteolysis 
Whilst tightly complexed with IGFBP, IGFs cannot bind to their receptors and their 
actions are inhibited (Holly et al., 1993). In order to activate IGF receptors on a 
target cell, IGF needs first to dissociate frmn its binding protein. Proteolysis is 
important in reducing the high affinity between IGF and their BPs (Holly et al., 
1993). IGF action can be regulated by IGFBP proteases such as prostate specific 
antigen (Cohen et al., 1994), cathepsin D (Claussen et al., 1997), plasmin (Booth et 
al., 1996), thrombin (Booth et al., 1996) and elastase (Gibson and Cohen, 1999). 
1.6.3.4 The relationship between etbnicity and IGFBP-1 
Ethnicity has been shown to be an independent predictor of the fasting serum 
IGFBP-1 level and the influence of ethnic background on IGFBP-1 has been 
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investigated in several different ethnic groups (Heald et a!., 2001; Liew et a!., 2005) 
(Table 1.7). However, few previous studies have correlated IGFBP-1 and insulin 
resistance or investigated this relationship with CVD in a population of defined 
ethnicity. 
1.6.3.5 Methods of quantification ofiGFBP-1 
Purification ofiGFBP-1 has resulted in the generation ofpolyclonal and tnonoclonal 
antibodies, and subsequently develop1nent of itnmunoassays. Using IGF-I or IGF-II 
as ligand binding proteins is not specific. Therefore today IGFBP-1 can be tneasured 
by different imtntmological 1neans e.g. radioimmunoassays (RIA), 
immunofluorometric assays (FMIA) (Koistinen et al., 1987), im1nunoradiometric 
assay (IRMA) (Pekonen eta!., 1989) and ELISA (Khosravi eta!., 1997). Due to the 
nmnerous im1nunoassays for hmnan IGFBP-1 which have been developed, wide 
differences in reference ranges have been reported. The heterogeneity in fonns of 
sermn IGFBP-1 may in part account for this. Therefore better characterised assays of 
IGFBP-1 have been developed. This characterisation depends on the ability of the 
immunoassay to specify different forms ofiGFBP-1 present in hmnan fluids i.e. less 
phosphorylated IGFBP-1 (Westwood et a!., 1994), phosphorylated IGFBP-1 
(Khosravi eta!., 2007) and total IGFBP-1 (Khosravi et al., 1997). These wide range 
of techniques available to 1neasure different fonns of IGFBP-1 are without major 
pitfalls but the n1ost specific, sensitive and reproducible is the preferred method of 
detecting IGFBP-1. 
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Table 1.7: Some previous studies comparing IGFBP-1 in different ethnicities. 
Ethnic group Protocol Findings Reference 
European and 272 subjects in this study IGFBP-1 was closely related (Heald et 
Pakistani underwent a 7 5 g oral to risk factors for diabetes al., 2001) 
glucose tolerance test and and CVD in both ethnicities. 
standardised anthropometry. IGFBP-1 could be used as a 
Fasting IGFBP-1, IGF-I, marker of hepatic insulin 
IGF-II, insulin, lipids and resistance and development 
HOMA-IR were estimated. of macrovascular disease. 
Asian Indians, To examine the relationships IGFBP-1 is independently (Liew et 
Chinese, and among IGFBP-1, insulin determined by ethnicity. a/. , 2005) 
Caucasians sensitivity and leptin in three Increased insulin resistance 
different ethnic groups (1 0 and decreased fasting 
healthy non-diabetic IGFBP-1 in Asian Indians 
subjects). Insulin sensitivity were due to increased risk of 
was estimated using developing diabetes and 
euglycemic clamp. cardiovascular disease 
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1. 7 Factors affecting test results 
The source of error in providing any biochetnical test result can be preanalytical 
(satnple preparation and handling), analytical (random or systematic) or 
postanalytical (data processing). Before analysis, the biological factors have an 
important role when two test results need to be cmnpared. The two main 
detenninants of biological factors which need to be considered are endogenous 
factors (age, sex, ethnicity, body tnass) and exogenous factors (time of sampling, 
stress, posture, food intake, drugs, excercise, etc.) (Marchall and Bangert, 2008). 
1.7.1 Biological and analytical variations 
Randmn variation around the hmneostatic set points contributes to overall 
itnprecision of analyte tneasurement. Intrinsic biological variation (e.g. pulsatility, 
rhythmicity) can be calculated by collecting a series of satnples from different 
individuals over a period of titne (tninutes, days or weeks). It is itnportant that the 
tests are taken under the same conditions to minimise the effects of extrinsic 
biological variation. In order to minhnise the influence of analytical variation, the 
analysis tnust be carried out using the satne instrument, operator, calibrators and 
reagent components. In addition to this, specitnens tnust be stored in such a way to 
avoid analyte degradation (e.g. sufficient freezing). Analytical variation or 
imprecesion can be calculated by repeating analysis on a single satnple within or 
between batches. This should be done over a range of concentrations. 
Precision is a reflection of reproducibility. Total reproducibility or variation for any 
analyte can be expressed in tenns of percentage coefficient of variation and 
calculated by using the following formula: 
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CV = (Standard deviation I tnean) x 100 
This total variation (CVt) is a cotnposite of analytical (CVa) and biological (CVb) 
variations (Fraser and Harris, 1989): 
CVt = ｾＨｃｖ｢ Ｑ＠ + CVa2 ) 
1. 7.2 Intr·a-individ ual variation of insulin resistance 
Several studies have identified considerable within individual variability in the 
results of the oral glucose tolerance test (OGTT) (Ganda et al., 1978; Mooy et al., 
1996). A few studies have investigated insulin resistance variability (reproducibility) 
in the satne subjects using either the reference clmnp technique (Bokemark et al., 
2000; Soop et al., 2000), the FSIVGTT technique (Duysinx et al., 1994) or using 
shnpler indices of insulin resistance (Sarafidis et al., 2007). As the gold standard 
technique, the CV of the clamp should reflect the true intra-individual variation. The 
few studies on the reproducibility of the clatnp technique have shown CV s ranging 
frmn 5.8 to 15% (Boketnark et al., 2000; Soop et al., 2000). 
Changes in serial insulin resistance results frmn subjects with specific clinical 
conditions would be interesting to investigate. Therefore in Chapter 3, 4 and 5 we 
will investigate intra-individual variability of the tnost con1tnonly used indices of 
insulin resistance and IGFBP-1 across different glycamic categories and over a range 
of body mass indices. 
40 
1.8 Hypothesis 
Our hypothesis was that serum IGFBP-1 concentrations will be positively correlated 
with insulin sensitivity measured by a variety of available assesstnent techniques in 
subjects with different levels of glucose tolerance, including: FSIVGTT (as a silver 
technique) and son1e other sitnple techniques e.g. HOMA, QUICK! and ISI-gly. 
1.9 Aims of thesis 
The tnain ahns of this thesis were to: 
i) establish analytical criteria and validate antibody binding for an IGFBP-1 ELISA 
technique. 
ii) correlate con1n1on indices of insulin resistance with the IGFBP-1 levels. 
iii) estitnate the overall variation of I GFBP-1 and to determine how its levels vary in 
subjects from different glycaetnic categories. 
iv) estimate the overall variation of simple indices of insulin resistance and 
FSIVGTT insulin sensitivity (Si) derived paran1eter and how they would be 
affected by different glycaetnic categories and body 1nass index (BMI). 
v) assess insulin sensitivity in Saudi and Caucasian populations. 
vi) investigate different fonns of IGFBP-1 in subjects with and without IHD and 
how they tnay be associated with IGF-1. 
Chapter 2 
Materials and methods 
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2. Materials and 1nethods 
2.1 Subjects 
The subjects involved in our studies were from three different populations, with 
various degree of glucose tolerance and 1nanifestation of cardiovascular diseases. 
The overall number of participants was 10 I. Suitable subjects were derived frmn 
different populations; Saudi Arabians (n = 34), Caucasians (n = 45) and Iranians (n = 
22). The subjects were divided into two tnain groups, those without IHD ( n = 56) 
and those with IHD (n = 45). Each group was further divided into four subgroups as 
follows: nonnal glucose tolerance (NGT), in1paired fasting glucose (IFG), itnpaired 
glucose tolerance (IGT) and type 2 diabetes (DM) (Figure 2.1). Blood smnples were 
collected from subjects in their hmne countries between February 2005 and July 
2008. Subjects were usually recruited during their routine visit to the hospital 
outpatient diabetic, cardiac or lipid clinics and they were frmn different genders. 
Ethical pennission was granted by the Saudi National Guard Health Affairs (NGHA) 
ethical cmntnittee, the South West Surrey Local Research Ethic Cmnn1ittee (LREC) 
and Mashhad Research Centre. Each subject gave infonned written consent. All 
potentially suitable subjects participated in one (Saudi, Caucasians and Iranians) or 
two visits (Saudi and Caucasians). Samples frmn Saudi Arabia and Iran were 
delivered to the UK in March 2006 and January 2009 respectively. 
At the first visit an oral glucose tolerance test (OGTT) was performed and on the 
second visit (on average one week after the first visit) subjects underwent a 
frequently sampled intravenous glucose tolerance test (FSIVGTT). Applying WHO 
1998 criteria (Alberti and Zimtnet, 1998) (see Chapter 1, Table 1.3) to the data of 
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the OGTT obtained frmn the fisrt visit yielded the following categories; NGT , IFG, 
IGT and DM. Saudi (n = 35) and Caucasian (n = 45) subjects were recruited from 
different glycaemic categories whilst Iranians subjects were all of normal glucose 
tolerance (n = 22). There were a total of 56 subjects without IHD (23 Saudis, 23 
Caucasians and 10 Iranians) and 46 subjects with IHD (12 Saudis, 22 Caucasians and 
12 Iranians). Regarding the glycaemic status, there were a total of 53, 14, 22 and 13 
subjects with NGT, IFG, IGT and DM respectively (Figure 2.1). Sample counts or 
distributions across each study or chapter were not the same. This is because of the 
nature, type of the population involved, satnples integrity and insufficiency in each 
study. 
2.1.1 Inclusion criteria 
Cmnn1on inclusion criteria for all subjects are as below: 
a. Subjects ages were between 20- 65 years 
b. Body tnass index (BMI) > 20 and< 35 kg/m2• 
For subjects without cardiovascular disease (CVD) 
c. Have had no sytnptmns of cardiovascular disease on questioning and also 
have had a recent nonnal 12 lead electrocardiogram (ECG). 
For subjects with CVD 
d. Have had established IHD defined as previous tnyocardial infarction (Ml), 
previous coronary artery bypass graft (CABG) operation or angina diagnosed 
by exercise test and/or coronary angiogram. 
2.1.2 Exclusion criteria 
Cmnn1on exclusion criteria for all subjects are as below 
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a. Diabetes treated with oral hypoglycae1nic medications or insulin and other 
drugs likely to Inodify insulin sensitivity e.g. steroids (Cagnacci et al., 2003). 
Treatment with sulfonylurea for example has been shown to be associated 
with decreased sermn levels of IGFBP-1 (Gibson et al., 1995) while 
treatment with thyroxine has been associatd with increased levels of I GFBP-1 
(Angervo et al., 1993). Thus the diabetic subjects were treated by diet alone 
or were involved before starting their 1nedical treatment. 
b. Current acute illness. In acute illness, the inverse relationship between insulin 
and IGFBP-1 is lost due to the effects of counter-regulatory honnones and 
cytokines (Van den Berghe, 2003). 
NGT 
(29) 
IGT 
(10) 
WithoutiHD 
(56) 
IFG 
(1 0) 
Total subjects 
(102) 
NGT 
(24) 
IGT 
(12) 
With IHD 
(46) 
IFG 
(4) 
DM 
(6) 
Figure 2.1: Classification of study subjects. Subjects were 1nainly classified 
according to their glycaemic status and ischaetnic heart disease (IHD) Key: NGT, 
non11al glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose 
tolerance; DM, type 2 diabetes. Number per group is in brackets. 
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2.2 First visit 
Participants were instructed to abstain frmn stnoking, alcohol and physical activity 
from 7 pm and to fast from 10 pm the previous night. The OGTTs were performed 
between 8 and 10 atn. Fasting blood satnples were collected into sodium fluoride, 
ethylenedimninetetra-acetic acid (EDTA) and plain tubes (without anti-coagulant). A 
standard 75g oral glucose tolerance test (OGTT) was performed involving lemon-
flavoured glucose anhydrate in 300 tnL of water taken orally over 5 tninutes. After 2 
hours further blood samples were collected into sodium fluoride and plain tubes. 
After separation of plastna or sermn by centrifugation (3000 x g) for 10 tninutes 
specimens were analysed imtnediately for plasma glucose, serum lipid profile (total 
cholesterol, HDL-C, calculated LDL-C, triglyceride) and uric acid. For glycated 
haetnoglobin Ale (HbAlc) analysis, whole blood was collected into EDTA tube and 
analysed on the same week. Sermn aliquots for specialised tests such as insulin, 
IGFBP-1 and IGF-I were stored at -80°C until analysis. 
Anthropmnetry; body mass index (BMI; kg/m2) and waist hip ratio (WHR) were 
detennined. Percentage total body fat (% TBF) was estimated using BF -680 Duo 
tetra-polar bioelectric itnpedance device (Tanita Body Fat scale, Japan). In King 
Khalid National Guard Hospital (Jeddah, Saudi Arabia) the tneasuretnent of blood 
pressure (BP; mmHg) was taken autmnatically by a device systetn from Accutorr 
Plus, Datascope, USA. In Royal Surrey County Hospital (Guildford, Ul() the blood 
pressure was taken autmnatically by Dinamap® Cmnpact TS (Johnson & Johnson 
Medical. Inc, Ul(). The glucose results on the fasting and 2 hours specimens in each 
subject were interpreted according to WHO criteria. See introduction Chapter (Table 
1.3). 
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2.3 Second visit 
A frequently satnpled intravenous glucose tolerance test (FSIVGTT) was carried out 
at this visit on most of the volunteers (Saudi and Caucasians only), except those with 
diabetes mellitus. The average titne between first and second vists was one week. 
Measuren1ents of BMI, WHR and % TBF were not repeated at the second visit due to 
the relative short-time interval (one week) between visits. This was undertaken in an 
Investigation Unit where all equipment necessary for managing medical etnergencies 
was available. All FSIVGTT procedures were petformed in the presence of a 
clinician. The test involved satnpling at a total of 29 tilnes points i.e. approximately 
58 tnL whole blood in total. At each titne point, at least 2 mL of blood satnples were 
collected for each of glucose (plasma) and insulin (serum). Glucose levels were 
measured inunediately while specitnens for insulin were separated prmnptly and the 
senun stored frozen at -80°C. 
2.4 Assays used for tests analysis 
Samples frmn Saudi Arabia and Iran were shipped by air to UK on dry ice and stored 
at -80°C until batch analysis. All routine biochemistry screening tests were 
performed on an Advia 1650 auto-analyser using comtnercial kits (Sietnens Clinical 
Chetnistry Systetn, previousely la1own as Bayer). Plasma glucose was assayed using 
the principle of glucose hexokinase (Sleit1 et al., 1950). Precision of glucose assay 
was assessed twice per run, two runs per day, for 13 days. For three different levels 
of sermn quality control satnples the estimated within-run precision was between 
0.8% and 1.2% while between-run precision was between 2.0% and 2.2% for the 
smne samples. Cholesteroltneasuretnent was based on an enzymatic tnethod utilizing 
cholesterol esterase (Allain et al., 1974). Triglycerides were 1neasured using a 
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method based on Fossati three-step enzytnatic reaction (Fossati and Prencipe, 1982). 
HDL-C was tneasured using a direct tnethod using a coloritnetric endpoint based on 
Trinder reaction (Warnick et al., 1982). LDL-C was estimated by calculation from 
total cholesterol, HDL-cholesterol and triglycerides using the Friedewald fonnula 
(Friedewald W, 1972). Uric acid tneasuretnent was based on an enzytnatic reaction 
using uricase (Fossati et al., 1980). HbA1c was tneasured by using ion exchange 
high-perfonnance liquid chrmnatography; Biorad Variant II (Kondo et al., 1989). 
Serum IGF-I was determined by chemilmninescent imtnunoassay using lmtnulite 
1000 auto-analyser. The kits were kindly donated by Sietnens Diagnostics UK, Al-
RedwanKSA. 
2.4.1 Insulin assay 
Insulin was tneasured using the Mercodia (Uppsala, Sweden, catelogue number 10-
1128-02) ELISA. It is a solid phase, two-site enzyme itnmunoassay with 6.0 pmol/L 
sensitivity and maximum 4.9% as a total %CV. In tenns of specificity, the Mercodia 
kit showed a specificity of< 0.1% and 54% cross-reactivity with C-peptide and 
intact pro insulin respectively. The kit is ready to use and briefly described as follows, 
50 J.LL of calibrators and samples were pipetted into appropriate coated wells 
followed by 50 J.LL of enzytne conjugate. The plate was incubated on a plate shaker 
(200 rptn) for 1 hour at romn temperature (RT; 18-25°C). By using automatic plate 
washer each well was washed by 300 ｾｴｌ＠ of wash buffer for 6 times. After a final 
wash, the plate was inverted and tapped finnly against absorbent paper. Then 200 J.LL 
of substrate tetrmnethylbenzidine (TMB) was added into each well. After 15 tninutes 
incubation at RT 50 ｾｴｌ＠ stop solution was added. Within 30 tninutes the optical 
density was read at 450 nn1 and results calculated using spectrophotmnetric analyser 
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(Multilabel Counter VICTOR tnodel 1420 from PerkinElmer, UK). Conversion 
factors between units for insulin and glucose used were as follow: 
Insulin: tnU/L x 6 = pmol/L 
Glucose: tng/dL x 0.0555 = 1nmol/L 
2.5 Insulin sensitivity assessment procedures 
Glucose and insulin values obtained frmn the first visit allowed calculation of insulin 
sensitivity using established simple indices including HOMA, HOMA2, QUICKI, 
FGIR, Raynaud index and lSI -gly. These indices with their equations and limitations 
have been described further in Chapter 1 (section 1.5.2). 
2.6 Principle of standard frequently sampled intravenous glucose tolerance test 
For the second visit, standard FSIVGTT was performed as follows; with the subject 
in the supine position baseline blood satnples for insulin and glucose were taken at 
15, 20, 25, 30 tninutes following placetnent of an intravenous cannula. Glucose 
(0.3g/kg of 50%) was then injected as a bolus over one minute. Blood satnples for 
glucose and insulin tneasuretnent were drawn 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 
25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160 and 180 tninutes after the start of 
the glucose injection (Bergman et al., 1979; Yang et al., 1987). The technique of 
short-satnple protocol is shnilar to the full one but instead of collecting 25 samples 
post-glucose dose it requires a total of 12 samples. These samples were collected at 
tilnes: 0, 2, 4, 10, 16, 22, 30, 50, 70, 90, 120 and 180 minutes (Duysinx et al., 1994). 
Parameters for insulin sensitivity (Si) and glucose effectiveness (Sg) were derived 
using Minilnal Model analysis which depends on glucose-insulin kinetics in subjects 
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undergoing FSIVGTT. The Bergman principle depends on uncoupled glucose and 
insulin responses. This expanded the glucose-insulin coupled system to two semi-
separated sub-systems. The first, the glucose tninimal 1nodel, uses insulin 
observations to drive the glucose response, and attempts to depict glucose dynamics 
to estimate the two parmneters of glucose responsiveness, and insulin sensitivity. The 
second, the insulin tninitnal model, uses glucose observations to drive the insulin 
response, and to depict insulin dynamics in tenns of another set of key parameters. 
The acute insulin response to glucose (AIRg) is another parameter which can be 
calculated by Mimnod Millennium (upgraded software) and is defined as the area 
under the insulin curve between 0 and 10 tninutes. Due to the availability of different 
software (Table 2.1) the tnost recent upgraded software was purchased and used in 
our project. The Minmod Millennimn software is a shnple Window' s-based version. 
Datasets for each subject that were entered into the Millennium data editor is shown 
in Table 2.2. The 'thne' colu1nn contains the sampling times for the FSIVGTT 
protocol and the data in the 'weight' column contains the rec01nmended weighting 
schetne of zero or one. In this example all observations fr01n 0 to 5 tninutes were 
given zero- weighting to allow for the initial glucose extracellular equilibration. 
Unlike other observations these early data points (0 to 5 tninutes) are not taken into 
account in analysis of the glucose tnodel. 
The output results of the dataset can be plotted graphically as in Figure 2.2 including 
all the esthnated parameters. Results output described in the Mimnod Millennium 
report consists of tninhnal model parameters and a chart of glucose and insulin data. 
For each database analysed, Millennhun produced a report shnilar to to that shown in 
Figure 2.2. 
50 
Table 2.1: Minmod software models and other conditioned programmes used to 
estimate different parameters of interest from FSIVGTT data. 
Programme 
Minmod 86 
Description References 
This is the original minimal model. It is a mathematical (Pacini and 
representation of the glucose kinetics during FSIVGTT. Bergman, 
It permits calculation of insulin sensitivity (Si) and 1986) 
glucose effectiveness (Sg) from data on plasma insulin 
and glucose levels. 
Some of the parameters in the original minimal model (Araujo-
Stellum-Ml equations do not have a simple relationship with the Vilar et al. , 
and Stellum- kinetic parameters. These programmes use versions of 1998) 
MM the Minmod equations which have been modified to 
overcome this problem. 
Comal3.11 
Minmod 
Millennium 
GAMMOD 
IS_ CIBA programme which uses Minmod equations. It (Mehring et 
uses a multivariate numerical algorithm which has a al. , 2002) 
lower variability than the standard approach. More 
details about this software are in Chapter 3. 
Windows-based version. User-friendly, quick and can (Boston et 
provide values for all the relevant parameters. It is able al., 2003) 
to produce charts of glucose and insulin and tables of the 
parameters. 
This new programme is based on Genetic Algorithms for (Morbiducci 
estimation of the minimal model parameters. It does not et al. 2006) 
require initial values for the parameters to be fixed and 
has improved usability. 
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Table 2.2: A typical dataset ofFSIVGTT, glucose and insulin entered into the data 
editor of Minmod Millennium. 
• Data [ditor paper . txt lXI 
Fte EcM: Insert 
Tine GU:oae tndn Wflidi 
0 92.25 6.125 0 
2 
- 340.2 111.9 0 
3 ｾＮＶ＠ 111.3 0 
---
- ---,-,:-4 Di. 0 
5 275.4 ＱｾＮＹ＠ 0 
--6 r- - 275.4 1(Mi.9 1 
8 255.6 95.1 1 
10 
-- 234. 74.1 1 
--- --12 225. n6 1 
14 2m.2 67.7 1 
--16 214.2 53.2 1 
19 181.8 ---:--45.1 1 
-- 22 160.2 33.3, 1 
25 167.4 35.41 1 
-ｾ ｾ＠ 142.2 28.5 1 
.w: 109.8 - 19.1 1 
50' 88.2 --11 .3 1 
so' 75.6 
:----
7.8 1 
--=w 66.6 - s.s 1 ---ｾ ｩ＠ n 6.7 1 
90' 75.6 5.6 1 
1001 
- 79.2:-- 4.6 --·---, 
1201 84.6 5.1 1 
1401 88.2 3.8 1 
-160 96.4 3.7 1 
Ｑｾ＠ 84.6 Ｓｾ＠
------:-
--
' 1 
Units; Time (minute), Glucose (mg/dL), insulin (mU/L). 
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Figure 2.2: The plot diagram using Minmod Millennium accompanied with multiple 
parameters. Glucose observation blue dots; insulin observations green dots; fit of 
minimal model to glucose observation red line; insulin action black line; unweighted 
observations hollow dots. Derived indices and Key; Si, insulin sensitivity; Sg 
glucose effectiveness; Dl, dissociation index; AIRg, acute insulin response to 
glucose; Gb, basal glucose; Ib, basal insulin; P(2), the removal rate of insulin from 
the interstitial space; P(3), the movement of circulating insulin to the interstitial 
space; G(O), distributed glucose concentration at time 0; FSD, fractional standard 
deviation error; GEZI, glucose effectiveness at zero insulin. IAGD, predicted insulin-
attributable glucose disposal. 
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2.7 Anti-IGFBP-1 antibodies 
There are several polyclonal and 1nonoclonal antibodies available for IGFBP-1 
binding. Some but not all tnonoclonal antibodies have been developed and 
characterised against IGFBP-1 that are specific for the different phosphorylated 
forms of IGFBP-1. This characterisation of specificity is ilnpmtant before 
developtnent of any quantitative assay. 
2.7.1 R&D anti-human IGFBP-1 antibodies 
The capture and labelled antibodies used in our first in-house ELISA were purchased 
frmn a commercial source (R&D Systetns Inc. Europe Ltd., Abingdon Science Park, 
UK). This capture antibody (cat. MAB 675) was produced frmn a hybridmna 
resulting from the fusion of a mouse tnyelmna with B cells obtained frmn a tnouse 
imtnunised with purified, E.coli-derived recombinant human IGFBP-1 (rhiGFBP-1). 
It is classified as tnouse IgG 1 by using protein G affinity chrmnatography. After 
reconstitution with 1 mL of sterile phosphate buffered saline (PBS) the antibody 
concentration will be 500 J.LgiinL. It has never been investigated for binding with 
different forms ofiGFBP-1. 
Biotinylated polyclonal anti-human IGFBP-1 antibody (R&D cat. BAF871) is the 
secondary labelled antibody. It is ready to use and silnilar to the capture antibody in 
preparation but produced in goats hnmunized with purified, E. coli-derived, 
recmnbinant human insulin-like growth factor binding protein 1. After reconstitution 
with 1 tnL of Tris-buffered saline pH 7.3 (20 1nM Trizma base, 150 mM NaCI) 
containing 0.1% BSA the antibody concentration will be 50 ｾｴｧＯｭｌＮ＠
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2. 7.2 Antibody of Medix Biochemica 6303 
The Inonoclonal antibody of Medix Biochemica 6303 was generously provided by 
Medix Biochetnica, Kauniainen, Finland. We utilised it as a capture antibody in our 
second in-house ELISA assay of piGFBP-1. The antibody of Medix Biochemica 
6303 was developed against IGFBP-1 imtnunogen purified fr01n human decidual 
placenta (Rutanen et al., 1988). It has been extensively investigated using Western 
ligand blotting (WLB) and during the develop1nent of a RIA it was found to bind 
preferentially to phosphorylated rather than the non-phosphorylated IGFBP-1 in 
human sennn (Westwood et al., 1994). The same antibody was used in ELISA as a 
capture antibody to estimate piGFBP-1 in cervical fluid (Nuutila et al., 1999). More 
details on this antibody are included in our study about subjects with and without 
IHD (Chapter 8). 
2.7.3 The anti-phosphoserine antibody 
This was a comtnercial tnouse IgG 1 antibody (Becton Dickenson Biosciences, 
Science Park, UK cat. 412546). Its reactivity has been studied in human serum and it 
specifically recognises protein phosphorylation of serine residues. In addition to this 
the antibody binding to IGFBP-1 phosphoserine residues has been investigated 
recently by Khosravi et al., (Khosravi et a!., 2007). As previously tnentioned in 
section 1.6.3.2, IGFBP-1 is phosphorylated at serine residues. Therefore this 
antibody has been utilised in our project for two tnain purposes; firstly for piGFBP-1 
immunoprecipitation using the WLB and secondly in the developtnent of our second 
in-house ELISA assay after labelling the antibody with a biotin to capture the 
phosphoserine residues of pi GFBP-1. 
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2.8 Characterisation of R&D anti-lunnan IGFBP-1 using Western ligand blotting 
Characterisation of R&D anti-human IGFBP-1 capture antibody (catalogue nmnber. 
MAB 675), including its binding properties and cross-reactivity have not been 
investigated previously. We intended to do this by using the Western ligand blotting 
(WLB) technique prior to the developtnent of an in-house ELISA. 
2.8.1 IGFBP-1 analysis by Western ligand blotting 
The WLB technique depends on the separation of the protein con1ponents using gel 
electrophoresis and then transfering to a tnetnbrane where it tnay be probed with 
reagents specific for a particular protein. In 1986, Hossenlopp and his colleagues 
outlined the method of IGFBPs WLB (Hossenlopp et al., 1986). This tnethod is the 
basis of all subsequent protocols related to IGFBPs and is sumtnarised schetnatically 
in Figure 2.3. WLB is a useful technique for qualitative and setni-quantitative 
analysis ofiGFBP-1. In addition to this, WLB tnay be used to validate the polyclonal 
or tnonoclonal antibodies which have been intended to be utilised by the quantitative 
assays. Therefore the capture antibodies of R&D (catalogue number. MAB 675) and 
Medix Biochetnica 6303 in addition to the antiphosphoserine antibody (BD, cat. 
61254 7) before biotin labelling were validated by using this technique before they 
were applied to our in-house assays. 
2.8.2 Preparation of samples for Western ligand blotting 
All samples, except the protein standard (MagicMark, Invitrogen, cat. LC5602) or 
those requiring imtnunoprecipitation were diluted 1:8 v/v in PBS (pH= 7.4). 2.5 J.LL 
of LDS (Lithium Dodecyl Sulphate, cat. NP0007) ready to use buffer solution was 
then added to 1 0 J.LL of the diluted sample. Protein satnples were then denatured by 
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Diluted serum (1 :8) v/v tnixed with sample buffer (Lithiutn Dodecyl Sulphate) 
l 
Smnples heated 100°C (5 minutes) 
l 
Diluted sample loaded into stacking gel 
l 
Electrophoresis (200V, 1 hour) 
l 
Electroblotting (30V, 2 hours) 
l 
Metnbrane Blocked with blocking reagent to tninimise 
non-specific binding (at least 30 minutes) 
l 
Membrane incubation with primary antibody (Anti-IGFBP-1) 
l 
Wash 
l 
Metnbrane incubation with secondary-labeled antibody (1 hour) 
l 
X-ray film exposure and development (15-25 tninutes) 
Figure 2.3: Electrophoresis and Western ligand blotting protocol. Adapted from 
(Hossenlopp et al., 1986). 
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heating to 1 00°C for 5 tninutes (Figure 2.3). The LDS sample buffer is a 4 times 
concentrated solution of high viscosity (2% LDS, 10% Glycerol). It was used to 
denature and reduce proteins with disulphide bonds (e.g. IGFBP-1) under alkaline 
condition (pH = 8.4). In our initial trials of WLB, 2.0 ｾｴｌ＠ of 2-mercaptoethanol 
(10%) (Sigma, catelogue number. M3148) was used as a sample buffer. It was 
intially added to the 1nixture of the diluted sermn satnple before heating. The reason 
for this was to intensify the process of protein denaturing by reducing the disulfide 
bridges between the IGFBP-1 tertiary structures as tnercaptoethanol is known to be a 
strong reducing agent. Adding 2-tnercaptoethanol to the tnixure was then 
discontinued due to complete reduction and defonnation of the IGFBP-1 which 
caused the IGFBP-1 bands to be dmnbelled in shape and unreliable in density 
particularly with different phosphorylated forms of IGFBP-1. Therefore, the LDS 
sample buffer was used instead. It enabled 1nore reliable distinction between 
isofonns of IGFBP-1 with variable band densities (Appendix 1 ). 
2.8.3 Immunoprecipitation of serum samples 
1J.Lg of antiphosphoserine antibody (Becton Dickenson, cat. 612547) was added to 1 
1nL of sennn san1ple and gently rocked for 1 hour in a microfuge tube. 50 J.LL of 
protein-0-agarose suspension beads (Roche, cat. 11-719-386-001) were then added 
to the tnixture and incubated overnight on a rocking platfonn at 2-8°C. Bound 
antibody was then separated by centrifugation at 12,000 x g for 20 seconds. After 
discarding the supernatant, hnL wash buffer 1 (50mM Tris-HCI, 150mM NaCl, 1% 
Nonidet P40, 0.05% sodium deoxycholate, pH 7.5) was then added to the beads and 
incubated for 20 tnin on a rocking platform. After repeating the centrifugation 
procedure, 1 1nL of the second wash solution (SOn1M Tris-HCl, 500tnM NaCl, 0.1% 
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Nonidet P40, 0.05% sodimn deoxycholate, pH 7 .5) was added to the beads and 
incubated for 20 tnin on a rocking platform as before centrifugation. 1 mL of the 
third wash solution (1 OmM Tris-HCl, 0.1% Nonidet P40, 0.05% sodium 
deoxycholate, pH 7 .5) was then added to the beads. The last trace following the final 
centrifugation was aspirated frotn the agarose pellet using a pipette. The aspirated 
fluid was then prepared as described in section 2.8.2 by adding LDS buffer followed 
by boiling before use in electrophoresis. 
2.8.4 Dephosphorylation of serum san1ples by alkaline phosphatase 
Senun satnples for IGFBP-1 were dephosphorylated by treating 200 ｾｌ＠ of the 
satnple with 200 units of calf senun alkaline phosphatase (Roche, cat. 38001). The 
1nixture was then dissolved in 10 ｾｌ＠ of 1 tnol/L diethanolmnine containing 0.5 
tnmol/L MgCh. After 2 hours incubation at 37 °C, the n1ixture was ready for use. For 
cmnplete sample dephosphorylation, the incubation was extended up to 24 hours 
(Khosravi et a/., 2007) . 
2.8.5 Electrophoresis and electroblotting 
The expression of IGFBP-1 was then investigated by neutral gel electrophoresis 
followed by WLB. Figure 2.3 shows details of the procedures. Neutral gel 
(NuPAGE Novex, Invitrogen, cat. NP0341), Bis-tris 12% pre-cast polyacrylatnide 
1nini-gel was used for electrophoresis. The gel tank was assetnbled and filled with 
electrophoresis running buffer [50tnM MOBS, 50mM Tris-Base, 0.1% SDS (Sodium 
Dodecyl Sulphate), l.OmM EDTA, pH 7.7]. 2.5 J.!L LDS (Lithimn Dodecyl Sulphate) 
as a satnple buffer was added to 10 ｾｬｌ＠ diluted sermn (1 :8 v/v in PBS), 
imtnunoprecipitated sample or 0.25 J..Lg/mL recmnbinant human IGFBP-1 (rhiGFBP-
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I). This rhiGFBP-I (R&D, cat. 871-BI) was used as a reference satnple. Molecular 
weight protein standard (2 ｾｴｌＩ＠ was used as a leader to visualize the reference 
standard bands (MagicMark, cat. LC5602). Each satnple was loaded into the well 
slots. Electrophoresis was then perfonned at constant voltage, (200V) for 
approximately I hour. After electrophoresis 2 sponges, 2 Whatmann filter papers, 
and one Polyvinylidine Fluoride (PVDF) tnetnbrane, cut to the satne ditnensions as 
the gel, were allowed to soak in transfer buffer (25tnM bicine, 25tnM bis-tris, hnM 
EDTA, pH 7.2). Regarding the PVDF metnbrane it tnust be kept in ethanol for 30 
seconds before soaking in transfer buffer. On the top of the anode plate a sandwich 
of sponge/ filter paper/ gel/ PVDF tnetnbrane/ filter paper/ sponge was constructed, 
and inserted in a transfer tank (Invitrogen) filled with transfer buffer. Transfer was 
achieved by electroblotting for 2 hours at 30V. Then the transfer tnembrane was 
washed in deionised water and placed in 1 0 mL blocking solution (Invitrogen Ltd, 
UK) for at least 30 tninutes at RT. After blocking the non-specific binding sites, the 
PVDF tnembrane was washed in deionised water and then incubated with primary 
antibody (R&D, cat. MAB 675). After washing as above, secondary anti-tnouse 
antibody (anti-species IgG) conjugated with alkaline phosphatase (Invitrogen, 
W esternBreez, cat WB71 04) was then added and incubated for I hour. Ready to use 
chen1iluminescent substrate (CDP-star, Invitrogen) was then blotted over the 
tnetnbrane for about 5 tninutes. To visualize the bands the tnetnbrane blots was 
covered with a transparent clean plastic sheet and exposed to X-ray fihn 
luminography (15-25 minutes). 
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2.8.6 IGFBP-1 binding and molecular weight verification 
Serial dilutions of nonnal serum samples showed that 1 :8 dilution in PBS was 
optimal for visual bands of phosphorylated IGFBP-1 (piGFBP-1) and non-
phosphorylated IGFBP-1 (npiGFBP-1). The tnolecular weight of IGFBP-1 is 25-28 
lcDa. The correct location ofthe IGFBP-1 on the gel was confinned by using a scaled 
tnolecular weight reference ladder (MagicMark, Invitrogen, cat. LC5602). For the 
correct location of the npiGFBP-1 band a standard of rhiGFBP-1 (R&D, cat. 871-
B1) was used. For clear observation of the rhiGFBP-1 band a concentration of 125 
J.tg/L was used. This rhiGFBP-1 is tnainly non-phosphorylated and migrated parallel 
to npiGFBP-1 (---28 lcDa) (Figure 2.4). Sennn IGFBP-1 immunoblotting revealed 
two bands of a single npGFBP-1 and piGFBP-1 forms of species but the later one 
was the predmninant band and had a faster 1nobility as described by Westwood et al., 
(Westwood et al., 1994). A gradation in intensity of the IGFBP-1 band (Figure 2.5), 
which correlated with the concentration of IGFBP-1 in a cmnmercial quality control 
sample (kindly provided by Diagnostic System Laboratories, UK) after serial dilution 
in satnple diluent (0.1% BSA diluted in PBS) was observed. Using a video-based 
cmnputerized densiton1etry (MCID image analyzer, InterFocus, Cambridge 
England), the relative optical density (ROD) of the IGFBP-1 bands were detennined 
and plotted against IGFBP-1 concentrations. The resulting standard curve is shown 
in Figure 2.6. 
2.8.7 Crossreactivity with different IGFBP-1 forms using WLB 
To investigate the possibility of R&D anti-IGFBP-1 antibody (catalogue number. 
MAB 675) cross-reacting with different fonns of IGFBP-1 norn1al hun1an serum 
sample (pooled sample) was applied on SDS NuPage after it has been 
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dephosphorylated by alkaline phosphatase and immunoprecipitated by anti-
phosophoserine antibody (Figure 2.7). The figure reveals that R&D monoclonal 
anti-human IGFBP-1 antibody binds to both forms of IGFBP-1 but more intensely to 
npiGFBP-1 than piGFBP-1. 
npiGFBP-1 __. 
piGFBP-1 __. 
2 3 4 
+-- 30 kDa 
+- rhlGFBP-1 
+-- 20 kDa 
Figure 2.4: IGFBP-1 expression in serum samples using Western ligand blotting and 
prepared by using 2-mercaptoethanol (I 0%) as a sample buffer: !.Sample (I :8 
dilution) 2. Same sample (1: 16 dilution) 3. Ladder (molecular weight 20 and 30 kDa) 
4. Recombinant human insulin like growth factor binding protein 1 (rhiGFBP-1 ). 
Key: npiGFBP-1, nonphosphorylated IGFBP-1; piGFBP-1, phosphorylated IGFBP-
1. 
62 
2 3 4 5 6 
npiGFBP-1 ---+ 
piGFBP-1 ---+ 
Figure 2.5: IGFBP-1 exprssion after Western ligand blotting using a serial dilution 
for IGFBP-1 quality control sample prepared using 2-mercaptoethanol (10%) as a 
sample buffer: 1) 412 JJ.g!L 2) 206 JJ.g/L 3) 103 JJ.g/L 4) 51.5 JJ.g!L 5) 25.8 JJ.g!L and 6) 
12.9 JJ.g!L. Key: npiGFBP-1, nonphosphorylated IGFBP-1 ; piGFBP-1 , 
phosphorylated IGFBP-1. 
2.5 
2.0 
1.5 
ROD 
1.0 
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/ 
ｾ＠
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0 100 200 400 
IGFBP-1 (p&IL) 
Figure 2.6: Standard curve for ligand plot analysis of IGFBP-1. Sample was applied 
to 12% Bis-Tris polyacrylamide gel. IGFBP-1 semi-quantitation was determined 
using Relative Optical Density (ROD) of each band. The curve shows good linearity 
between 12.9 - 1 03 JJ.g/L JGFBP-1. 
1 2 3 
30kDa---+ 
20kDa---+ 
4 5 
+-- npiGFBP-1 
+-- piGFBP-1 
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Figure 2.7: IGFBP-1 expression by Western ligand blot using R&D anti-human 
IGFBP-1 antibody (catalogue number. MAB 675) and LOS (Lithium Dodecyl 
Sulphate) as a sample buffer: 1. rhiGFBP-1 2. Ladder (molecular weight 20 and 30 
kDa) 3. Normal human serum (pooled) 4. Serum after precipitation by 
antiphosphoserine antibody 5. Serum after dephosphorylation by alkaline 
phosphatase. Key: npiGFBP-1 , nonphosphorylated IGFBP-1; piGFBP-1 , 
phosphorylated IGFBP-1. 
2.9 Characterisation of R&D anti-human IGFBP-1 using ELISA 
2.9.1 IGFBP-1 ELISA protocol 
The protocol and concentrations followed m the IGFBP-1 ELISA were as 
recommended by the R&D antibody kit insert (cat. MAB 675). Briefly the two steps 
ELISA assay using anti-human IGFBP-1 (Figure 2.8) was carried out as follows; 96-
well (Nunc, cat. 820848, Denmark) plates were coated with 100 tJ.L of R&D anti-
human antibody, catalogue number MAB 675, (4 J..lg/mL) diluted in PBS. After an 
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overnight incubation, the plates were washed (x6) using 300 ｾｴｌ＠ of 0.05% Tween-20 
diluted in PBS at pH 7.4. Wells were then blocked for minimmn of one hour with a 
blocking solution (5% Tween-20, 5% sucrose and 0.05% NaN3 dissolved in PBS). 
After washing step (x6) 100 ｾｌ＠ of standards rhiGFBP-1 (R&D, catalogue number. 
871-Bl) using lowest to highest standard values (0.01, 0.64, 0.125, 0.25, 0.50, 1.0 
and 2.0 ｾｧＯｌ＠ diluted in PBS, 0.1% BSA) and serum samples (1 :20 v/v diluted in 
PBS, 0.1% BSA) were added, followed by plate incubation for 2 hours at room 
tetnperature. After further washing step R&D biotinylated anti-human IGFBP-1 
antibody was then added to each well at a concentration of 200 ｾｧＯｌ＠ (diluted in PBS, 
0.1% BSA and 2% heat-inactivated normal goat serum, Sigma catalogue nmnber. 
09023, at pH 7.3) and incubated for 2 hours at romn temperature. After washing the 
plate as above, 100 ｾｌ＠ of streptavidin horse-radish peroxidase (R&D cat. DY998) 
was then added to each well and incubated for a further 20 n1inutes. Substrate 
solution tetratnethylbenzidine (TMB) containing hydrogen peroxide (H20 2) (R&D 
cat. DY999) was then added to each well and the plate incubated for a further 20 
tninutes at romn temperature. The reaction was stopped by addition of 1M sulphuric 
acid (50 flL/ well). Using a microplate reader (Multilabel Counter VICTOR model 
1420 from PerkinElmer, UK), the optical densities were read at two wavelengths and 
then the corrected optical density was calculated by subtracting absorbance at 540 
nm frotn absorbance at 450 nn1. A calibration curve was generated using GraphPad 
Pristn v5.01 {Figure 2.9). 
2.9.2 Sensitivity and reproducibility 
The lower lhnit of detection was 0.01 ｾｧＯｌ＠ as determined by tnean plus 2SD of the 
blank satnple (PBS, 0.1% BSA) run ten thnes. Within-run hnprecision was estitnated 
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by five titnes repeating analysis of three satnples with different concentrations 
(Table 2.3). The coefficient of variation (CV) ranged from 5.0 to 7.0 %. Between-
run itnprecision was calculated by observing data for 3 samples in duplicate wells 
over 5 assays and ranged frmn 8.9 to 9.1 %. 
2.9.3 Linearity and recovery 
For linearity studies, a patient's sample with a known high value was diluted to tnake 
five pools [Pool 1 = 0% : sample diluent (0.1% BSA in PBS); Pool 5: neat smnple 
only; Pool 2 = 25% : mixture of 3 volmnes Pool 1 plus 1 volume Pool 5; Pool 3 = 
50% : tnixture of2 volumes Pool 1 plus 2 volumes Pool 5; Pool4 = 75%: tnixture of 
1 volmne Pool 1 plus 3 volumes Pool 5]. The tnean of each sample assayed in 
triplicate was plotted against the obtained percentage after dilution. The linear trend 
relationship was observed to be ahnost cmnpatible to the linear trend of .zero 
intercept (Figure 2.10). 
Linearity was also investigated in 3 individual serum satnples with varying 
concentrations of IGFBP-1. The recovery after correcting for dilution ranged frmn a 
minimum of91% to a maximum of 127% (Table 2.4). 
Percentage recovery was estimated by adding known amounts of rhiGFBP-1 to 4 
senun satnples with different estitnated concentrations of IGFBP-1. Percentage 
recovery after adding rhiGFBP-1 was calculated after correction for dilution as 
shown in the Table (Table 2.5). 
IGFBP-1 Biotinylated Ab (R&D) 
TMB substrate 
+ 
Streptavidin-HRP 
0 
Colour 
(product) 
IGFBP-1 Capture Ab (R&D) 
Figure 2.8: The IGFBP-1 two steps sandwich ELISA using anti-human IGFBP-1 
(R&D) as a capture (cat. MAB 675) and labelled antibodies (R&D cat. BAF871). 
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Beat-fit values 
Slope 
Y-intercept w henX•O.O 
X-intercept w hen Y•O.O 
1.109 :t 0.01268 
-0.003252 :t 0.01035 
0.002933 
0.0 
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 
rhiGFBP-1 (IJg/L) 
Figure 2.9: IGFBP-1 ELISA standard curve using GraphPad Prism v5.01 software. 
The curve shows the absorbances of serially diluted standard (rhiGFBP-1). 
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2.9.4 Interferents 
In order to investigate possible interference by bilirubin and haetnoglobin in the 
IGFBP-1 ELISA, four samples obtained frmn nonnal individuals with different 
concentrations of IGFBP-1 (6.0 , 3.0, 1.8 and 1.5 j.!g/L) were diluted using a diluent 
consisting of 0.1% BSA in PBS without the addition of haemoglobin or bilirubin. 
Three different aliquots from each of the four samples were then prepared. A known 
amount of different interferent standards (bilirubin or haemoglobin) were added to 
each of the aliquots using equal volumes. The effect of each different standard of 
bilirubin or haetnoglobin on each of the three aliquots of the four different san1ples 
then was esthnated by tneasuring the final concentration ofiGFBP-1. 
2.9.4.1 Bilirubin interference 
Standards frotn human conjugated bilirubin were prepared frmn Sigma-Aldrich 
Chetnicals, catalogue nmnber. B4126. Due to the water insoluble nature of bilirubin 
the high standard (340 ｾｵｮｯｬＯｌ［＠ assmning a molecular weight of 584.7) was prepared 
using, 2 mL of dimethyl suphoxide and 0.5 ml of 0.4 M NaOH adding the required 
weight of bilirubin and shaking vigorously in dim light until the bilirubin had 
dissolved. To obtain different concentrations of bilirubin (85 and 170 j.!mol/L) the 
highest standard (340 j..ltnol/L) was serially diluted using the diluent (0.1% BSA, 
PBS). These concentrations of bilirubin standards were selected to be higher than 
that nonnally present in human serun1 (< 17 ｾｵｮｯｬＯｌＩＮ＠ At concentration of 170 
ｾｵｮｯｬＯｌ＠ of added bilirubin the absorbance of the IGFBP-1 concentration started to be 
significantly decreased by> 20% (p < 0.05) (Figure 2.11, A). 
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2.9.4.1 Haentoglobin interference 
The human haen1oglobin standards were prepared from Sigma-Aldrich Chemicals, 
catalogue nmnber. H7379. The high standard of haetnoglobin (0.6 g/dL) was 
prepared using the required weight in grams. The haemoglobin highest standard was 
diluted using 0 diluent to achieve final concentrations of 0.3 g/dL and 0.15 g/dL. 
These concentrations of haemoglobin standards were selected to be higher than that 
normally present in hun1an serun1 (0.16 g/dL). At concentration of 0.15 g/dL of 
added haemoglobin the absorbance of the IGFBP-1 concentration increased 
significanly by approximately 30% (p < 0.05) (Figure 2.11, B). 
2.9.5 Crossreactivity with different IGFBP-1 forms 
There is no available piGFBP-1 standard material, therefore R&D anti-IGFBP-1 
antibody crossreactivity with different phosphorylated forms using ELISA was 
evaluated by the following techniques: 
i) Sa1nple dephosphorylation: 
Preferential binding of the capture antibody (R&D, catalogue nmnber. MAB 675) to 
the different fonns of phosphorylated IGFBP-1 was estimated in 8 serun1 samples 
before and after pretreatlnent with alkaline phosphatase using the ELISA (section 
2.9.1). IGFBP-1 tnean concentrations± SD before (1.30 ± 0.29 ｾｴｧＡｌＩ＠ and after (3.61 
± 0.64 ｾｧＯｌＩ＠ enzytne treatment was significantly increased (p < 0.01). This increase 
in concentration was almost 300% of that prior to treatment with alkaline 
phosphatase. 
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ii) Total IGFBP-1 
IGFBP-1 phosphorylation can significantly alter its immunoreactivity with the 
capture antibody and thus the apparent final IGFBP-1 concentration. Therefore, an 
ELISA imtnunoassay was developed by Diagnostic Systems Laboratories (DSL) to 
tneasure the total IGFBP-1 (Khosravi et al., 1997). This itntnunoassay utilizes a 
particular capture detection antibody that can bind the total IGFBP-1 circulating in 
different human fluids, including sermn, without preferential binding to specific 
forms of IGFBP-1. Compared to the total IGFBP-1, the concentrations of less-
phosphorylated or nonphosphorylated fonns were lower in values as reported in 
previous studies (Heald eta!., 2002; Khosravi eta!., 2007; Khosravi eta!., 1997). 
Therefore we carried out the following experitnent of crossreactivity by using a 
cmntnercial ELISA kit to estitnate the total IGFBP-1 concentration (Diagnostic 
Systetn Laboratories, cat. DSL-1 0-7800). This kit was designed by Khosravi eta!., in 
1997 as described before. They found a significant correlation between total and 
piGFBP-1 in serum (r = 0.99, p < 0.001) (Khosravi et al., 2007). Therefore, we used 
twelve serum samples to confirm this observation. The tnean (± SD) value of 
IGFBP-1 tneasured by our in-house assay using R&D capture antibody was 
significantly lower in concentration (10.6 ± 2.9 J!g/L) than total IGFBP-1 (36.4 ± 9.1 
J!g/L) and p < 0.01. In spite of the different tneans, strong association between the 
obtained values frotn the two itnmunoassays was observed (r = 0.82, p < 0.001) and 
regression square linear= 0.79. 
iii) Normal circulating levels 
Normal levels in circulation of total IGFBP-1 ranged frmn 0 - 100 flg/L (Rutan en 
and Pekonen, 1991). In view of this fact, our ELISA using R&D anti-IGFBP-1 
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antibody which has linear range up to 2 flg/L was considered inappropriate for total 
IGFBP-1 assesstnent. Senun satnples were diluted (1 :20 v/v diluted in PBS, 0.1% 
BSA) before the ELISA and therefore, tnost of the serum samples results were within 
the standard range of 0.01 - 0.5 f..Lg/L while few other samples required further 
dilution using a higher standard range (1.00- 2.00 ｾｴｧＯｌＩＮ＠ The reason for using this 
relatively high initial dilution (1 :20 v/v) factor was to limit the necessity for 
reanalysis due to the lhnited availability of serum volutnes. Furthermore the assay 
characteristics (i.e. sensitivity, specificity, linearity and reproducibility) were 
obtained using the satne dilution factor (1 :20 v/v). 
In conclusion regarding R&D anti-hmnan IGFBP-1 crossreactivity, the antibody 
preferentially binds to npiGFBP-1 and lpiGFBP-1 rather than highly phosphorylated 
piGFBP-1 or total IGFBP-1. In the technique of WLB and after dephosphorylation 
by alkaline phosphatase the observed and disappeared bands of npiGFBP-1 and 
piGFBP-1 respectively was evidence of binding to both phosphorylated and 
nonphosphorylated IGFBP-1 bands. Preferential binding to non- and less-
phosphorylated forn1 was confinned by using the ELISA technique. As in case of 
antibody binding to the total IGFBP-1, levels of IGFBP-1 should remain constant 
before and after satnple dephosphorylation (Khosravi et al., 1997) while in case of 
predmninant binding to piGFBP-1 the levels of IGFBP-1 should be decreased after 
satnples dephosphorylation (Khosravi et al., 2007). Therefore, the increased 
concentrations of IGFBP-1 after dephosphorylation found in this study suggests that 
the capture R&D antibody is specific for non- and less-phosphorylated IGFBP-1 
rather than highly phosphorylated or total IGFBP-1. 
Table 2.3: Precision study (%CV) of the IGFBP-1 ELISA using three samples 
(duplicate) run five times with three different concentrations 
Sample 
Within assay x 5 
Between assays x 5 
100 
ｾ＠ 90 
; so 
il :: 
c:! !it so 
0 ":1 -40 
u 0 ｾＭ
'ti 30 
u 20 
tJ 
ｾ＠ 10 
% 
Trend line (-): 
y • 85.603x- 2.0772 
R: • 0 .9961 
II 
III 
1 
II 
III 
Mean (J.tg/L) 
1.26 
4.2 
23.2 
1.26 
4.8 
24.9 
SD 
0.06 
0.3 
2.3 
0.12 
0.5 
2.3 
%CV 
5.0 
7.0 
7.0 
8.9 
9.1 
9.1 
• Pool 5 
100% 
Trend line(---) 
lntHCtpt set as nro: 
y• 83.263x 
R: • 0 .995 
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Figure 2.10: IGFBP-1 ELISA linearity validation study using five pools of different 
serum dilutions, as indicated on the graph. Pool I: 0% (sample diluent); Pool 5: neat 
sample only; Pool 2: 25% (mixture of 3 volumes Pool 1 plus 1 volume Pool 5); Pool 
3: 50% (mixture of 2 volumes Pool 1 plus 2 volumes Pool 5); Pool 4: 75% (mixture 
of 1 volume Pool I plus 3 volumes Pool 5). The solid line (-) indicates the original 
trend of the diluted samples after using a different ratio of Pool 1 and Pool 5. The 
dotted line ( ---) indicates the same trend line but with the intercept set as zero. 
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Table 2.4: Linearity study of IGFBP-1 after dilution. Three serum samples with 
different levels ofiGFBP-1 were diluted using 0.1% BSA in PBS as a diluent. 
Expected Observed Reco-
Sample Dilution IGFBP-1 IGFBP-1 very 
ＨｾｧｩｌＩ＠ ＨｾｧｩｌＩ＠ (%) 
0.25 
1 part of observed IGFBP-1 (0.25 ｾｧｩｌＩ＠ + 1 part diluent 0.13 0.12 98 
1 part of observed IGFBP-1 (0.25 ｾｧｩｌＩＫ＠ 3 part diluent 0.06 0.06 101 
n 0.19 
1 part of observed IGFBP-1 (0.19 ｾｧ Ｏ ｌＩ＠ + 1 part diluent 0.09 0.12 127 
1 part of observed IGFBP-1 (0.19 ｾｧｩｌＩＫ＠ 3 part diluent 0.05 0.05 105 
III 0.13 
1.5 part of observed IGFBP-1 (0.13 ｾｧｩｌＩ Ｋ＠ 1 part diluent 0.09 0.08 91 
1 part of observed IGFBP-1 (0.13 ｾｧｩｌＩ Ｋ＠ 1 part diluent 0.07 0.06 92 
The percentage recovery was estimated by calculating the ratio between the observed 
and the expected values multiplied by 100. The expected value was calculated by 
using the original observed value on the same sample divided by the new dilution 
factor. 
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Table 2.5: Percentage recovery of IGFBP-1 after adding different amounts of 
rhiGFBP-1 to four serum samples with different original concentrations ofiGFBP-
1. 
Endogenous Added Expected* Observed Recovery 
Sample IGFBP-1 rhiGFBP-1 IGFBP-1 IGFBP-1 (%) 
(J.lg/L) (J.lg/L) (J.lg/L) (J.lg/L) 
0.07 0.031 0.039 0.04 97 
0.125 0.063 0.08 129 
0.5 0.092 0.12 133 
II 0.27 0.031 0.14 0.14 101 
0.125 0.164 0.19 113 
0.5 0.25 0.22 86 
III 0.38 0.031 0.197 0.21 107 
0.125 0.221 0.26 117 
0.5 0.25 0.28 113 
IV 0.61 0.03 0.31 0.33 108 
0.13 0.38 0.36 93 
0.5 0.6 0.45 74 
*The expected concentration of IGFBP-1 was calculated by dividing the total 
absorbance (abs. of endogenous IGFBP-1 + abs. of added rhiGFBP-1) by 2 (the 
varying concentrations of rhiGFBP-1 were added in each serum sample as a 
diluent). The percentage recovery was calculated by taking the ratio of the observed 
and expected values multiplied by 100. 
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Figure 2.11: Effects of interferences on ELISA of IGFBP-1 concentration. Mean 
concentration of IGFBP-1 after adding blank (0.1% BSA, PBS) in four sermn 
samples compared to tnean concentrations of IGFBP-1 after adding the san1e volume 
of different known amounts of interferent substance in the same four smnples (A) 
Effect of bilirubin; *p < 0.05 at a concentrations 170.0 ｾｵｮｯｬＯｌ＠ or higher (B) Effect 
ofhaen1oglobin; *p < 0.05 at a concentrations 0.15 g/dL or higher. 
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2.10 Statistical analysis 
Statistical analyses were perfonned using SPSS 15 (PC Inc., Chicago, IL, USA) in 
n1ost cases. In addition, other Windows software was used as demanded by the 
nature of study as described and listed below: 
i) Reproducibility of insulin sensitivity (Si) & its assessment in lean and 
obese subjects using two different protocols and software 
For triplicate tneasuretnents tnade during FSIVGTT, the intra-individual coefficient 
of variation (CV) was calculated classically by dividing the standard deviation (SD) 
by the n1ean of the triplicate readings in the satne subject. The average CV was 
calculated as the 1nean CV for the 4 subjects. Comparisons of the tneans were 
perfonned using Mann-Whitney and paired student's t-tests. The Si and log-
transformed Si paratneters were subjected to analysis of Spearn1an's and Pearson's 
correlation coefficients respectively. Comparison of the two protocols was based on 
the Bland and Altman (Bland and Altman, 1986) graphical approach using MedCalc 
statistical software version 10. P-values were obtained frmn two-sided t-tests. The 
sample size was estimated to have 80% power at p = 0.05 to calculate the effect size 
between the two groups detected by Araujo-Vilar et al., (Araujo-Vilar et al., 1998). 
Data are reported as tneans ± standard error of tnean (SE) unless otherwise indicated. 
ii) IGFBP-1 and other sintple indices reproducibility 
Mann-Whitney and Student's tests were used to compare tnean values between both 
visits. For the longer-term interval IGFBP-1 coefficient of variations were calculated 
using the tnodified method of paired satnples (Raggatt, 1989) as described below: 
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The standard deviation (SD) for each pair is the difference between the two values 
(d) divided by the square root of 2. 
d 
SD=-
.fi 
The tnean SD then can be derived frmn the cmnbined SD values. Where n is the 
number of pairs. 
ｾｌ ＱＱ＠ SD( + SDj + ... SDJ 
mean SD = n-l 
The mean within subject CV is the 1nean SD divided by the tnean X of all pooled 
results frmn the two occasions. 
For the short-tenn interval, the intra-individual CV was calculated classically by 
dividing the standard deviation by the tnean of the four readings in the satne subject. 
In each glycaetnic category the average CV was calculated as the n1ean CV for all 
individuals. Data correlations were calculated by Speannan's tnethod. Data are 
expressed as mean ± SE or unless otherwise mentioned. 
The tnethod of calculation of biological (%CVb) and analytical (%CVa) variations 
was described previousely in Chapter I (section 1.7.1). 
--------------------------------------------- --
77 
iii) IGFBP-1 as a marker of insulin resistance 
Data were transfonned using natural Logarithm (Ln) to approxi1nate a normal 
distribution. Cotnparisons between different 1neans were by Student's t-test and data 
correlation before and after Ln-transfonnation were examined using Speannan's and 
Pearson's correlation coefficients respectively. Data were expressed as Ineans ± SD. 
iv) Insulin resistance in Saudi and Caucasian populations 
Due to deviation from nonnal distribution HbAlc, IGFBP-1, insulin and all other 
insulin sensitivity indices were log-transforn1ed before analysis. Student's paired, 
unpaired and Mann-Whitney t-tests were used. The sample size of 80% power with 
5% significance was esthnated to have the same sizes of effect detected by Araujo-
Vilar et al (1998) and Liew et a/., (2005) (Araujo-Vilar et al., 1998; Liew et al., 
2005). Area under the curve for glucose (AUC glucose) was calculated by the 
trapezoid rule frmn 0 to 10 tnin after glucose injection. Data were expressed as 
means ± SD or with 95% Confidence intervals (Cl). 
v) Different fornts ofiGFBP-1 in subjects with and without IHD 
Statistical significance was done by using Student's unpaired and Mann-Whitney t-
tests. Association between paratneters was perfonned using Speannan's coefficient. 
Analyse-it v2.12 software was used to study receiver-operating characteristic (ROC) 
and to estimate the optin1al cut-off points in addition to area under the curve (AUCs). 
A p-value of< 0.05 was considered statistically significant. Data were reported as 
1nean ± SE or with 95% Confidence intervals (CI). 
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Chapter 3: 
The assessment of insulin sensitivity and its reproducibility 
in lean and overweight subjects using two different 
protocols and minimal model software 
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3.1 Introduction 
The frequently-sampled intravenous glucose tolerance test (FSIVGTT) represents a 
relatively sitnple alternative to the clan1p technique (Bergman et al., 1979; DeFronzo 
et a!., 1979) for the assesstnent of insulin sensitivity. In Chapters 1 and 2 the 
comtnonly used techniques for estimating insulin resistance and the available 
FSIVGTT software have been reviewed. The standard FSIVGTT is one of the 
FSIVGTT protocols, which is detnanding and requires tnultiple blood samples to be 
collected. This protocol depends on the release of endogenous insulin after it has 
been stitnulated by exogenous intravenous glucose. Therefore the standard FSIVGTT 
is suitable for those individuals who have sufficient endogenous insulin secretion. 
The standard FSIVGTT should be distinguished from the tolbutatnide and insulin 
modified protocols which are better suited for studying subjects with poor glucose 
tolerance or diabetes (Finegood et al., 1990; Yang et al., 1987). The FSIVGTT 
protocol can be simplified by reducing the number of satnples. This short protocol is 
simpler and therefore better suited for epidemiological studies when a large number 
of subjects tnay need to be recruited (Steil et al., 1994). 
In the study described below we have investigated insulin sensitivity (Si) in lean and 
obese individuals using the full and short protocols and analysed the results using 
two different software packages. In addition to this the intra-individual 
reproducibility was evaluated to determine the variance in the Si fron1 data obtained 
using the standard FSIVGTT. In 1994 the only report available on Si reproducibility 
of the standard FSIVGTT using duplicate values of Si used the older version of 
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Minmod software (Duysinx et al., 1994). In view of the availability of upgraded 
software it was considered timely to re-evaluate intra-individual variation of Si. 
The goal of the work presented here was to detennine the validity of reproducibility 
of the Si paratneter derived frmn the standard FSIVGTT with both full (29 samples) 
and short (12 samples) protocols and by analysing the satne data using two updated 
analysis software programmes. The Mimnod Milletmium version 6.02 was released 
in 2003 while COMAL 3.11 was released in 2002. Given this relatively short interval 
between availability of the two software packages we considered that such a 
dedicated study directly cmnparing the two packages will be of interest to FSIVGTT 
technique users and an itnportant addition to the literature in this area. In this study 
we siinply present our observations as regular program operators and are not 
inventing any new tnethodology or editing equations. 
3.2 Subjects and methods 
3.2.1 Subjects 
The standard FSIVGTT was carried out on four healthy tnales of normal glucose 
tolerance age 40 ± 4. 7 years (1nean ± SE) with 1ninimum and tnaxitnmn body tnass 
index (BMI) frotn 19.3 to 33.2 kg/n12 whose nonnal daily physical activities ranged 
from low to high on questioning. FSIVGTT was perfonned on three occasions for 
three subjects and on two occasions for the fourth subject. A further 1 7 normal 
subjects (9 males, 8 females) were recruited separately for single FSIVGTT 
1neasure1nent. Age and BMI for lean (::; 25 kg!tn2) and overweight (> 25 kg!tn2) 
subjects were (34.2 ± 2.5 years; 21.1 ± 0.5 kg/m2) and (47.5 ± 2.8 years; 30.7 ± 0.8 
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kg!tn2) respectively. All subjects had a standard 75g oral glucose tolerance test 
before participation. All tests were separated by an interval of approximately one 
week for the purpose of assessing FSIVGTT reproducibility and 10 days for other 
subjects involved in the study. Participants were instructed to eat an unrestricted diet 
and to avoid changing their daily activities, lifestyle, exercise and eating patterns 
frmn one week preceding the first blood test until cmnpletion of the study. Subjects 
were excluded frmn the study if they were under treatment with steroids or any other 
tnedication. The study was approved by the South West Surrey Local Research 
Ethics Cmnmittee (LREC) of Royal Surrey County Hospital, Guildford, UK. 
Informed written consent was obtained frmn all subjects prior to participation. See 
Chapter 2 (section 2.4) for tnore details about assays used for tests analysis (glucose 
and insulin). 
3.2.2 FSIVGTT and software pacl{ages 
The standard FSIVGTT was carried out as described in Chapters 1 and 2 (sections 
1.5.1.2 and 2.6) for the full and short protocols. For the short sampling protocol 12 
smnples were selected at different titne intervals: 0, 2, 4, 10, 16, 22, 30, 50, 70, 90, 
120 and 180 minutes. This selected thne scale was the smne as previously described 
by Duysinx eta!., and the reason for this was for the purpose of study comparison 
(Duysinx et al., 1994). Dataset analysis was carried out using two different software 
packages viz COMAL 3.11 (IS_CIBA program) (Mehring eta!., 2002) and Minmod 
Millennium 6.02 (Boston et al., 2003). The characteristics of each software package 
are listed in Table 3.1. More detail on Mimnod Millennimn has been provided in 
section 2.6. The COMAL 3.11 programtning system is made by UniCotnal A/S, H.J. 
Holst Vej SA, SK-2605 Brondby. Mehring created COMAL 3.11 based on the 
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tninitnal model assumption. This software can be used to estitnate insulin resistance 
and glucose effectiveness by itnplementing Quardts' s algorithtn and using integration 
of the differential equations performed by a Raunge-Kutta procedure with a variable 
step-size. The COMAL 3.11 program-version used in our study became available 
free of charge and has been widely used by other studies (Jolly et al., 2003; Kousta et 
al., 2003). An example ofCOMAL plot report can be shown in Figure 3.1. 
3.3 Results 
3.3.1 Si reproducibility comparison between full and short protocols 
Means and CVs for the 11 tneasurements of Si using both full and short protocols 
determined using two different software packages are shown in Table 3.2, A and B. 
The mean Si calculated from the 12 sample (short protocol) using COMAL was not 
significantly different frmn Si calculated from the 29 sample (full protocol) (p = 
0.65). Correlation analysis indicated a slope of 0.95 and intercept of 0.44 with r = 
0.99. The average relative error (RE) ± SD in Si (RE = 100 x [Si (29)- Si (12)] /Si 
(29) was -16 ± 33 but was not significantly different frmn zero (p = 0.41). This 
indicates that there was no systematic deviation in Si between the two protocols 
calculated using COMAL software, but surprisingly the observed intra-individual 
%CV ± SE was reduced using the 12 sample protocol than the full protocol as shown 
in Table 3.2, A. 
Minmod Millennium software was used to analyse the satne data (Table 3.2, B). The 
tnean Si calculated fron1 the short protocol was not statistically different frmn Si 
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calculated frmn the full protocol (p = 0.26). Correlation analysis indicated a slope of 
1.18 and intercept of0.92 with r = 0.99. The average relative error RE (-2.11 ± 12.4) 
was not significantly different frmn zero (p = 0.76). 
3.3.2 Cmnparison of Si between lean and overweight subjects 
The 1nean Si in lean and overweight subjects was calculated using full and short 
protocols by COMAL and Minmod Millenniutn (Table 3.3). As expected the Si was 
significantly lower (p < 0.001) in overweight cmnpared to lean subjects using the 
standard protocol data in both software packages. Similarly with the short protocol, 
Si was significantly lower in overweight compared to lean subjects using both 
software packages (p < 0.001). 
3.3.3 Statistical agreements between full and short protocols ofFSIVGTT 
In correlation analysis of Si values between full and short protocols in lean subjects 
using COMAL software, there was a significant positive correlation (r = 0.98, p < 
0.001). This correlation was less strong in overweight subjects (r = 0.89, p < 0.001) 
(Fgire 3.2, A). 
When using Mimnod Millennimn, the correlation in Si between full and short 
satnpling protocols was strongly associated in lean compared to overweight subjects 
(r = 0.99, p < 0.001) and (r = 0.85, p < 0.001) respectively (Figure 3.2, B). 
Confinnatory analysis was perfonned to assess agreetnent between the two protocols 
using a Bland-Altman plot. The agreetnent assessments between the two protocols 
using COMAL and Mimnod Millennium are represented in (Figure 3.3, A) and 
(Figure 3.3, B) respectively. 
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Table 3.1: Comparison between Minmod Millennium and CO MAL software 
packages. 
Characteristic Minmod Millennium 6.02 COMAL3.11 
Source Minmod Millennium is an Independent software written 
updated version of Minmod by Mehring et. , el to derive 
series released (Bergman et estimates of insulin sensitivity 
a!. , 1979; Boston eta!., 2003; (Mehring et al. , 2002) 
Pacini and Bergman, 1986) 
Software Widows-based DOS and Windows-based 
Default zero weights 8 min (adjustable) 5 min (adjustable) 
Time for analysis 5-30 seconds 2-5 min 
Failure rate of fitting 3% 15-20% 
Graphics Colour Colour or black and white 
Operator intervention Minimally required Required 
Cost Needs to be purchased Available free of charge 
Methods of computation 
Iteration procedure Marquardt' (non-linear Marquardt' (non-linear 
least squates estimation) least squates estimation) 
Integration procedure Runge-Kutta Runge-Kutta 
Modified virtues -Automatic estimation of -Adhere to minimal model 
initial values. assumption but based on 
-Baseline correction algorithm examining the univariate and 
-Robust numberical integrator multivariate techniques. 
-Further differential equation 
was introduced 
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Figure 3.1: Example of the graphic presentation of the results for a plot diagram 
using standard FSIVGTT. The parameters of insulin sensitivity (Si) and glucose 
effectiveness (Sg) were derived using COMAL software from the full protocol. Key; 
P2, the removal rate of insulin from the interstitial space; P3, the movement of 
circulating insulin to the interstitial space; GO, distributed glucose concentration at 
time 0; SSE, sum of square error or residual error. Remote insulin: the estimated 
plasma concentration for insulin. 
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Table 3.2: Means and CVs (%) for insulin sensitivity parameter (Si) derived from 
frequently sampled intravenous glucose tolerance (FSIVGTT) test. The test was 
performed in triplicate on three healthy subjects and duplicate on the 4th subject. The 
Si parameter derived from analysis of the full (29 samples) and short (12 samples) 
protocols using COMAL 3.11 CIBA (A) and Minmod Millennium 6.02 software (B). 
Si (10-4min -1[pmoiiLr1) 
A Full protocol Short protocol 
(COMAL) (CO MAL) 
Subject Mean CV(%) Mean CV(%) 
1 (x3) 0.80 51.3 1.34 18.9 
2 (x3) 6.40 9.8 6.44 8.3 
3 (x3) 7.39 8.5 7.31 15.8 
4 (x2) 15.50 3.6 15.25 11.6 
Mean 6.80 18.3 6.89 13.7 
SE ± 0.34 ± 11.1 ±0.59 ± 1.9 
Si (10-4min -1[pmol/Lr1) 
B Full protocol Short protocol 
(Millennium) (Millennium) 
Subject Mean CV(%) Mean CV(%) 
1 (x3) 2.11 18.8 1.82 20.0 
2 (x3) 7.28 20.8 7.73 13.7 
3 (x3) 7.91 13.3 7.92 14.5 
4 (x2) 21.65 4.2 25.10 11.3 
Mean 8.65 14.3 9.33 14.9 
SE ±0.65 ± 3.8 ± 0.84 ± 1.9 
SE: Standard error of mean 
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Table 3.3: Si parameters of lean (BMI :S 25) and overweight (BMl > 25) subjects. 
The Si parameter was derived from FSIVGTT analysis of the full and short protocols 
using COMAL and Minmod Millennium software. 
Si (10-4min -1[pmol!Lr1) 
CO MAL Minmod Millennium 
Subjects Full Short Full Short protocol Protocol protocol protocol 
BMI :S 25 (n = 14) 8.57 ± 1.15*** 8.67 ± 1.26*** 11.53 ± 1.75*** 13.22 ± 2.29*** 
BMI>25(n=l4) 2.49 ± 0.45 2.76 ± 0.52 3.75 ± 0.58 3.56 ± 0.65 
Total (n = 28) 5.53 ± 0.84 5.72 ± 0.88 7.64±1.17 8.39 ± 1.49 
Data are expressed as mean ± SE. BMI; body mass index. ***p < 0.001; lean 
subjects (BMI :S 25) vs. obese subjects (BMI > 25). 
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Figure 3.2: Correlation between the log-transformed (Si) parameters using different 
sampling protocols and software packages. A. Correlation between Si parameters 
derived from COMAL software using the full (29 samples) and short (12 samples) 
protocols. B. Correlation between Si parameters derived from Minmod Millennium 
software using the full and short protocols. Solid circles ( •) overweight subjects; 
open circles ( o) lean subjects. 
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Figure 3.3: Differences between the results obtained using two protocols of 
measurement against mean results for the insulin sensitivity (Si) parameter in (A) 
COMAL and (B) Millennium. The Si parameter was calculated using full (29 
samples) or short (12 samples) protocols. Open circles (o) lean subjects (n = 14); 
solid circles (•) overweight subjects (n = 14). 
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3.4 Discussion 
3.4.1 Reproducibility comparison of Si using full and short protocols 
The reproducibility of Si estitnation using either software package did not differ 
significantly between the full and short protocols. Therefore in nonnal individuals a 
short sampling protocol is sufficient where insulin sensitivity (Si) is to be 
detennined. This outcmne confinns previous studies using the FSIVGTT shmt 
protocol (Duysinx eta!., 1994; Steil et al., 1993). From the CV values obtained for 
full and short protocols Mimnod Millennimn showed greater reproducibility of Si 
when cmnpared to the COMAL software package. This is 1nost probably due to the 
new features of Windows based version of Mimnod Millennium which has a more 
advanced algoritlun and tninilnally required intervention. 
3.4.2 Previous reports about Si reproducibility 
The overall observed reproducibility of Si using either software package was very 
close to that reported by other studies where the older version of Bergman's tninilnal 
modeltnethod was used. Duysinx et al, using the standard FSIVGTT and observing 
the variation in duplicate tneasures separated by 1 week in 7 lean subjects reported a 
variability of 16.2% and 19.3% for full and short protocols respectively (Duysinx et 
a!., 1994). Steil et al (1994) used the tolbutatnide-tnodified FSIVGTT and tnade 
triplicate 1neasuren1ents at 4 day intervals in 11 normal subjects. The authors 
reported Si CVs of 20.2% for the full protocol and 27.7% for the short one (Steil et 
a!., 1994). In another study duplicate tolbutatnide-modified FSIVGTT in 8 subjects 
within two days and reported CV of 16.9% (Abbate et al., 1993). In spite of the low 
nmnber of subjects in the study presented here, our estimation of reproducibility is 
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likely to be accurate given the use of triplicate 1neasurements and that the outcmnes 
given by the two different software packages had the satne trends of the Si tneans. 
3.4.3 Means comparison of Si using full and short protocols 
Regarding the mean values of Si frmn both full and short protocols, COMAL was 
observed to yield lower tnean values for all subjects when con1pared to Mimnod 
Millennimn. This could be due to the advanced statistical principle introduced in the 
COMAL programme which is based on univariate to tnultivariate analysis in addition 
to the further differential equation introduced into the software (Mehring et al., 
2002). The observation of higher tnean Si values obtained using the short protocol in 
our study (Table 3.3) was in agreetnent with the previous report of Duysinx et a!., 
using the standard FSIVGTT technique as the Si n1eans (SD) of their lean and obese 
subjects using full protocol were 6.95 ± 1.12 and 2.13 ± 0.42 respectively but after 
using short protocol higher means were obtained (7.97 ± 1.29 and 2.14 ± 0.34 
respectively) (Duysinx et al., 1994). 
Recently the Minmod Millennium software was validated by Smnner and colleagues 
for both the full and shott protocols using the insulin modified FSIVGTT (Sumner et 
al., 2009). They repmted that the percentage of failure of resolution (insulin curve 
fitting failure) of Si by using the short protocol was 3%. Then Smnner et al., 
cmnpared the tertile distribution of Si for each protocol of the FSIVGTT. Si values of 
the involved subjects were grouped into tertiles using both protocols of FSIVGTT 
(full and short). Afterwards, rank order agreetnent for both protocols was assessed 
using percentage agreetnent. Sumner et al., then used the histogran1s of the frequency 
of Si according to FSIVGTT protocol (full and shmt) to represent and con1pare the 
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tertiles. The exact agreement for tertile categorisation was 92% between insulin 
resistant (lowest tertile) and insulin sensitive ( cotnbined middle and upper tertiles ). 
Therefore by using the short protocol in subjects with insulin resistance there was a 
chance of 8% error of misclassification compared to the full protocol. 
Our conclusion stated that the use of short protocol in overweight subjects may lead 
to less precise esthnation of Si. This outcmne was based on our correlation between 
Si's of full and shmt protocols in lean (r = 0.99, p < 0.001) vs. overweight subjects (r 
= 0.85, p < 0.001). The correlation in overweight subjects (higher insulin resistance) 
are still highly significant which 1neans results are mostly accurate but rather less 
accurate than in lean subjects who are less insulin resistant. Therefore, our 
conclusion agrees with the conclusion of Saumner et al., about using short protocol 
of the standard FSIVGTT rather than insulin tnodified technique. 
3.4.4 Si estilnation in lean and overweight individuals 
It was noted that the subjects with high BMI had low Si values using either the full or 
short protocols cmnpared to lean subjects but the correlation between the Si 
parameter obtained from both protocols became weaker in overweight than lean 
subjects. This would tend to increase the likelihood of an error in Si estimation for 
overweight subjects who already have low insulin sensitivity. This outcome is in 
according with the findings of Coates eta/., who have reported that subjects with 
type 2 diabetes had less accurate estitnation of insulin sensitivity (Si) using a short 
protocol (Coates et al., 1993). Therefore the BMI for the first subject (BMI = 33.3 
kg!In2) could be the reason for the poor overall reproducibility for Si derived by both 
software packages. It appears that lower reproducibility is associated with increasing 
93 
BMI (i.e. low insulin sensitivity) but this point needs further confinnation using a 
larger number ofnonnal overweight subjects in such reproducibility study. 
3.5 Conclusions 
By using both software packages COMAL 3.11 and Minmod Millennimn 6.02, a 
simplified standard FSIVGTT protocol (12 samples) in lean subjects provides 
accurate measures of Si that were not systematically different frmn those derived 
frmn the full protocol (29 samples). When compared to COMAL, Minmod 
Millennium shows tnore consistency in reproducibility. However, use of the shmt 
protocol in overweight subjects tnay lead to less precise estimation of insulin 
sensitivity (Si). These findings suggest that where Si is the paran1eter of interest and 
when studying large numbers of normal subjects a simplified FSIVGTT is a suitable 
alternative to the full protocol as this 1nay offer advantages to the researcher in tenns 
of labour intensity and expense. As the work carried out in subsequent chapters and 
investigations involved a nmnber of overweight subjects, the full protocol FSIVGTT 
was chosen. In addition to this Minmod Millenium software was selected to estimate 
the Si parmneter instead of COMAL. This is due to its features including high 
consistency and easy of operation. 
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Chapter4 
Comparative study of the reproducibility of simple methods 
for estimating insulin resistance 
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4.1 Introduction 
The oppmtunity for simple, non-invasive estimation of insulin resistance was made 
possible with the introduction of hmneostasis model assesstnent (HOMA) (Matthews 
et a/., 1985). More recently other indices derived from fasting samples have proven 
to be useful in epidetniological studies. Although a number of studies have compared 
some of the simpler n1ethods for esthnating insulin resistance with reference 
tnethods, data on the precision of these methods especially in subjects with varying 
degrees of glucose tolerance are lhnited (Atabek and Pirgon, 2007; Garcia Cuattero 
et al., 2007; Hennans et al., 1999; Radikova et al., 2006; Sarafidis et al., 2007). 
The ability to assess insulin resistance in the clinical setting would be potentially 
advantageous. At present, the bioche1nical assessment of insulin resistance is largely 
confined to research studies but when it becmnes clinically available then the 
precision of these indices is key requirement for the clinical utility. We supposed 
intra-individual variation of smne indices tnay be largely affected by the tnethod of 
calculation and/or by the stage of the glycaetnic status (Bokemark et al., 2000; 
Matthews et al., 1985; Sarafidis et al., 2007). Poor reproducibility is one of the main 
factors limiting the use of these indices in clinical contexts (Rabasa-Lhoret and 
Laville, 2001). 
In this study we present data on intra-individual reproducibility (within subject 
variation) for seven cotntnonly used indices of insulin resistance and ｾＭ｣･ｬｬ＠ function 
in subjects with a range of glucose tolerance. 
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4.2 Subjects and methods 
4.2.1 Subjects 
In order to study the reproducibility of son1e of the simpler 1nethods for detennining 
insulin resistance, data analysis was carried out on 55 of the study subjects. Of these 
21 had nonnal glucose tolerance (NGT), 10 iinpaired fasting glucose (IFG), 14 
itnpaired glucose tolerance (IGT), and 10 type 2 diabetes (DM). Clinical 
characteristics of the subjects are listed in (Table 4.1). Subjects were between 20 and 
65 years of age with body 1nass index (BMI) > 20 and < 35 kgfln2• Separated by an 
average interval of 10 days, each subject attended the diabetic clinic of King Khalid 
National Guard hospital (Jeddah, KSA) or lipid clinic of Royal Surrey County 
Hospital (Guildford, UK) on two different occasions. 
The glycaemic status of each individual was determined using a standard 75g oral 
glucose tolerance test (OGTT) on the first visit. A further 4 fasting samples were 
collected at 5 n1inute intervals during the second visit. DM subjects had been treated 
by dietary tneans alone and had not previously received oral anti-diabetic 
medications or insulin. None of the subjects were being treated with steroids or 
thyroxine. Participants were instructed to avoid tnodifying their lifestyle, exercise 
and eating patterns frmn one week preceding the first blood test until completion of 
the study. See Chapter 2, sections 2.1, 2.2 and 2.3 for tnore details about preparation 
and sample collection. 
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Table 4.1: Clinical characteristics for subjects in different glycaemic groups 
NGT IFG IGT DM 
(n = 21) (n = 10) (n = 14) (n = 10) 
Male(%) 67 60 79 70 
Age (years) 39.1 ± 14.6 48.3 ± 6.3 53.1 ± 7.7 49.6 ± 10.9 
BMI (kg/m2) 25 .6 ± 4.7 30.8 ± 3.1 30.4 ± 3.1 31.5 ± 3.5 
HbA1c (%) 5.4 ± 0.5 6.1 ± 0.5 5.8 ± 0.8 7.0 ± 1.3 
Average glucose 5.2 ± 0.4 6.1 ± o.5 *** 6.3 ± 0.6··· 7.6 ± 2.2··· 
(mmol/L) 
Average insulin 64.5 98.4 II 0.3 II8.8 
(pmol/L) (55.4 -75.3) (78.5 - I18.4) •• (88.3 - I32.2) ••• (86.2- I51.4)··· 
Data shown are the mean± SD or with 95% Confidence interval. •• p < 0.01 , ••• p < 
0.001: The average of glucose or insulin in NGT (visit 1 plus visit 2) was compared 
to the average of the same parameter in IFG, IGT and DM categories. Key, BMI, 
body mass index; HbA1c, glycated haemoglobin; NGT, normal glucose tolerance; 
IFG, impaired fasting glucose; IGT, impaired glucose tolerance; DM type 2 
diabetes. Comparisons between groups were performed using ANOV A one-way 
analysis. 
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4.2.2 Indices derived fro1n fasting samples and biochemical assays 
Homeostasis n1odel assessment (HOMA) was first described in 1985 (Matthews et 
al., 1985). It was used to assess insulin resistance (HOMA-IR) and ｾＭ｣･ｬｬ＠ function 
ＨｈｏｍａＭｾＩ＠ derived from fasting glucose and insulin concentrations (Table 4.2). 
HOMA version 2.2 is an updated c01nputerised version which can be downloaded 
free of charge (www.dtu.ox.ac.uk) (Wallace et al., 2004). Quantitative Insulin 
resistance check index (QUICKI) takes both logarithn1s and the reciprocal of the 
fasting glucose insulin product (Katz et a!., 2000). Fasting glucose insulin ratio 
(FGIR) was estitnated fr01n fasting glucose and insulin levels (Legro et al., 1998). 
The Raynaud index was calculated fron1 the fasting insulin level using a siinple 
equation (Raynaud et al., 1999). See Chapter 2, section 1.5.2 for tnore details about 
simple indices. 
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Table 4.2: Indices of insulin sensitivity and ｾＭ｣･ｬｬ＠ function with their formulae using 
fasting glucose and insulin levels. 
Index Formula Reference 
P-ce/1 function 
HOMA-P% 20 x fasting insulin (mU/L)/[fasting glucose (mmol/L)- 3.5] (Matthews et al., 
1985) 
HOMA2-P% HOMA2 calculator version 2.2 (Wallace et al. , 
2004) 
Insulin sensitivity indices 
HOMA-IR 
HOMA2-S 
FGIR 
Raynaud 
QUICK I 
Fasting glucose (mmol/L) xfasting insulin (mUlL) /22.5 
HOMA2 calculator version 2.2 
Fasting glucose (mg/dL) I Fasting insulin (mUlL) 
40/ Fasting insulin (mUlL) 
(Matthews et al. 
1985) 
(Wallace et al., 
2004) 
(Legro et al. , 
1998) 
(Raynaud et al., 
1999) 
1/[log fasting insulin (mUlL)+ log fasting glucose (mg/dL)] (Katz et al., 
2000) 
Key: ｈｏｍａＭｾＬ＠ homeostasis model assessment beta-cell activity; HOMA-IR, 
homeostasis model assessment insulin resistance; QUICKI, quantitative insulin 
sensitivity check index; FGIR fasting glucose insulin ratio. 
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4.3 Results 
Results of total mean of plasma glucose and insulin measure1nents for both visits in 
each glycaemic category are shown in Table 4.1. A significant difference was 
observed in the total 1nean glucose and insulin levels for the IFO, lOT and DM 
groups compared to the respective tnean values of the subjects within the NOT 
category. 
4.3.1 Sintple indices long-term variation 
Between day precision for each index was calculated for each glycaetnic category 
(Table 4.3) and are presented in Figure 4.1, A. As shown, the CV for HOMA-J3% 
tnodel was 17.4% in the NOT subjects, and increased with deteriorating glucose 
tolerance to 68.7% in DM subjects. This was hnproved by application of HOMA2-
ｾＥ＠ but neither procedure showed a significant difference in the total mean values for 
the NOT group cotnpared to those frmn other glycaetnic categories except in the case 
of ｈｏｍａＲＭｾＥ＠ in the DM group (p < 0.05). 
Regarding the reproducibility of the indices of insulin resistance, the CV of HOMA-
IR in the NOT group was 25.7% which rose to 52.1% in bM subjects. Using 
HOMA2-S, these CV s fell to 20.0% and 31.9% respectively. Reproducibility of the 
Raynaud index was very shnilar to that of HOMA2-S. QUlCKI showed the best 
reproducibility with a tnaximum CV of 5.8% for DM subjects. Unexpectedly, the CV 
for FOIR was lower in the DM group at 25.9% than in the lOT group at 30.0% as 
shown in (Figure 4.1, A) but this was not significantly different frmn that of the 
NOT group. 
--------------------------------------------------
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4.3.2 Simple indices short-tenn variation 
Intra-individual variation with short-term interval (4 fasting satnples in 20 tninutes) 
had a different trend in reproducibility. The tnaximmn CV of ｾＭ｣･ｬｬ＠ activity (Table 
4.3 and Figure 4.1, B) was 15.4% in ｈｏｍａＭｾ＠ and 5.8% as a tninitnum CV in 
ｈｏｍａＲＭｾ＠ of lOT category. Regarding indices of insulin resistance, the NOT 
category was the least reproducible category with highest and lowest CV s of 16.2% 
in Raynaud index and 2.4% in QUICK! respectively. Reproducibility in the lOT 
category was the highest con1pared to other categories with lowest CV of 1.4% in 
QUICK! and highest ev of 10.1% in FGIR index. In the NOT category, HOMA2-S 
reproducibility was 12.8% while in HOMA-IR it was 15.1% and for the same indices 
but in IGT it was 7.4% and 9.3% respectively. All other indices had a very close 
range of CV values in all categories. All insulin resistance indices (except FOIR) 
show significant changes in the total tnean of the 4 satnples across each of the 
glycaetnic categories IFG, IGT and DM as compared to the total mean of the NGT 
category. 
4.3.3 Other factors effects on variability 
The value for reproducibility for insulin resistance/ sensitivity calculated in this study 
is total intra-indvidual variation (eVt). This variation includes biological and 
analytical variations as described in Chapter 1 (section 1.7.1). The result of the 
insulin assay is the most essential paratneter involved in the calculation of the fasting 
sitnple indices of insulin resistance. However, its analytical variation (CVa) may 
affect the total variation. Therefore, the eva of the insulin assay was calculated from 
replicate analysis of quality control satnples. The eva values for different levels of 
quality control sera (within and between insulin assays) were between 4.1% and 
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4.9% as n1initnmn and Inaxilnmn values respectively. We used the maxhnum value 
of 4.9% for the control sera to be utilised as the analytical variation (eVa) of the 
insulin assay. Therefore, biological variation (eVb) for each simple index was then 
calculated by subtracting eva from evt using the general fonnula (Fraser and 
Harris, 1989; Talwar et al., 2005) (see appendix 2): 
The effect of the analytical variation of glucose was not incorporated into the 
previous equation, to esthnate the biological variation of each shnple index. This 
was justified as follows: 
a) The high analytical precision of the glucose assay utilised in the project; the 
calculated values of the eva for repeated different levels of quality control sera 
(within and between glucose assays) were between 0.8% and 2.2% (tninimutn and 
1naxi1num values respectively). 
b) Inclusion of the low glucose eva values in the above equation would not yield a 
substantial effect on the calculated biological variation. 
c) Insulin as a Inajor detenninant of insulin resistance esthnated by using the siinple 
indices of insulin resistance. Therefore its analytical variation 1nay significantly 
affect the calculated biological variation of any simple index of insulin resistance; 
furthermorethe standardisation of insulin assays remains a confounding problem. 
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Table 4.3: Coefficient of variation (%CV) for techniques used to assess ｾＭ｣･ｬｬ＠
function and insulin sensitivity in different glycaemic categories. 
Simple index Long-term interval Short-term interval Total mean %CV Total mean %CV 
NGT 117 (101- 134) 17.4 106 ± 15 15.4 
%HOMA-P IFG 119 (94- 144) 29.2 110 ± 14 12.0 
IGT 133(95-171) 30.9 104± 9 9.6 
DM 1 06 { 69 - 144 2 68.7 114 ± 11 10.6 
NGT 97 (88- 115) 12.3 90± 8 8.9 
%HOMA2-P IFG 99 (84- 115) 16.6 92±8 8.3 
IGT 101 (80- 121) 22.7 85 ± 5 5.8 
DM 83 {61- 104t 44.9 86±6 7.6 
NGT 2.0 (1.7- 2.3) 25.7 1.7 ± 0.2 15.1 
HOMA-IR IFG 3.6 (2.8- 4.3t 30.1 3.0 ± 0.4b 12.4 
IGT 4.1 (3.3- 4.8t 33.4 3.3 ± 0.3c 9.3 
DM 5.5 {3.8- 7.3t 52.1 5.0 ± o.sc 12.2 
NGT 107 (86- 127) 20 122 ± 15 12.8 
%HOMA2-S IFG 67 (48- sst 26.3 75.5 ± 8.7a 11.3 
IGT 68 (49- 87t 29.8 76± sa 7.4 
DM 53 {42- 64t 31.9 63 ± ga 12.0 
NGT 0.353 (0.343 - 0.364) 3.8 0.363 ± 0.010 2.6 
QUICK! IFG 0.324 (0.312- 0.336t 4.1 0.330 ± O.OlOb 1.7 
IGT 0.320 (0.308 - 0.331 t 5 0.328 ± o.oosc 1.4 
DM 0.309 {0.296- 0.321t 5.8 0.316 ± 0.006c 1.8 
NGT 14.0(11.4-16.6) 19.2 16.4 ± 3.0 16.1 
FGIR IFG 10.7 (7.5- 13.8t 20.5 11.9 ± 1.4 11.7 
IGT 11.6 (11.6- 8.1t 30 13.6 ± 1.4 10.1 
DM 10.6 {8.3- 12.82 25.9 12.1 ± 1.6 11.8 
NGT 6.1 (4.9- 7.2) 20.3 7.2 ± 1.3 16.2 
Raynaud IFG 3.9 (2.8- 5.0)b 25 4.4 ± o.sa 11.7 
IGT 4.0 (2.9- 5.2)c 29.6 4.6 ± o.sa 10.0 
DM 3.2 (2.5- 3.9t 31.3 3.8 ± o.sa 12.4 
Data are means ± SD or with 95% Confidence Interval. Total mean in both visits (1 0 
days interval) or the four fasting samples (5 minute intervals) of the NGT group has 
been compared with the total mean in each other glycaemic category; IFG IGT, and 
DM. a p < 0.05; b p < 0.01; c p < 0.001. Key: NGT, normal glucose tolerance; IFG 
impaired fasting glucose; IGT, impaired glucose tolerance; DM, type 2 diabetes; 
ｈｏｍａＭｾＬ＠ homeostasis model assessment ｾＭ｣･ｬｬ＠ activity; HOMA-IR, homeostasis 
model assessment insulin resistance; QUICK!, quantitative insulin check index; 
FGIR fasting glucose insulin ratio. 
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Figure 4.1: Reproducibility (%CV) trends for P-cell functions and insulin indices in 
subjects with different degrees of glucose tolerance. A: Long-term interval (2 fasting 
samples x 1 0 days average). B: Short-term interval ( 4 fasting samples x 5 minute 
intervals). 
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4.4 Discussion 
4.4.1 Previous studies of reproducibility 
Relatively, few studies have cmnprehensively cmnpared the CV s of the tnethods in 
normal and diabetic subjects. Other studies which have done so have observed 
different results in subjects with different clinical conditions. In 1985 Matthews et 
al., reported CVs for HOMA-IR and ｈｏｍａＭｾＥ＠ of 31% and 32% respectively for a 
cotnbination of normal and diabetic subjects (Matthews et al., 1985). In 1999, Etnoto 
et a!., estimated HOMA-IR and QUICKI on two occasions in 45 subjects with 
diabetes receiving oral sulphonylureas and reported values of 11.7% and 2.0% 
respectively (Etnoto et a!., 1999). In a study lasting five consecutive days, Bonora et 
a!., reported a CV of 13.8% for HOMA-IR in 20 non-diabetic subjects and 11.2% for 
20 subjects with diabetes tnost of whmn were taking oral hypoglycaemic tnedications 
(Bonm·a et a!., 2000). The tnost recent study which estimated reproducibility was 
conducted over two visits in 78 subjects with hypertension and diabetes having 
on1itted their n1orning oral anti-diabetic medication. The CV s reported were 23.5% 
for HOMA-IR and 7.8% for QUICK! (Sarafidis eta!., 2007). 
4.4.2 Limitations of the previous studies 
Smne limitations are noted in previous studies. Most did not categorise subjects with 
diabetes according to whether they were treated with anti-diabetic tnedications or by 
dietary tneans alone. This is significant as the half-lives of active tnetabolites of these 
n1edications vary frmn 4 and 24 hours (Melchior and Jaber, 1996; Selatn, 1997). 
Tetnporary overnight discontinuation of the tnedications may not have allowed 
sufficient time for total eliinination of the drugs. Thus, the low CV reported in some 
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studies such as the type 2 diabetes group in Emoto eta/., (Etnoto et al., 1999) might 
potentially be explained by the presence of active metabolites of these tnedications 
resulting in itnproved reproducibility of the tneasured index. In addition, tnost reports 
do not indicate whether patients were receiving other tnedications such as steroids 
(Poldern1an eta/., 1994) or thyroxine (Ohguni et al., 1995). In contrast to previous 
studies, the present study excluded subjects taking tnedications which could have 
tnodified insulin resistance or glycaetnic control. Further studies are required to 
compare the reproducibility of insulin resistance indices in subjects with type 2 
diabetes taking anti-diabetic medications with those who are treated by dietary means 
alone. This will clarify whether anti-diabetic tnedications have any effects on the 
reproducibility of insulin resistance indices. 
In tnost previous studies CV s for the derived paratneters of long-term interval 
reproducibility were calculated from the SD based on tneasuretnents made on two 
occasions. The tnethod by which the SD is calculated varies between studies, some 
having used the tnethod of paired samples (Etnoto et al., 1999; Sarafidis eta/., 2007) 
(see Chapter 2, section 2.1 0), others having used the classical formula for duplicates 
(Mather et al., 2001; Matthews eta/., 1985). Use of the classical fonnula usually 
yields a lower CV cotnpared to the paired samples tnethod (Duysinx et al., 1994 ). 
When the classical fonnula was applied to our long-term interval data, lower CV s 
were obtained for all the indices cotnpared to the tnodified procedure for paired 
smnples but the trend of reproducibility was preserved atnongst all the glucose 
tolerance categories. 
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HOMA is well recognised to be subjected to high intra-individual variability. The 
study by Jayagopal and his colleagues was concerned primarily with intra-individual 
variation of HOMA in postmenopausal wmnen with and without type 2 diabetes 
(Jayagopal et al., 2002). However, they reported a high degree of intra-individual 
variation of HOMA-IR in subjects with type 2 diabetes (restricted to diet-controlled 
and without previous anti-diabetic medications) compared to non-diabetic subjects 
while in normal subjects HOMA-IR retnained within a narrow range. These findings 
are similar to our observations in the long-term interval study. 
Parmneters derived frmn the HOMA2 model showed hnproved reproducibility which 
spanned the glycaemic categories. QUICKI showed better reproducibility than the 
other indices studied. In general the log and reciprocal correlation between glucose 
and insulin in QUICKI is successful in n1aintaining a relatively low CV compared to 
the other indices. This finding was also observed by previous studies (Mather et al., 
2001; Sarafidis et al., 2007). More validation studies are required to detennine cut-
off values and reference ranges for these indices in different populations. For 
exatnple Radikova and his colleagues investigated the range and cut-off values for 
different simple indices of insulin resistance in rural Caucasians (Radikova et al., 
2006). 
4.4.3 P-cell activity and its reproducibility 
The fasting insulin level should be interpreted with caution as a nmnber of factors 
conspire to increase its variability including the cyclical secretion and short half-life 
of the honnone and its rapid responsiveness to other regulatory honnones (Matthews 
et al., 1983). This variability is particularly high in subjects with type 2 diabetes due 
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to fluctuation of ｾＭ｣･ｬｬ＠ activity. This might explain the high CV s obtained for 
ｈｏｍａＭｾ＠ (68.7%) and ｈｏｍａＲＭｾ＠ (44.9%) in this group. These findings support our 
previous contention that fasting senun insulin levels should not be used in clinical 
contexts for making treatment decisions on individual patients, though they tnay be 
of value in identifying patients with advanced insulin resistance where the level is 
likely to be unequivocally elevated (Borai eta!., 2007). 
4.4.4 Silnple indices long-term variation 
It has been observed that over the long-tenn interval the CV s for all surrogate indices 
were lower in subjects with NGT compared to other glycaetnic categories. Moreover, 
in the absence of interfering agents (e.g. drugs n1odifying insulin resistance) the 
reproducibility of indices decreased progressively with increasing severity of glucose 
intolerance. This is an observation of which those carrying out epidemiological 
studies should be aware. 
4.4.5 Simple indices short-term variation 
Our results of the short-term reproducibility showed that in contrast to the long-tenn 
interval, NGT is the category with the least reproducible estitnate of insulin 
resistance. Few previous studies have investigated reproducibility of insulin 
sensitivity indices over the short term (5 to 10 tninutes ). For exatnple for a study of 3 
fasting samples at 5 tninute intervals was done by Bonm·a and his group (Bonora et 
al., 2000). This estimated HOMA-IR reproducibility at 9.4% in NGT and 7.8% in 
type 2 diabetes while our outcmnes were 15 .I% and 12.2% respectively. Although 
the results are not identical they are similar and tnatching in trend. In another study 
of duplicate satnples taken at 10 n1inute intervals the CVs of insulin, HOMA-IR, 
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Raynaud and QUICK! in lean subjects were 24%, 24%, 51% and 6% and in obese 
subjects (insulin resistant) they were 59%, 58%,21% and 3% respectively (Mather et 
al., 2001 ). Here we observed smne discrepancies between the trends of these indices 
between lean and obese subjects. This could be due to the tnajor points which we 
have discussed in detail before about insulin secretion. But why were opposite trends 
obtained over long and short-tenns intervals in our study? It is known that insulin 
release is pulsatile in nonnal individuals reported at 6 - 10 tnin per pulse (Matthews 
et al., 1987; Porksen et al., 2002) and in DM, rapid pulsatile secretion becomes 
impaired (Polonsky et al., 1988). Therefore, given that our 4 satnples were collected 
within 20 tninutes it is likely that the pulsatility of insulin secretion could play a 
tnajor role on the short-tenn interval CV obtained particularly in individuals with 
deteriorating glucose tolerance. So, we suggest this point needs to be investigated 
further in a separate study. 
4.4.6 Other factors effects on variability 
Technical issues (known as biological noise) such insulin assay specificity, 
sensitivity and precision could be crucial to tninitnize the variability effects of 
analysis and consequently on the final reproducibility of the indices (Porksen et al., 
1995). This was not the case with the insulin assay used in this study. Even when 
analytical variation was excluded frmn the total variation the san1e trend was 
preserved without any change in the long- and short-tenn variation. 
However in2008, Antuna-Puente and colleagues reported that the CV should be used 
to evaluate the reproducibility of techniques to estimate glucose and insulin, not of 
tnathetnatical fonnulae of the sitnple index. When evaluating sitnple indices of 
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insulin resistance, the key point is how strongly the index correlates with the 
reference technique (Antuna-Puente et a!., 2008). In addition to this key point we 
think that any clinical condition affecting insulin secretion could be another key 
point in determining reproducibility of insulin resistance. 
4.5 Conclusions 
In conclusion, we have exa1nined the validity of reproducibility of simple 1nethods 
used for assessing insulin sensitivity. Whilst smne of the available indices may be 
reproducible in testing nonnal individuals they Inay not yield values sufficiently 
accurate for 1naking clinical decisions about individual patients. Reproducibility of 
the silnple insulin indices over both long and short tenn intervals can clearly be 
adversely influenced by glycae1nic status. 
Ill 
ChapterS 
Reproducibility of human fasting serum insulin-lil{e growth 
factor binding protein 1 (IGFBP-1) in individuals with 
varying degrees of glucose tolerance 
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5.1 Introduction 
Insulin-like growth factor binding protein 1 (IGFBP-1) is one of the six known 
plasma insulin-like growth factor binding proteins. Its sermn concentrations are 
inversely related to those of fasting insulin. It also appears to be a reliable marker of 
insulin resistance in nonnal subjects as serum concentrations of IGFBP-1 are 
strongly associated with insulin sensitivity as assessed by hyperinsulinaetnic 
euglycaen1ic clatnp (r = 0.73, p < 0.004) (Maddux et al., 2006). However, the utility 
of a surrogate marker of insulin resistance that was reproducible, stable, cost 
effective and easily tneasured would be invaluable for clinical and research purposes. 
Therefore before evaluating IGFBP-1 as a tnarker of insulin resistance it tnust be 
evaluated for intra-individual variation, which has not been reported previously 
particularly when different categories of glucose tolerance have been involved. Such 
information is essential for assessing the validity of IGFBP-1 results and 
consequently their biochemical interpretation in subjects with different status of 
glucose tolerance. This study was therefore undertaken to assess IGFBP-1 variation 
across a range of glucose tolerance. 
5.2 Subjects and methods 
We have assessed the reproducibility of senun IGFBP-1 over both long and short 
tenn intervals. Reproducibility of fasting serum insulin and IGFBP-1 over the long-
term interval was detertnined in subjects from different glycaemic categories over 
two visits separated by an average of 10 days. A standard 75g oral glucose tolerance 
test (OGTT) was carried out at the first visit and subjects classified according to 
WHO criteria (Alberti and Zimtnet, 1998) as nonnal glucose tolerance NGT (n = 15), 
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iinpaired fasting glucose IFG (n = 9), impaired glucose tolerance IGT (n = 9) and 
type 2 diabetes (n = 9). Diabetic subjects had been treated by dietary 1neans alone 
and had not previously received oral anti-diabetic medications or insulin. None of the 
subjects were being treated with steroids or thyroxine as described in section 2.1. The 
forty two subjects were classified into subcategories as shown in Table 5.1. In order 
to investigate reproducibility over the short-term, fasting sermn insulin and IGFBP-1 
were 1neasured four times in the fasting state at 5 1ninute intervals during the second 
visit. Fore more details on glucose, insulin and IGFBP-1 n1easurements the reader is 
referred to n1ethods and materials sections 2.4, 2.4.1 and 2.9 .1 respectively. 
5.3 Results 
The average coefficient of variation (CV) was calculated as the 1nean CV for all 
subjects in each glycaemic category. Across these categories gender was evenly 
distributed. 
5.3.1 IGFBP-1long-term variation 
The longer-term reproducibility of sermn IOFBP-1 was 20.9%, 29.5%, 33.1% and 
48.0% for NOT, IFO, lOT and type 2 diabetes respectively. In the smne order for 
glycaen1ic category, reproducibilities for the longer-tern1 interval were 24.7%, 
28.5%, 33.7% and 40.1% for fasting insulin and for fasting glucose were 3.3%, 
5.6%, 4.9% and 10.0% (Figure 5.1). 
5.3.2 IGFBP-1 short-term variation 
The short-term reproducibility of senun IOFBP-1 was 8.2%, 16.1 %, 29.2% and 
13.8% for NOT, IFO, lOT and type 2 diabetes respectively. In the same order for 
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glycaemic category, reproducibilities for the longer-term interval were 15.0%, 
11.9%, 10.3% and 12.7% for fasting insulin and for fasting glucose were 2.8%, 
0.9%, 0.8% and 1.3% (Figure 5.1). 
Table 5.1: Clinical and biochemical characteristics for subjects in different 
glycaemic categories. Fasting glucose, insulin and IGFBP-1 results are included in 
visit 1 (1st) and visit 2 (2nd). 
NGT IFG IGT DM 
(n = 15) (n = 9) (n= 9) (n=9) 
Male(%) 60% 67% 77% 62% 
Age (years) 41 ±4 48±2 53± 3 48±4 
BMI (kg/m2) 24.6 ± 1.2 30.5 ± 1.0 30.4 ± 1.1 31.8 ± 1.4 
HbA1c (%) 5.4 ± 0.1 6.0± 0.2 5.8 ± 0.2 7.2± 0.5 
FPG (1st) 5.3 ± 0.1 6.3 ± 0.1 6.5 ± 0.2 8.2± 0.9 
FPG (2nd) 5.2 ± 0.1 6.0 ± 0.1 6.3 ± 0.2 7.4 ± 0.9 
Insulin (1st) 68± 7 108 ± 17 134 ± 18 130 ± 20 
Insulin (2nd) 57± 6 89 ± 12 94± 16 86 ± 15 
IGFBP-1 (1st) 6.1 ± 1.4 3.0± 0.7 2.2±0.6 8.8 ± 1.5 
IGFBP-1 (2nd) 6.3 ± 1.8 2.2± 0.6 1.7 ± 0.4 4.6 ± 1.3 
Data are mean± SE. Key: BMI, body mass index; HbA1c, glycated haemoglobin; 
FPG, fasting plasma glucose; NGT normal glucose tolerance; IFG, impaired fasting 
glucose; IGT impaired glucose tolerance; DM, type 2 diabetes. Units: FPG, mmol/L; 
insulin, pmol/L and IGFBP-1, J.tg/L. 
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Figure 5.1: Variation for fasting glucose, insulin and IGFBP-1 in different 
glycaemic categories for samples taken over long-term (2 samples collected within 
an average of 10 days) and short-term (4 samples each separated by 5 minutes) 
intervals. 
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5.3.3 IGFBP-1 variability in different glycaemic categories 
At both visits, fasting IGFBP-1 levels decreased with deteriorating glucose tolerance 
but clhnbed significantly in subjects with type 2 diabetes (Figure 5.2). In each 
category there was no significant difference between IGFBP-1 levels at both visits 
except in subjects with type 2 diabetes (p < 0.05). IGFBP-1 correlations between the 
two visits were as follows; NGT, r = 0.93, p < 0.0001; IFG, r = 0.92, p <0.001; IGT, 
r = 0.81, p < 0.01 and type 2 diabetes, r = 0.79, p < 0.05. 
5.3.4 Other factors effects on IGFBP-1 variability 
The value for reproducibility calculated in this study corresponds to the total intra-
individual variation (CVt) of IGFBP-1. This variation includes biological and 
analytical variations as described in Chapter 1 (section 1. 7.1 ). Therefore, the CVa for 
insulin was calculated to be 4.9% as described in Chapter 4 (section 4.3.3). For 
IGFBP-1 assay the CVa was calculated frmn replicate analysis of different levels of 
quality control samples within and between assays (see Chapter 2, Table 2.3). 
Analytical variation for different levels of control samples were averaged at 6.3% 
and 9.0% for within and between IGFBP-1 assays respectively. The biological 
variation for fasting insulin and IGFBP-1 was calculated as described in section 4.3.3 
and is shown in appendix 3. For glucose the biological variation was not considered 
or calculated due to the low analytical variation of the glucose assay (section 4.3.3). 
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Figure 5.2: Levels of IGFBP-1 obtained fr01n first and second visits in each glucose 
tolerance status. IGFBP-1 values are tneans [Confidence interval (95% CI)]. Key: 
NGT, normal glucose tolerance; IFG, in1paired fasting glucose; IGT, impaired 
glucose tolerance and *p < 0.05 (visit 1 vs. visit 2). 
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5.4 Discussion 
This is the first study to show that inter- and intra-individual variation in IOFBP-1 
deteriorate with deteriorating glucose tolerance. Since IOFBP-1 is an insulin 
dependent variable, we had anticipated its reproducibility would be cmnparable to 
that of fasting insulin in all glycaetnic categories. 
5.4.1 IGFBP-1 variation 
Over the long-tenn interval IGFBP-1 and insulin were tnost reproducible in 
individuals with NOT and deteriorated with deteriorating stage of glucose tolerance. 
Intra-individual variation for insulin of 24.7% in individuals with NOT is 
cmnparable to that reported by Mooy et al., of 21.4% from two visits (Mooy et al., 
1996). 
It seetns that the total reproducibility (%CV) of IGFBP-1 over the short-term (not the 
long-term) vatiation is not sitnilar to insulin reproducibility in the trend of values. 
That tneans when NOT subjects were cmnpared to other glycaetnic categories of 
IFG, lOT and type 2 diabetes the short-term variation of IOFBP-1 was highly 
reproducible while fasting insulin was least reproducible. This could be due to 
different biological characteristics between insulin and IGFBP-1 such as half-life, 
clearance rate and insulin oscillation phenomena but this needs further investigation. 
Our outcotnes regarding the variation of IGFBP-1 in subjects with NOT indicate that 
the difference between two consecutive IOFBP-1 samples (with an average of ten 
days) tnust not rise or fall by> 20.9% in the long-term and> 8.2% in the short-tenn 
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otherwise the two values obtained would be considered significantly different frmn 
each other. 
Previous studies on variation of sitnple insulin sensitivity indices were mentioned in 
Chapter 4. One of those previous investigations was carried out in 2002 by Jayagopal 
and his colleagues using hmneostasis tnodel assesstnent of insulin resistance 
(HOMA-IR). The outcomes of their study indicated that subjects with type 2 
diabetes had significantly greater variability of HOMA-IR compared to normal 
subjects (Jayagopal et a!., 2002). Our study is consistent with this outcome as both 
parmneters (IGFBP-1 and HOMA-IR) are insulin dependent. At the satne time this 
point supports the idea of using IGFBP-1 levels as a reliable parameter to estitnate 
insulin resistance. 
5.4.2 IGFBP-1 in type 2 diabetes 
In type 2 diabetes variable levels of IGFBP-1 are due to declining and irregular 
secretion of insulin by ｾＭ｣･ｬｬｳ＠ in these individuals who become less able to exert 
negative regulation upon IGFBP-1 secretion frmn the liver (Heald eta!., 2001). This 
tnight explain the weak association between the two measuretnents of IGFBP-1 in 
these subjects cotnpared to subjects with NOT. Therefore, there was a significant 
difference yielded between the means ofiGFBP-1 obtained frotn the first and second 
visits. Secreted IGFBP-1 reflects portal insulin delivery (Yki-Jarvinen et al., 1995). 
Reduced hepatic extraction of insulin could therefore alter its relationship with 
IGFBP-1 (Kotronen et al., 2007). Other factors tnay have also an impact on the 
relative increase ofiGFBP-1 level in type 2 diabetes e.g. inflammatory cytokines and 
counter-regulatory honnones. Factors other than the plasma insulin level must 
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therefore be taken into account when interpreting IGFBP"1 results in subjects with 
type 2 diabetes. In this particular study the average interval between first and second 
visits was approxitnately 10 days. The interval was 14 days tnaximum for a few 
subjects other than those with diabetes. At the first visit, weight, BMI and % TBF 
were tneasured and these were not repeated at the second visit. 
Frystyk et al., did not observe any significant difference in the tnean levels of 
IGFBP-1 between type 2 diabetic and lean subjects (Frystyk et al., 1999). This could 
have been due to blood satnpling being obtained at one visit rather two. Therefore 
unlike our investigation, IGFBP"1 variability was not considered by Frystyk et al. 
Secondly tnost of the diabetic subjects recruited to the study of Frystyk et al were 
being treated with antidiabetic medication or insulin while our diabetic subjects were 
not receiving such tnedications. The significant effects of antidiabetic medication and 
insulin on the IGFBP-1 levels has been investigated previously by Heald et al., 
(Heald et al., 2002). 
Therefore when the IGFBP" 1 levels in subjects with type 2 diabetes (not taking 
antidiabetic tnedications or insulin) were cotnpared to subjects with NGT, 
differences tnay be confounded due to the high variation of the IGFBP-1 levels in 
subjects with type 2 diabetes. 
As previously reported by Jayagobal and colleagues biological variation of sex 
hortnone binding globulin (SHBG) in insubjects with type 2 diabetes was less 
variable than IGFBP-1 (Jayagopal et al., 2004). The study indicated that in subjects 
with type 2 diabetes a subsequent sample 1nust rise or fall by> 14% to be considered 
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significantly different frotn the first. Fasting insulin variability in type 2 diabetes was 
not reflected by sitnilar variability on SHBG results. This low variation of SHBG 
cotnpared to IGFBP-1 is due to the inherent tetnporal variability of insulin and 
IGFBP-1 levels cmnpared to SHBG. 
5.4.3 Otber factors effects on IGFBP-1 variability 
Analytical variation tnight have a critical effect on the final total variation of both 
fasting plastna insulin and IGFBP-1. This was not the case with the insulin or 
IGFBP-1 assays utilised in this study. Even though analytical variation was excluded 
frmn both assays the trend of total variabilities was preserved without any changes 
within both long- and short-tenn variations. 
5.5 Conclusions 
In conclusion IGFBP-1 n1easuretnent was tnost reproducible in NOT individuals 
over both long-term and short-tenn intervals and worsened with deteriorating 
glucose tolerance. It appears that variation of IGFBP-1 over the long-tenn is related 
predominantly to variability in fasting plastna insulin levels while over short-tenn 
intervals other factors may override insulin variability. In type 2 diabetes levels of 
IGFBP-ltnust be interpreted carefully. 
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6.1 Introduction 
After assessing the variation of IGFBP-1 further evaluation of serun1 IGFBP-1 as a 
tnarker of insulin resistance is required for subjects with normal glucose tolerance 
and individuals within other glycaetnic categories. Insulin resistance tneasurement 
tnay be of particular value in research studies. As we have stated before the standard 
frequently sampled intravenous glucose tolerance test (FSIVGTT) is considered to be 
safer and sitnpler than the reference clamp technique. However, both techniques are 
unsuitable for large population studies. Therefore, simple indices using fasting 
insulin and glucose values have been developed viz hon1eostasis tnodel assessment 
(HOMA-IR) (Matthews et al.) 1985), quantitative insulin sensitivity check index 
(QUICI<I) (Katz et al., 2000), fasting glucose to insulin ratio (FGIR) (Legro et a!., 
1998) and the Raynaud index (Raynaud et al., 1999). Other indices can be estimated 
by using fasting levels of glucose and insulin and levels taken at 2 hours in the 
context of an oral glucose tolerance test e.g. insulin glycaetnic index (ISI-gly) 
(Belfiore eta!., 1998). We have smnmarised these indices with their lhnitations in 
the first and second Chapters. 
Insulin-like growth factor binding protein 1 (IGFBP-1) is unique amongst the 
insulin-like growth factor binding proteins in that its circulating concentrations are 
tightly regulated and influenced by insulin concentrations. This is primarily due to 
the inhibitory effect of insulin on IGFBP-1 transcription and correlates strongly with 
tneasuretnents of insulin sensitivity tnade using the hyperinsulinaemic euglycaetnic 
(Maddux et a/., 2006). In addition to its potential to be a marker of insulin resistance 
serum IGFBP-1 levels may have other clinical applications (Table 6.1). 
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Table 6.1: Potential clinical uses of insulin like growth factor binding protein 1. 
IGFBP-1 clinical uses References 
Assessment of insulin status (Clauson et al., 1998) 
Differential diagnosis of hypoglycaemia (Levitt Katz et al., 1997) 
Cardiovascular risk screening (Gibson et al., 1996) 
Marker for metabolic syndrome (Lemne and Brismar, 1998) 
Marker for insulin resistance (Maddux et al., 2006) 
Prediction insulin resistance in children (Saitoh et al., 1999) 
Assessment of growth failure in CRF (Powell et al., 1997) 
Monitoring lGF-l treatment ofLaron dwarfism (Cotterill et al., 1992) 
Fetal assessment and surveillance (Hakala-Ala-Pietila et al., 
1993; Hills et al., 1996) 
Diagnostic tool for trisomy-18 pregnancies (Miell et al. 1997) 
Prediction of severe pre-eclampsia (Giudice et al., 1997) 
Detection of premature rupture of membranes (Lockwood eta/., 1994) 
Marker of leakage of endometrial products (Hahn et al. 1996) 
Assessment of risk of endometrial malignancy (Rutan en et al., 1994) 
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The nature of the statistical correlation between indices of insulin resistance is 
critical in determining the strength of association between these parameters and 
consequently on the accuracy of insulin resistance estimation. A non-linear 
hyperbolic relationship between the simple indices and insulin sensitivity paratneters 
derived from euglycaetnic clamp (M) and its alternative FSIVGTT (Si) technique 
have been observed in tnany previous studies (Bon ora et a!., 2000; Etnoto et a!., 
1999; Fukushilna et al., 2000). This has pr01npted researchers to transfonn the 
proposed indices to either the base of logaritlun (log) or natural logarithtn (Ln) prior 
to carrying out correlation analysis. In addition to this, some other authors have used 
untransfortned data (Conwell et al., 2004; Sarafidis et al., 2007). Here we have 
investigated and compared the relationship between different indices of insulin 
sensitivity before and after logarithm transformation. To our knowledge, no previous 
study has correlated log or Ln-transfonned IGFBP-1 with the standard FSIVGTT 
(Si). As a result of declining levels of insulin in subjects with type 2 diabetes, the 
IGFBP-1level is likely to be oflitnited value in such individuals (Heald et al., 2001). 
For this reason we restricted our subjects to those with nonnal glucose tolerance 
(NGT) or impaired fasting glucose (IFG). 
6.2 Subjects and methods 
Out of the cohort investigated 22 subjects with nonnal glucose tolerance (NGT) (15 
n1ales, 7 fetnales, aged (tnean ± SD, 38.5 ± 13.6 years and BMI 26.2 ± 4.7 kg/m2) 
and 9 with itnpaired fasting glucose (IFG) (6 tnales, 3 fetnales, aged 49 ± 8.7 years 
and BMI 30.3 ± 3.1 kg!tn2) were involved in this study (all data tnean+/-SD). It 
should be noticed that subjects involved in this study are not the same (NGT) or 
different (IFG) from those involved in Chapter 5. Therefore, in spite of the same 
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number of subjects involved in the previous study with IFG (n = 9) (Chapter 5), 3 
subjects involved in this category of this study were different. This was due to 
smnple volume insufficiency. Regarding the nmnber of subjects involved in the NGT 
category it was 15 but in this study it has been increased to 22. Therefore, the reader 
should be aware that this accounts for the different mean values between the two 
categories (NGT and IFG) in the previous and current studies were expected to be 
1naintained in terms of their the trends but not in the scores particularly when 
relatively low number of subjects were involved.. As described in Chapter two, 
subjects attended the Investigation Unit for two visits. A standard 75g oral glucose 
tolerance test was carried out at the first visit and glycaemic status classified into two 
categories according to WHO criteria. At the second visit, subjects underwent a 
standard FSIVGTT. The study was approved by the Ethical Committee of King 
Khalid National Guard Hospital (Jeddah, Saudi Arabia) and South West Surrey 
Local Research Ethics Committee, Guildford, UK. For 1nore details about glucose, 
insulin and IGFBP-1 assays please refer to Chapter 2, sections 2.4, 2.4.1 and 2.9.1. 
The full standard FSIVGTT protocol was perfonned as described in section 2.6. For 
Minimaltnodel analysis Mimnod Millennium 6.02 software was used. Other utilised 
shnple indices of HOMA-IR, QUICKI, FGIR and Raynaud index, with their 
formulae were listed in Table 4.2. Regarding the insulin sensitivity index-glycaemia 
(ISI-gly) was calculated as follow: 
2/[(INSp X GLYp) + 1] 
Glusose and insulin concentrations were 1neasured at baseline and post oral glucose 
load (Belfiore et al., 1998). More details about this fonnula were described previousely 
in the first Chapter, section 1.5 .2.1. 
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6.3 Results 
In this section the outcotnes have been categoried according to the data of each 
glycaemic status (NGT and IFG) and results pooled. The most significant association 
was between IGFBP-1 and the Si parameter which has been derived from the 
FSIVGTT. The IGFBP-1 association with other different sitnple indices was less 
significant than with the Si. These associations seem to be enhanced after Ln-
transformation. Detailed outputs are as follow. 
6.3.1 Normal glucose tolerance (NGT) data analysis 
The Si (10-4tnin -1[pmol1Lr1) index was significantly different (p < 0.05) between the 
two categories, NGT and IFG (n1ean ± SE; 9.70 ± 2.3 vs. 3.52 ± 0.74 respectively), 
but the fasting serum IGFBP-1 level was not significantly different (p = 0.36) (see 
section 6.2). The untransfonned and Ln-transfonned indices were each correlated in 
turn with untransfonned and Ln-transformed Si (Table 6.2). Upon analysis of 
untransfonned data in NGT subjects, IGFBP-1 was the index which showed the 
strongest correlation with Si (r = 0.76, p < 0.0001) (Figure 6.1, A). Visual inspection 
suggested a positively skewed hyperbolic relationship between Si and other indices 
including IGFBP-1. In the satne glycaemic category and after Ln-transfonnation the 
highest correlation coefficient observed was between Si and IGFBP-1 (r = 0.79) 
(Figure 6.1, B). For the other indices the weakest correlation was between 
untransfonned data for Si and FGIR (r = 0.46, p < 0.05) (Figure 6.2, A) but after Ln-
transfonnation the correlation coefficient was significantly better (r = 0.54, p < 0.01) 
(Figure 6.2, B). Therefore, a stronger association between Si and IGFBP-1 was 
observed in NGT subjects when cotnpared to other indices of insulin resistance and 
the use ofLn-transfonned IGFBP-1 can enhance this association. 
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6.3.2 Impaired fasting glucose (IFG) data analysis 
Compared to the NGT category, the association between IGFBP-1 and Si in the IFG 
category showed the weakest association, both when untransformed data were 
analysed (r = 0.55, p = 0.16) and after Ln-transfonnation (r = 0.56, p = 0.15). 
Regarding the other indices, untransfonned data showed strong association with Si. 
This association improved further after Ln-transformation (Table 6.2). The index 
which correlated tnost strongly with Si in this category was the ISI-gly index (r = 
0.77, p < 0.05) and (r = 0.85, p < 0.01) before and after Ln-transformation 
respectively. Stronger associations between Si and the other indices (except IGFBP-
1) were observed in the IFG cmnpared to the NGT category. 
6.3.3 Pooled data analysis 
As in each category the Ln-transfonnation of the pooled data frmn both categories 
strengthened the association between Si and other indices (Table 6.2). The 
correlation coefficients after using log transfonned data were exactly the same after 
Ln-transfonnation. In the same pooled data BMI was significantly associated with 
both Si (r =- 0.73, p < 0.0001) and IGFBP-1 (r =- 0.50, p < 0.01). 
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Table 6.2: Correlation of insulin sensitivity indices with Minmod Millennium 
derived Si before and after Ln-transformation 
Correlation model Insulin HOMA-IR FGIR Raynaud QUICKr ISI-gly IGFBP-1 
NGT(22) 
Sivsindex -0.54* * -0.61 ** 0.46* 0.54** 0.61 ** 0.58** 0.76**** 
Ln (Si) vs Ln (index) -0.59** -0.63 ** 0.54** 0.59** 0.62** 0.65** 0.79**** 
IFG (9) 
Sivsindex -0.68* -0.68* 0.73* 0.68* 0.68* 0.77* 0.55 
Ln (Si) vs Ln (index) -0.79* -0.76* 0.80** 0.82** 0.77* 0.85** 0.56 
Total (31) 
Sivsindex -0.62*** -0.68**** 0.54** 0.62*** 0.68**** 0.68**** 0.71 **** 
Ln (Si) vs Ln (index) -0.64*** -0.72**** 0.61 *** 0.68**** 0.72**** 0.73**** 0.72**** 
" Untransformed values were used for QUICKI as the original calculation of this 
index uses logarithms. *p < 0.05, **p < 0.01 , ***p < 0.001 , ****p < 0.0001. Key: 
HOMA-IR, homeostasis model assessment insulin resistance; FGIR, fasting glucose 
insulin ratio; QUICK!, quantitative insulin check index; ISI-gly, insulin sensitivity 
glycaemic index; IGFBP-1 insulin-like growth factor binding protein 1; NGT, 
normal glucose tolerance; IFG, impaired fasting glucose. 
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Figure 6.1: Correlation coefficients before and after Ln-transformation using 
Spearman' s and Pearson' s methods respectively for A: Si vs. IGFBP-1 ; B: Ln (Si) vs. 
Ln (IGFBP-1 ). 
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6.4 Discussion 
For the pooled data frmn NGT and IFG subjects (section 6.3.3) strong correlations 
between BMI with both paratneters of Si and IGFBP-1 were consistent with previous 
studies (Cruickshank et al., 2001; Heald et al., 2001) and provide a further clinical 
validation ofthe in-house ELISA assay ofiGFBP-1. 
We perfonned this study to confinn the previous studies which concluded that 
IGFBP-1 could be used as a n1arker of insulin resistance as IGFBP-1 correlated 
strongly with hyperinsulinaetnic euglycaetnic clamp in fasting 23 non-diabetic 
subjects (r = 0.73, p < 0.004) (Maddux et al., 2006). In 2007, Motaghedi and his 
colleagues indicated that IGFBP-1 could be used as a convenient marker of insulin 
resistance in 6 children (:S 10 years old) but in this study the Si parameter of 
tobutamide modified FSIVGTT was associated with IGFBP-1 (r = 0.81, p = 0.04) 
(Motaghedi et al., 2007). 
6.4.1 IGFBP-1 as a marker of insulin resistance 
In the present study, we found that fasting sermn IGFBP-1 could be used as a simple 
and sensitive tnarker of insulin resistance which correlates tnore strongly with the 
insulin sensitivity paratneter (Si) derived from standard FSIVGTT than do the other 
sin1ple indices in NGT subjects. This has been investigated previousely by Maddux 
et al though these authors used the clamp technique as their reference method rather 
than the standard FSIVGTT used here. The present outcmnes of strong correlation 
betweeniGFBP-1 and Si is in line with that of Maddux et al., (Maddux et al., 2006) 
but at the same titne not with those of Van Haeften et al., where a tnodest correlation 
coefficient between IGFBP-1 and clatnp was found (r = 0.228, p = 0.074) (van 
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Haeften eta/., 2007). These conflicting findings could reflect the type of IGFBP-1 
assay used. Both the study by Maddux eta/., and the current study used enzyme-
linked immunosorbent assay (ELISA) while Van Haeften et al., used 
radioitnmunoassay (RIA). It is believed that the direct detection 1nethod of ELISA 
has relative advantages over cmnpetitive RIA including tnore potential sensitivitiy 
and specificity in addition to the easier technical performance (Lee eta/., 1997b). 
Another possible reason could be due to the type of IGFBP-1 form measured. In the 
circulation, different forms of IGFBP-1 phosphorylation can be detected and the 
binding of antibodies to each of these forms might have different characteristics. 
6.4.2 Correlations improve1nent after Ln-transformation 
In both NGT and IFG groups the correlation coefficients between Si and other 
insulin sensitivity paratneters including IGFBP-1 were observed to improve 
following Log- or Ln-tansfonnation. This is likely due to the positively skewed non-
transfonned indices becmning nonnally distributed following transfonnation. A 
sitnilar improvement has been reported by some previous studies after using 
logarithm transfonnation for insulin sensitivity indices cmnpared to the 
untransfonned raw data (Fukushhna et al., 2000; Straczkowski et al., 2004). This has 
been demonstrated where the untransforn1ed data to be correlated had the 
disadvantage of being related in a non-linear n1anner. The effect of transformation on 
the relationship between euglycaetnic clan1p and HOMA-IR was investigated before 
by Bonm·a et al., 2000. The conclusion was that the correlation coefficient between 
the two untransformed indices itnproved from -0.627 to -0.82 after Ln-
transformation (Bonm·a et al., 2000). 
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In another study Fukushitna et al., investigated the correlation between HOMA-IR 
and Si before and after Ln-transfonnation using a wide range of subjects with 
different glucose tolerance (Fukushhna et al., 2000). However, they observed a 
significant correlation between HOMA-IR and Si in the whole group of subjects (r = 
0.45, p < 0.0001) which improved following Ln-transformation to (r = 0.61, p < 
0.0001). After the subjects were reclassified according to their HOMA-IR scores no 
difference was observed in correlation coefficient after Ln-transfonnation in those 
subjects with HOMA-IR < 1 (r = 0.49, p < 0.005), that is for those subjects most 
likely to have a normal glucose tolerance. In those subjects most likely to have 
iinpaired glucose tolerance (with HOMA-IR > 2) the correlation coefficient clearly 
hnproved from (r = 0.33, p = 0.1 0) to (r = 0.49, p < 0.05). The author's conclusion 
was that when HOMA-IR increases, logarithn1 transfonned HOMA-IR will be a 
better predictor of insulin sensitivity. This itnprove1nent in correlation coefficients 
after logarithm transformation is in agreetnent with our outcmnes both for pooled 
data and frmn each individual category investigated. The degree of iinprovetnent in 
correlation coefficients after Ln-transfonnation in each glycaemic category obtained 
by Fukushima et al., study was similar to that observed in our indices except in the 
NGT category but as we utilised 1nore indices in our study we found that this 
ilnprovement was 1nore apparent for smne indices (e.g. FGIR and ISI-gly) than 
others. 
Cmnpared to other simple fasting indices, estimation of the ISI-gly index takes 
account of both fasting and post load glucose and insulin concentrations. Therefore, 
in subjects with IFG the ISI-gly index was 1nore accurate in esti1nating insulin 
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sensitivity as its correlation with Si was stronger than that of other indices (Carnevale 
Schianca et al., 2006). 
6.5 Conclusions 
After we had investigated IGFBP-1 variation in the previous chapter our work in this 
section has produced useful prelin1inary data about using fasting sermn IGFBP-1 
levels as a tnarker of insulin resistance. Further studies are required to validate other 
criteria to define cut-off levels in different clinical conditions. The IGFBP-1 offers 
advantages over other sitnple indices in tenns of stability and simplicity of 
measurement. Therefore, in subjects with normal glucose tolerance, IGFBP-1 
appears to be as suitable and reliable a marker as other comtnonly used indices of 
insulin sensitivity. This reliability appears to deteriorate in subjects with IFG. In 
these subjects, other insulin sensitivity indices which depend on glucose-insulin 
kinetics are preferable. Either in each glycaetnic category or total, the base of 
logarithm or natural logarithtnic transfonnation of the indices equally itnproves 
insulin sensitivity prediction. 
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Chapter7 
A comparative study of insulin resistance between Saudi 
and Caucasian population samples: the relationship 
between glycosylated haemoglobin (HbAlc) and measures 
of insulin resistance across the glucose tolerance range 
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7.1 Introduction 
Metabolic syndrmne is a cmntnon public health problem around the world including 
the Western world and Middle East. The prevalence of the tnetabolic syndrmne 
among Saudis and other populations has been discussed before in sections 1.1, 1.2 
and 1.3. The high prevalence of metabolic syndrome associated with an increased 
risk of developing cardiovascular disease (CVD) and type 2 diabetes in the Saudi 
population (Al-Hazzaa, 2004; Kariln et al., 2000) is believed to be due to 
environmental and dietary factors (Alissa et a!., 2005; Heald et al., 2005) and tnay 
also be partly genetically detennined (Alstnadi et a!., 2008). In particular, recent 
changes in nutrient intake and physical inactivity in the Saudi population are thought 
to have contributed (Al-Hazzaa, 2004; Alissa et a!., 2005). As described in section 
1.1 insulin resistance is one of the tnain aggravating factors of tnetabolic syndrmne, 
and appears to develop early. It was therefore considered of interest to compare 
insulin sensitivity in Saudi individuals with that of Caucasians as this has not been 
investigated previously. Caucasians have however been cotnpared to African-
Atnericans and Pima Indians and observed to have greater insulin sensitivity 
(Brancati eta!., 2000; Lillioja et al., 1987). 
The frequently sampled intravenous glucose tolerance test (FSIVGTT) and other 
simpler insulin resistance techniques including hmneostasis model assesstnent 
(HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) are 
cmnmonly used indices of insulin resistance and they were selected be studied. In 
addition to these indices we wished to invistigate insulin-like growth hormone 
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binding protein I (IGFBP-1) as it has been proved to be a reliable tnarker of insulin 
resistance as described in the previous chapter. 
Haemoglobin Ale (HbAlc) is a well recognised glycoprotein and widely used as a 
tneasure of glycaetnic control in diabetic subjects, reflecting the 1nean blood glucose 
level over the preceding tnonths. However, recent prospective studies have shown 
that increased HbAlc levels in non-diabetic subjects predict the development of 
CVD and type 2 diabetes. HbA 1 c has also been proposed as a surrogate marker of 
tnetabolic syndrome in predisposed high risk individuals (O'Sullivan et al., 2006; 
Osei et al., 2003). Therefore in this study we assessed HbAlc as a glycoprotein 
1narker of insulin resistance via its association with other indices of insulin resistance 
in subjects with different glycaen1ic categories. 
As we have described in Chapter 6, IGFBP-1 is a protein of particular interest in the 
context of assessing insulin resistance. Furthennore, IGFBP-1 is capable of 
tnodulating the actions of insulin-like growth factors. IGFBP-1 kinetic variation after 
oral glucose tolerance was reported previously (Maddux et al., 2006) but in this 
current study tnore details about this kinetic will be examined across different 
glycaetnic categories. In addition to this IGFBP-1 kinetic variation following 
intravenous glucose administration will be investigated in normal subjects. 
The current study was established to assess and compare insulin sensitivity in BMI 
tnatched Saudi and Caucasian populations using various techniques including 
FSIVGTT and other sitnple indices in subjects from across the glycaemic spectrum. 
This is because of the early incidence of insulin resistance cmnpared to other 
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tnetabolic risk factors. Therefore it is very useful early predictor of diabetes. In this 
study the HbA 1 c test was evaluated as a 1narker of insulin resistance and associated 
with different indices of insulin resistance in subjects frotn different glycaetnic 
categories. In addition to this, kinetics of ｉｇｆｂｐｾ＠ 1 were investigated following oral 
and intravenous glucose adtninistration. 
7.2 Subjects and methods 
7 .2.1 Subjects 
Subjects were frotn two different populations; Saudi (n = 33) and white Caucasian (n 
= 28). This study was approved by the ethical committee of King Khalid National 
Guard Hospital (Jeddah, Saudi Arabia) and South West Surrey Local Research 
Ethics Cotnmittee (Guildford, Ul(). Subjects attended on two visits except those with 
type two diabetes as they attended the first visit only. For tnore details see Chapter 2 
(sections 2.1, 2.2 and 2.3) about the subjects and their visit schedule. Briefly at the 
first visit standard 75g oral glucose tolerance test (OGTT) was carried out. The 
glycaemic status of each subject then was classified according to WHO criteria 
(Albetti and Zimtnet, 1998). The subjects were categorised as follows: normal 
glucose tolerance (NGT, n = 24), ilnpaired fasting glucose (IFG, n = 12), hnpaired 
glucose tolerance (IGT, n = 12) and type 2 diabetes (DM, n = 12). For the purpose of 
the cotnparative study between the two populations and owing to the low nmnber of 
subjects, the IFG and IGT categories in each population were cmnbined and 
categorised as 'glucose intolerance'. Out of the total nmnber of subjects, 39 did not 
have ischaemic heart disease (IHD) (21 Saudis, 18 Caucasians) and 22 had IHD (11 
Saudis, 11 Caucasians). DM subjects were either newly diagnosed or achieving good 
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glycaemic control by dietary tneans alone. Detailed information about diabetic 
subjects and their criteria have been presented in Chapter 2 (section 2.1, 2.2 and 2.3). 
Biochetnical characteristics of the subjects and their insulin resistance indices are 
shown in Table 7.1 and Table 7.2 respectively. Subjects were aged between 20 and 
65 years with BMI >20 and <35 kg/tn2 and were tnatched as closely as possible in 
each ethnic group. Subjects of the NGT category of each ethnic group were not 
significantly different in BMI and age. This was to avoid the confounding effects of 
obesity and age on the level of insulin resistance. Percentage total body fat (%TBF) 
estimation was measured as described before (section 2.2). Other clinical 
measuretnents such as blood pressure (BP) and waist-hip ratio (WHR) were 
included. Data for subjects with type 2 diabetes from both populations were not 
included in Table 7.1 or Table 7 .2. This was due to the low nmnber of diabetic 
subjects involved frmn each population to be compared. The clinical data for subjects 
with type 2 diabetes frmn both populations were pooled (Male, 69%; Mean ± SD; 
BMI, 28.9 ± 4.4; Age, 52.2 ± 11.1) and included with the data frmn other glycaemic 
categories in Table 7.3. 
7 .2.2 Assays 
Insulin was tneasured by solid phase two-site ELISA (Mercodia, Uppsala, Sweden). 
Other biochemical measuretnents including glucose, uric acid and lipids were 
assayed using the satne analyser (Siemens, Advia 1650 auto-analyser) on both 
hospital laboratories cited in Jeddah and Guildford and using the same quality 
control specimens and progratn. The satne analyser at both sites was also used for 
glycated haemoglobin (HbA 1 c) analysis which was based on the principle of high 
pressure liquid chromatography (Bim·ad Variant II). More details of the previous 
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assays are given in Chapter 2, section 2.4. All other assays were carried out in 
Guildford, ill(. Satnples were transported on dry ice by air fron1 Jeddah, Saudi 
Arabia to Guildford, UK. Sermn IGF-1 levels was detennined by imtnunoassay using 
In11nulite kits. IGFBP-1 was assayed by an in-house ELISA. Its capture antibody has 
been validated for binding preferentially with none- and less-phosphorylated IGFBP-
1 forms as described in Chapter 2 (sections 2.8 and 2.9). All sermn samples were 
stored at -80°C until analysis. 
7 .2.3 Indices of insulin resistance 
At the second visit, all subjects except those who were previously diagnosed as 
having type 2 diabetes underwent a full standard FSIVGTT as described in section 
2.6. Minimal tnodel analysis software (Mimnod Millennimn 6.02) was used to 
calculate insulin sensitivity (Si), glucose effectiveness (Sg) and acute insulin 
response (AIRg) (Table 7.2). The parameters of insulin sensitivity index (Si) and 
glucose effectiveness (Sg) have been dicribed in Chapter I (section 1.5.1.2). The 
acute insulin response to glucose (AIRg) is defined as the area under the plasma 
insulin curve between 0 and 10 tninutes after glucose injection of the FSIVGTT 
technique. Area under the curve for glucose (AUCglucose) was calculated by the 
trapezoid rule frmn 0 to 10 n1in after glucose injection in the same technique. 
In 7 (NGT = 2; Glucose intolerance = 5) out of the total 48 subjects Si, Sg, AIRg and 
AUC glucose paratneters could not be tnodelled due to tnodel assumption violation 
(curve fitting failure). This is to be expected for son1e subjects using the Mimnod 
fitting procedure (Boston et al., 2003). Other simple fasting indices of insulin 
resistance were as follows; version 2 of the hotneostasis tnodel assessn1ent with 
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nonlinear tnodelling was used to calculate insulin resistance (HOMA2-IR) and ｾＭ｣･ｬｬ＠
function ＨｈｏｍａＲＭｾＩ［＠ see section 1.5.2.2. In addition, QUICKI and insulin 
glycaemic index (ISI-gly) were determined. Their fonnulae have been described 
before in sections 1.5.2.3 and 1.5.2.1 respectively. Raynaud index is another sitnple 
index which has been described in section 1.5.2.5. It has been proved to be 1nore 
precise 1narker of insulin resistance than fasting insulin alone but has not been 
validated as yet in different populations (Raynaud et al., 1999). 
7.3 Results 
7.3.1 General characteristics 
The clinical and biochetnical characteristics of the two populations are shown in 
Table 7.1. Across both categories of NGT and glucose intolerance no significant 
differences in BMI, % TBF and WHR were observed in either population. However, 
Caucasians were significantly older than Saudis (p < 0.05) in the impaired category. 
In Saudis diastolic blood pressure was significantly higher than in Caucasian, both in 
NGT (p < 0.001) and hnpaired categories (p < 0.05). 
7.3.2 Variation of insulin sensitivity indices and HbAlc by population 
For subjects in the NGT (Table 7.2) category, insulin sensitivity (Si), was higher in 
Caucasians than Saudis (p < 0.01). In the same category ISI-gly showed higher 
insulin sensitivity in Caucasians cmnpared to Saudis but the difference did not reach 
statistical significance. The index of ｾＭ｣･ｬｬ＠ activity ＨｈｏｍａＲＭｾＩ＠ was higher in 
Caucasians than Saudis in both NGT and glucose intolerance categories. This 
difference becmne statistically significant (p < 0.05) in subjects within the glucose 
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intolerant category. In the smne category fasting glucose was significantly higher in 
Saudis compared to Caucasians (p < 0.05) (Table 7.1). Regarding HbA1c, this was 
significantly higher in Saudis than Caucasians, both in NGT subjects and in glucose 
intolerance categories (p < 0.01 and p < 0.05 respectively) (Table 7.1). 
7 .3.3 The metabolic syndrome 
When Adult Treatment Panel (ATP) III criteria (see section 1.1; Table 1.1) for the 
diagnosis of 1netabolic syndrotne were applied to the subjects, 42% of the Saudi and 
29% of the Caucasian subjects had tnetabolic syndrome as defined by presence ｯｦｾ＠
3 of the criteria. The prevalences oftnetabolic syndrmne when International Diabetes 
Federation (IDF) guidelines (Zitnmet et al., 2005) were 48% and 42% respectively. 
7.3.4 HbA1c and IGFBP-1 across different glycaentic categories 
In order to assess the variation in different parameters according to glycaemic 
category data was reclassified according to the glucose tolerance results (Table 7 .3) 
HbAlc was higher in IFG than in NGT subjects (p < 0.05) and lower in IGT subjects 
than in DM subjects (p < 0.05). Cmnpared to the fasting serum IGFBP-1 level, the 
IGFBP-1 levels at 2 hours following 75g oral glucose administration expressed as a 
% of the fasting values fluctuated according to the glucose tolerance category 
(Figure 7.1). 
The extent to which values of each index overlapped between the NGT [95% 
Confidence intervals (95% CI)] and DM groups was assessed. In the case of fasting 
serum insulin concentration 59% of values overlapped and for the other indices the 
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percentage of overlapping values were IGFBP-1 , 79%; HOMA2-IR, 57%; Raynaud 
index 50%; QUICK!, 4.2%; ISI-gly 0.0% and HbA I c 0.0%. 
Table 7.1: Biochemical data in Saudi and Caucasian subjects. Glycaemic categories 
were compared within normal glucose tolerance and glucose intolerance (combined 
IFG & IGT) in each of the two populations. 
Normal glucose tolerance 
Male% 
Age (years) 
BMI (kg/m2) 
%TBF 
WHR 
SBP (mmHg) 
DBP(mmHg) 
TC (mmol/1) 
HDL-C (mmol/L) 
LDL-C (mmol/L) 
TG (mmol/L) 
Uric Acid {flmol!L) 
Saudi 
(n = 13) 
77% 
39.4 ± 13 
26.1 ± 4.6 
25.4 ± 10.2 
0.90 ± 0.10 
118 ± 7 
73 ±9 
4.5 ± 1.2 
1.2 ± 0.2 
2.7 ± 0.8 
1.7 ± 1.0 
322 ± 48 
%HbA lc 5.6 ± 0.5 
Glucose (mmol!L) 5.4 ± 0.4 
Glucose (2hr) (mmol/L) 5.4 ± 1.4 
IGF-1 (nmol/L) 21.9 ± 8.7 
Insulin (pmol/L) 
Insulin 2hr (pmol!L) 
IGFBP-1 (flg/L) 
IGFBP-1 (2hr) (flg/L) 
70±26 
296 (190 - 403) 
3.7 (1.8- 5.6) 
1.2 (0.5- 1.9) 
Caucasian 
(n = 11) 
64% 
42.7 ± 17.8 
26.4 ± 5.2 
25.5 ± 11.6 
0.90 ± 0.10 
115 ± 20 
64 ± 4 ••• 
4.6 ± 1.2 
1.4 ± 0.4 
2.7 ± 1.3 
1.1 ± 0.6 
323 ± 47 
5.2 ± 0.4 .. 
5.2 ± 0.5 
5.5 ± 1.0 
20.6 ± 8.7 
87 ± 49 
272 (126- 418) 
9.8 (5.6 -14.0) •• 
4.5 (2.1 - 7.0)* 
Glucose intolerance 
Saudi 
(n = 12) 
58% 
47.6 ± 7.2 
31.8 ± 2.2 
36.5 ± 8.3 
0.93 ± 0.10 
127 ± 9 
84 ± 10 
4.7 ± 0.9 
1.1 ± 0.3 
2.9 ± 0.6 
1.4 ± 0.7 
331 ± 48 
6.1 ± 0.5 
6.5 ± 0.4 
7.8 ± 1.6 
13.1±3.3 
Caucasian 
(n = 12) 
83% 
54.1 ± 7.4* 
29.8 ± 3.0 
32.3 ± 7.0 
0.96 ± 0.10 
126 ± 16 
74 ± 11 . 
4.6 ± 0.8 
1.2 ± 0.2 
1.2 ± 0.2* 
1.9 ± 0.9 
362 ± 68 
5.8 ± 0.4* 
6.0 ± 0.7· 
8.5 ± 1.2 
17.3±6.1 
123 ± 34 138 ± 57 
734 (640- 828) 668 (557- 778) 
3.3 (1 .7- 4.8) 4.3 (2.1 - 6.5) 
0.7 (0.3 - 1.0) 1.7 (0.5- 2.9) 
Data are mean ± SD or with 95% Confidence intervals. •p < 0.05 , ••p < 0.01 , ***p < 
0.001. Key: BMI, body mass index; HDL-C high density lipoprotein cholesterol; 
LDL-C, low density lipoprotein cholesterol; TBF, total body fat; TC, total 
cholesterol; WHR, waste to hip ratio; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; TG, triglycerides· HbAlc; glycated haemoglobin. 
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Table 7.2: Comparison of simple indices of beta-cell function and insulin resistance 
and parameters derived from the FSIVGTT within each category of Saudi and 
Caucasian subjects. 
Normal glucose tolerance Glucose intolerance 
Saudi Caucasian Saudi Caucasian 
(n =13) (n = 11) (n =12) (n = 12) 
ＥｈｏｍａＲＭｾ＠ 96 112 * 101 130 
(87- 105) (88- 137) (87- 116) (95- 165) 
HOMA2-IR 1.3 1.6 2.4 2.6 
(1.0- 1.6) (1.0- 2.2) (2.0- 2.8) (1.9- 3.2) 
QUICK I 0.34 0.34 0.31 0.31 
(0.33 - 0.36) (0.31 - 0.36) (0.30 - 0.32) (0.30 - 0.32) 
Raynaud 4.83 4.45 2.6 3.6 
(3.69- 5.97) (2.68 - 6.21) (2.1 - 3.1) (0.5 -6.7) 
ISI-gly 0.93 1.04 0.65 0.60 
(0.77- 1.10) (0.78- 1.30) (0.57- 0.74) (0.48 - 0. 73) 
sit 4.9 6.9 ** 3.3 3.6 
(1 o-4min-1[pmol/Lr1) (3.6- 6.2) (5.4 - 8.4) (2.3- 4.3) (1.9-5.3) 
sgt 0.020 0.024 0.019 0.016 
[min-1] (0.015- 0.025) (0.015- 0.031) (0.012- 0.026) (0.01 0- 0.024) 
AIRgt 489 328 335 335 
(pmol/L h) (316- 659) (178- 478) (109- 561) ( 87- 582) 
AUCglucoset 134 122 * 155 140 
(mmol/L h) (120- 147) (110- 133) (146- 164) (131 - 150) 
Data are presented as mean (95% Confidence interval). *p < 0.05 **p < 0.01. P-values 
are for comparisons between the Saudi and Caucasian groups by unpaired Student' s 
t-test and Mann-Whitney t-test. iN umber of subjects; normal glucose tolerance 
(NOT) Saudi (n = 12) and Caucasian (n = 10); impaired glycaemic, Saudi (n = 10) 
and Caucasian (n = 9). Key: ｈｏｍａＲＭｾ Ｌ＠ homeostasis model assessment ｾＭ｣･ｬｬ＠
activity; HOMA2-IR, homeostasis model assessment insulin resistance; QUICKI, 
quantitative insulin sensitivity check index; ISI-gly, insulin glycaemic index; Si, 
insulin resistance; AIRg acute insulin response to glucose. AUCglucose, area under 
the curve for glucose from 2 to 10 min. 
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Table 7.3: Insulin sensitivity indices and other related parameters in different 
glycaemic categories. 
NGT IFG IGT DM 
(n = 24) (n = 12) (n = 12) (n = 13) 
Glucose (mmol/L) 5.3 ± 0.4 6.2 ± 0.5b 6.4 ± 0.6c 7.5 ± 2.1c 
Glucose 2hr (mmol/L) 5.4 ± 1.2 7.1±0.9 9.2 ± 1.0 13.9 ± 3.0 
Insulin (pmol/L) 77.9 ± 44.0 108.9 ± 47.0 152.5 ± 34.0c 110.4 ± 56.8 
Insulin 2hr (pmol/L) 284.6 637.4c 783.5c 619.2c 
(202.8- 366.4) (514.5- 760.3) (756.1 - 81 0.8) (474.1 - 764.3) 
%HbA1c 5.4 ± 0.5 6.2 ± 0.98 5.8 ± 0.6d 6.8 ± 1.2c 
IGF-1 (nmol/L) 22.7 ± 9.1 14.0 ± 3.88 16.4 ± 6.3 14.5 ± 4.48 
IGFBP-1 (flg/L) 6.4 4.5 3.1 d 8.9 
(3.9- 8.8) (2.2- 6.8) (1.6- 4.5) (5.8- 12.0) 
IGFBP-1 2hr (flg/L) 2.8 1.4 0.7d 2.6 
(1.5- 4.1) (0.5 - 2.3) (0.2- 1.2) (1.1-4.1) 
%HOMA2-P 103 103 127d 71 b 
(92- 115) (79- 126) (99-154) (56- 85) 
HOMA2-IR 1.5 2.0 2.9 2.2 
(1.2 - 1.8) (1.5- 2.5) (2.6- 3.3t (1.5- 2.9) 
QUICK! 0.34 0.31 8 0.298c 0.31 8 
(0.33 - 0.35) (0.30 - 0.32) (0.294 - 0.303) (0.29- 0.33) 
ISI-gly 0.98 0.728 0.52c 0.61 c 
(0.84- 1.12) (0.62- 0.83) (0.49 - 0.55) (0.47- 0.75) 
Raynaud 4.7 3.1 2.1 c 3.4 
(3.7- 5.6) (2.3- 4.0) (1.8- 2.3) (2.3- 4.6) 
Si 5.65 3.528 3.40 
(10.4min -1[pmol/Lr1)t ( 4.64 - 6.66) (1.83 - 5.22) (2.75- 4.78) 
Sg [min-1] t 0.021 0.017 0.013 8 
(0.0 17 - 0.025) (0.012- 0.021) (0.011 - 0.015) 
Data show means± SD or with 95% Confidence intervals. ANOVA one-way post-
hoc analysis between groups. 8 p < 0.05; bp < 0.01; cp < 0.001: NGT vs IFG, IGT and 
type 2 diabetes. dp < 0.05: IGT vs type 2 diabetes. ｾｵｭ｢･ｲ＠ of subjects; NGT 22· 
IFG, 9; IGT, 10. Key: NGT normal glucose tolerance; IFG, impaired fasting 
glucose; IGT impaired glucose tolerance; DM, type 2 diabetes. 
147 
-
0 Fasting IGFBP-1 
-,-
D IGFBP-1 (2hr) 12.0 
10.0 -
ｾ＠ -
= 8.0 -
- .,_ 
6.0 -
.. .. 
• • • T 
..
,_ 
T T • t 4.0 
,_ 
" T .. 21 .. .. .. 2.0 
31,., 1 T ｾｉ＠0.0 
NGT IFG IGT Type 2 diabetes 
Glucose tolerance categories 
Figure 7.1: Fasting and 2 hour serum IGFBP-1 levels (mean ± 95% CI) in different 
categories of glucose tolerance. ***p < 0.001; significant differences in 2 hour 
IGFBP-1 levels following a 75g oral glucose load when compared to their 
corresponding fasting levels for each glycaemic category. The fasting level of 
IGFBP-1 in each category represents 100% of each corresponding level of 2 hour 
IGFBP-1. Key: NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, 
impaired glucose tolerance. 
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7.3.5 Relationship of HbAlc to indices of insulin resistance 
Data analysis was carried out in order to investigate how well HbA 1 c correlated with 
different indices of insulin sensitivity in each ethnic and glycaetnic category. Table 
7.4 smntnaries this relationship across each glycaemic category. In the case of 
HbA 1 c untransfonned data was used as it becmnes non-normally distributed after 
Log-transfonnation. HbA1 c was found to be positively correlated with fasting 
glucose in each glycaemic category and tnore strongly in diabetic subjects (r = 0.68, 
p < 0.05). In overall subjects HbA1c was significantly associated with glucose (r = 
0.67, p < 0.001). This association becatne stronger after excluding the 2 outliers (r = 
0.70, p < 0.001) (Figure 7.2). HbA1c was tnore strongly associated with fasting 
glucose in Saudi subjects overall (r = 0.59, p < 0.001) than in Caucasians (r = 0.45, p 
< 0.05) (Figure 7.2). In the NGT category insulin sensitivity (Si) was the index tnost 
strongly associated with HbA1c (r = - 0.65, p < 0.001). In the IFG category, the 
correlation between Si and HbA1c becatne weaker than in the NGT category (Figure 
7.3, A). In the NGT category no significant correlation was observed between 
HbA 1 c and Si in Saudis who had lower Si values and higher HbA 1 c levels compared 
to Caucasians (Figure 7.3, B). Linear stepwise regression analysis for total subjects 
in each population demonstrated that HbA1c Ｈｾ＠ = 0.62, p < 0.001) was directly 
associated with fasting glucose in Saudi subjects while in Caucasians, HbA1c Ｈｾ＠ =-
0.74, p < 0.001) was inversely associated with insulin sensitivity (Si). 
7.3.6 l(inetic changes of insulin, glucose and IGFBP-1 after intt·avenous 
glucose administration 
The response to intravenous glucose in nonnal Saudi and Caucasian subjects over 
180 minutes of glucose and insulin values are shown in Figure 7.4, A and B 
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respectively. AUCglucose was higher in Saudis than in Caucasians and reached 
statistical significance in glucose intolerance (p < 0.05) but not in NOT category 
(Table 7 .2). After dextrose injection and at all time intervals (0 - 180 tninutes) the 
tnean (95% Confidence interval) levels of glucose and insulin were observed to be 
higher in Saudis cmnpared to Caucasians (Figure 7 .4, A and B) but at the time point 
(t = 8 tnin) the tnean (95%CI) level of glucose in NOT is significantly higher (p < 
0.05) in Saudis [14.6 tnmol/L (13.4- 15.8)] cmnpared to Caucasians [13.2 mtnol/L 
(12.2 - 14.2)] (Figure 7.4, A), while insulin levels were significantly higher in 
Saudis cmnpared to the Caucasians at (t = 8, 10 and 12 tnin) (p < 0.05) (Figure 7.4, 
B). In glucose intolerance subjects the AUCglucose was significantly higher (p < 
0.05) in Saudis compared to Caucasians (Table 7.2). 
For the purpose of kinetic analysis of IGFBP-1 after intravenous glucose 
administration, data frmn 17 normal subjects were evaluated. As shown in Figure 
7.5 IGFBP-1 levels initially remained constant but a slight increase was observed at 
4 and 12 tnin [mean (95%CI), 6.9 f.lg/L (4.5 - 9.1) and 7.2 f.lg/L (4.5 - 9.2) 
respectively] without any significant difference frmn the baseline level [6.8 f.lg/L (4.8 
- 9.0)]. This was followed by a gradual decline in IGFBP-1 levels to reach a nadir at 
120 min [3.4 J.Lg/L (2.3 - 4.5)]. IGFBP-1 level in this titne point was significantly 
different frmn the baseline level (p < 0.05) and considered to be about 50% thereof. 
After 120 tninute, the IGFBP-1 levels rapidly increased up to 6.5 f.lg/L (4.0- 9.2) at 
180 tnin which was ahnost the satne level as the baseline. 
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Table 7.4: Correlations between HbA1 c and other insulin sensitivity indices in 
addition to glucose effectiveness. Subjects were classified according to their 
glycaemic status. 
NGT IFG IGT DM All 
(n = 24) (n = 12) (n = 12) (n = 13) (n = 61) 
IGFBP-1 -o.5o· -0.36 -0.41 0.2 -0.08 
Fasting insulin 0.53 ** 0.28 -0.64 0.11 0.30 
Fasting glucose 0.46* 0.14 0.05 0.68* 0.67··· 
HOMA2-IR 0.52** 0.44 -0.67* 0.22 0.35•• 
QUICK I -0.55 •• -0.27 0.67* -0.33 -0.43··· 
ISI-gly -0.45* -0.11 0.31 0.08 -0.36** 
Raynaud -0.53** -0.28 0.64* -0.11 -0.30* 
Sg" -0.46* 0.08 -0.35 -0.53 ... 
Si" -0.65 ... -0.48 0.61 -0.59··· 
*p < 0.05 , **p < 0.01 , ***p < 0.001. "Number of subjects; NGT, 22; IFG 9; IGT, 10; 
All, 41. Key: NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, 
impaired glucose tolerance; DM, type 2 diabetes; IGFBP-1 , insulin like growth factor 
binding protein 1; HOMA2-IR, homeostasis model assessment; QUICK!, 
quantitative insulin check index; ISI-gly, insulin sensitivity glycaemic index; Sg, 
glucose effectiveness; Si insulin sensitivity. 
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All subjects: r = 0.67, p < 0.001 
Saudis <•>: r = 0.59, p < 0.001 
Caucasians ( o): r = 0.45, p < 0.05 
8.0 10.0 12.0 14.0 
Fasting Glucose (mmolll) 
Figure 7.2: Relationship between overall HbAlc (including outliers) and fasting 
glucose for Saudis (n = 33) and Caucasians (n = 28). In all subjects a stronger 
association without the outliers (circled) was observed (r = 0.70, p < 0.001). 
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Figure 7.3: Relationship between Minmod Si and HbA1c levels: A) normal glucose 
tolerance (NGT, o) (n = 22) and impaired fasting glucose (IFG, •) (n = 9) categories 
respectively. B) Saudi (+, n = 12) and Caucasians (0, n = 10) in the NGT category 
only. Key: NS not significant. 
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Figure 7.4: Plotted time intervals for 12 Saudis and 10 Caucasian normal subjects 
after intravenous glucose infusion (0.3 g/kg of 50%), (A) Glucose levels, 
significance of difference compared to Caucasians at t = 8 min, *p < 0.05 (B) Insulin 
levels, significance of difference compared to Caucasians at t = 8, 10 and 12 min, 
*p < 0.05. Data are mean (95% Confidence interval). 
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Figure 7.5: The kinetics of insulin like growth factor binding protein I OGFBP-1) 
after intravenous infusion of glucose (0.3g/kg of 50%) at 0 minute for 17 normal 
subjects. Mean concentrations at 120 min were significantly different from the 0 
minute (p < 0.05). Time intervals shown as means (95% Confidence interval). 
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7.4 Discussion 
7.4.1 Insulin sensitivity (Si) and other risk factors in Saudis and Caucasians 
In spite of there being no significant differences in WHR, BMI, % TBF or age in the 
NGT category Saudis were observed to have lower insulin sensitivity (Si) than 
Caucasians. This finding was not unexpected given the greater prevalence of 
· tnetabolic syndr01ne and metabolic derangetnents in the former population. Further 
evidence for a higher prevalence of tnetabolic syndrome in Saudi subjects was the 
raised levels of HbA 1 c and diastolic BP in NGT Saudis compared to Caucasians. 
Significant increase of the age of the Caucasians in the glucose impaired category 
can be explained by the following; according to the United Nations, the prospect for 
average lifespan in UK Caucasians is 78.9 years while in Saudis it is 72.8 years. 
Obtaining subjects fulfilling the same inclusion criteria particularly in the impaired 
glycaetnic category was a difficulty encountered in this study. Although there was no 
significant difference in glucose effectiveness (Sg) in NGT subjects between the two 
populations, the lower tnean value in NGT Saudis suggests that as well as having 
higher insulin resistance, these subjects also had less efficient disposal of glucose 
independently of the effects of insulin. This outc01ne can predict future development 
of itnpaired glucose tolerance in some populations (Osei et al., 2004). 
Increased diastolic BP in Saudis compared to Caucasians needs a dedicated study but 
at the smne titne confinns the strong association between impaired diastolic BP and 
insulin resistance which has been investigated recently (Zizek et al., 2008). 
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7.4.2 Simple indices of insulin resistance between the two populations 
The rationale for using various insulin sensitivity techniques in this study was to 
avoid lhnitations of the study that _n1ay have occurred had analysis been confined to a 
single technique and to detect . any difference in insulin sensitivity which tnight be 
observed by some simple techniques but not others. ｾｭｯｮｧｳｴ＠ the insulin sensitivity 
indices examined viz HOMA2-IR, QUICK!, Raynaud, ISI-gly and Si, the only two 
which estimated insulin resistance to be higher in NOT Saudi cotnpared to NOT 
Caucasian subjects were Si and ｉｾｉＭｧｬｹＮ＠ As an alternative technique to the reference 
tnethod, FSIVGTT was expected to be tnore accurate in estimating insulin resistance 
than the other indices used in this study. Although the difference was not significant 
for ISI-gly it has been considered by a previous study to be tnore accurate in 
estimating insulin sensitivity cmnpared to other shnple fasting indices as its 
estimation depends on fasting and post-dose samples (Carnevale Schianca et al., 
2006). Other simple fasting indices ｣ｾｵｬ､＠ not detect any significant differences 
between the two populations. The reason for this could be that these shnple indices 
rely on fasting values alone and do not take post-load glucose and insulin values into 
account. 
7.4.3 IGFBP-1 levels in Saudis and Caucasians 
Our observation of higher fasting IGFBP-1 levels in Caucasians compared to Saudis 
is in line with our previous conclusion in Chapter 6 and with the study of Maddux et 
a! (Maddux et al., 2006) that IGFBP-1 can be used as a tnarker of insulin resistance 
in normal subjects. Inter-ethnic differences in fasting IGFBP-1 levels in NOT 
subjects have also been observed in a previous study of three different populations 
(10 each) viz Caucasians, Chinese and Asian Indians (Liew et al., 2005). For more 
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details about IGFBP-1 in different populations refer to section 1.6.3.4 in Chapter 1. 
However, in our Caucasian subjects fasting IGFBP-1 levels were not as low as 
expected for their degree of hyperinsulinaemia. This tnay reflect greater hepatic 
insulin sensitivity in addition to higher ｾＭ｣･ｬｬ＠ activity in Caucasians than in Saudis. 
In the Saudi population, 2 hour IGFBP-1 was clearly suppressed by the greater 
postprandial hyperinsulinaetnia present at this titne point presutnably reflecting 
greater peripheral insulin resistance in these subjects. Another possible explanation 
of high prevalence of insulin resistance in the Saudis is a reduced activity of the post 
insulin receptor signalling pathway which contributes to the developtnent of insulin 
resistance and consequently to type 2 diabetes (Youngren, 2007) but this point needs 
tnore investigation in this patticular population. 
To tninilnise the impact of pre-analytical factors including satnple transportation, 
assays were undertaken in Guildford and Jeddah using the same assay platfonn and 
tnethodologies (for glucose and HbAlc), or perfonned at one site using kits from a 
single batch (insulin assay), and samples that had been frozen at -20 °C imtnediately 
after collection and during transport. 
7 .4.4 IGFBP-1 ldnetics after oral glucose administration 
It is well known that insulin is the tnain regulator of IGFBP-1 levels. Therefore, in 
the context of our data the extent of the decrease in the percentage of 2 hour IGFBP-
1 post oral glucose administration (when cmnpared to the percentage of the fasting 
level of IGFBP-1) depends on the degree of the status of glucose tolerance 
particularly in the NGT, IFG and IGT glycae1nic categories. In subjects with NGT 
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the 2 hour IGFBP-1 expressed as a percentage of the fasting level was least affected 
(44%) cmnpared to the percentages of other categories ofiFG (31 %) and IGT (23%). 
The observed decrease in these nonnal subjects ( 44% of baseline) is in accordance 
with results observed in previous studies where the level fell to about 50% of 
baseline (Maddux et al., 2006; Suild(ari et al., 1989). However, in subjects with type 
2 diabetes the percentage of 2 hour IGFBP-1 (29%) was higher than expected when 
cmnpared to the decline trend of percentages with other categories (NGT = 44%, IFG 
= 31% and IGF = 23%). This is likely due to the decline in levels of insulin secreted 
by the pancreatic beta cells as secretion capacity declined in diabetic subjects (Table 
7.3). Consequently, the low insulin levels in these subjects will be less able to exert 
negative regulation upon IGFBP-1 secretion. 
7.4.5 IGFBP-1 kinetics after intravenous glucose administration 
Rapid dynamic changes in serum levels of IGFBP-1 are about 10-fold or more in 
relation to tneals (Lee et al., 1993). Flanagan et a!., 2006 exatnined the IGFBP-1 
response after intravenous glucose tolerance (Flanagan et al., 2006). The level of 
IGFBP-1 was rapidly suppressed in the first few tninutes, but our finding showed a 
fairly constant tnean level of serum IGFBP-1 in the first 12 tnin following 
intravenous glucose injection and this was unexpected. It has been described 
previously in Chapter 1 (section 1.6.1) that sennn IGFBP-1levels lag behind those of 
insulin. A possible reason for these different lags is due to the form of the IGFBP-1 
being tneasured as the capture antibody used in this in-house ELISA assay 
preferentially binds to non- and less-phosphorylated IGFBP-1 forms as described 
previousely in Chapter 2 (sections 2.8 and 2.9) while Flanagan eta/., n1easured total 
IGFBP-1. Another reason could be due to dextrose concentration or infusion time as 
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in the Flanagan study 0.5 g/kg of 50% was infused intravenousely over three minutes 
while in our study 0.3 g/kg of 50% dextrose was infused over one tninute. This high 
concentration of dextrose tnay offset the insulin regulation of IGFBP-1. 
After 120 tninutes of intravenous glucose tolerance the serun1 IGFBP-1 increased 
rapidly which could be due to low concurrent levels of insulin level. Other authors 
suggested that it could be due to the low free IGF-I available at this stage of the test 
(Nyomba et al., 1997). 
7.4.6 HbAlc association with diffe.-ent indices of insulin resistance 
As expected in the present study, increased HbAlc levels paralleled the deteriorating 
glycaetnic status except in IGT category as tnost of the subjects were under 
controlled-diet. HbA 1 c correlations with indices of insulin sensitivity were highly 
associated in the NGT category. In a previous study by Sung et al., sitnilar outcmnes 
were obtained between HbAlc and HOMA-IR in non-diabetic Korean adults (Sung 
and Rhee, 2007). Regarding other categories weak associations between HbA1c and 
indices of insulin sensitivity have been observed. This is similar to our previous 
results (Chapter 6) on IGFBP-1 association with different indices of insulin 
resistance in NGT and IFG categories. This could be due to disturbed insulin 
secretions in these categories (Porksen, 2002). The relatively weak correlation 
between HbA1c and Si observed in Saudis in the present study was due to the 
confounding strong association between elevated levels of both HbA1c and fasting 
glucose in this population. 
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7.4.7 HbAlc as a marl{er of insulin resistance 
In addition to the accepted clinical utility of HbAlc tneasuretnent as a measure of 
glycae1nic control, it can also be used as a tnarker of insulin sensitivity in NGT 
adults. As such it is 1nore easily assessed (e.g. by near patient testing) cmnpared to 
other indices which 1nay not be routinely available e.g. insulin and IGFBP-1. 
Secondly HbAlc, unlike other insulin sensitivity indices, has the potential of 
reflecting the 1nean insulin sensitivity over the preceding weeks or months whilst 
other indices reflect only the current status of insulin sensitivity. Another advantage 
of using HbAlc as tnarker of insulin sensitivity is the minitnal overlap between NGT 
and subjects with type 2 diabetes. This outcome agrees with a previous study of 
HbAlc overlap between different glycae1nic categories (Lapolla et al., 1988). The 
defects in insulin secretion and increased glucose levels which are present in type 2 
diabetes might lead to values for the shnple fasting indices including IGFBP-1 to 
overlaping with those in healthy individuals. However, this does not appear to be the 
case with HbA 1 c. 
7.5 Liinitations of this study 
There are several limitations that 1night have affected our study. Firstly, the standard 
FSIVGTT used in our study cannot estimate insulin sensitivity (Si) and other derived 
parameters accurately in subjects with low insulin secretion i.e. type 2 diabetes. 
Secondly, a relatively low number of subjects was involved in the study. Despite 
these two tnain limitations significant differences in metabolic risk factors were 
noted between Saudi and Caucasian populations. This study is relatively small 
preliminary investigation but obviously demonstrates a clear difference between the 
two populations that is worthy of further investigation. As this study is the first to 
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cotnpare these two populations it should help focus future investigations ultimately 
ahned at solving the epidetnic problem of diabetes not only in Saudi Arabia but in 
neighbouring countries as well. 
7.6 Conclusions 
In conclusion, these data are novel and iinpm1ant as they provide objective evidence 
for the nonnal Saudi population being tnore insulin resistant than a Caucasian 
population. With a stnall number of subjects simple fasting indices of insulin 
resistance are not adequate tools to estimate insulin resistance between different 
groups. HbA1c proved to be a simple, non-invasive marker which could accurately 
esthnate insulin sensitivity in nonnal individuals. Its estimation should be 
accotnpanied by anthropotnetric measuretnents and glucose tolerance testing. In 
nonnal individuals at 2 hours the IGFBP-1 level will be about half the baseline level 
regardless of the route of glucose adtninistration. The kinetics of different forms of 
IGFBP-1 in response to intravenous glucose needs further investigation. 
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Chapter 8 
Phosphorylation status of insulin lil{e growth factor binding 
protein 1 in subjects with and without ischaemic heart 
disease 
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8.1 Introduction 
Insulin-like growth factors (IGF-I and IGF-II), are present in extracellular fluid 
bound to specific insulin-like growth factor binding proteins (IGFBPs). These 
binding proteins tnodulate IGF tnitogenic and tnetabolic activity as described in 
Chapter 1, section 1.6. One of these binding proteins, IGFBP-1, may either inhibit or 
potentiate the binding of the IGFs to their cellular receptors. Furthennore it can 
extend the biological half-life of IGFs (Elgin et al., 1987; Ritvos et al., 1988) 
thereby influencing their biological activity as discussed in sections 1.6. The 
differential effects of IGFBP-1 tnay be due to the existence of phosphorylated and 
non-phosphorylated forms of IGFBP-1. Supernatants of purified human amniotic 
fluid or HepG2 cell culture were found to contain a non-phosphorylated fonn and 
four phosphorylated fonns of IGFBP-1. The affinity of binding of IGFs to IGFBP-1 
depends on the degree of the phosphorylation of IGFBP-1. IGFBP-1 is 
phosphorylated at three different serine residues: 101, 119, and 169 (Jones et al., 
1993) by several kinases (Ankrapp eta!., 1996). The bioavailability of IGF-1 may 
therefore be influenced the phosphorylation status of IGFBP-1. Metabolic and 
tnitogenic effects ofiGF-I tnight also be affected by such phosphorylation (Gibson et 
a!., 1999). The phosphorylation status of IGFBP-1 varies in different body fluids 
(Koistinen et al., 1993). In amniotic fluid non-phosphorylated IGFBP-1 is the 
predmninant form of IGFBP-1 in addition to other less-phosphorylated fmns while in 
normal adult serum phosphorylated form of IGFBP-1 is the predotninant fonn 
(Westwood et al., 1994). See section 1.6.3.2 for tnore detail on IGFBP-1 
phosphorylation. 
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Detection of IGFBP-1 was enabled by using radioiinmunoassay (Lee PDK, 1994) 
and enzyme itntnunoassays (Khosravi et al., 1997; Rutanen and Pekonen, 1991). A 
few versions of these assays have been reported to be unaffected by phosphorylation 
status, whilst others were reported to recognise a specific form of IGFBP-1 
(Khosravi et al., 2007; Khosravi et al., I 997). It has also been repmied that different 
phosphorylation states of IGFBP-1 tnay alter its imtnunoreactivity (Westwood et al., 
1994). Most of the published assays for piGFBP-1 recognise partially 
phosphorylated forms of IGFBP-1 but it would be desirable to be able to tneasure 
accurately absolute levels ofpiGFBP-1. 
However, it is well known that IGFBP-1 levels are associated with a variety of 
cardio-tnetabolic risk factors including increased body tnass index (BMI), raised 
triglyceride levels and high sennn insulin (Heald et al., 2002). In Chapter 6 we 
showed that fasting serum levels of IGFBP-1 can be used as a tnarker of insulin 
resistance in nonnal individuals. In addition to this low levels of serum IGFBP-1 are 
associated with increased cardiovascular risk (Heald et al., 2002). 
In this study different fortns of IGFBP-1 have been investigated in patients with and 
without established ischaetnic heart disease (IHD) as the phosphorylation status of 
IGFBP-1 tnay have an itnportant role in the development of cardiovascular disease 
(Heald et al., 2002). An in-house enzyme-linked immunosorbant assay (ELISA) to 
esthnate lpiGFBP-1 quantitatively, has been described in Chapter 2 (section 2.9). In 
this study absolute levels of piGFBP-1 were determined by establishing a novel in-
house ELISA assay. Both assays were used to determine serum levels of the 
npiGFBP-1, lpiGFBP-1 and piGFBP-1 in addition to their ratio in patients with and 
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without cardiovascular disease (CVD) and particularly in those with ischaetnic heart 
disease (IHD). 
8.2 Subjects and methods 
8.2.1 Subjects 
Subjects involved in the study were frotn different ethnicity and glycaetnic 
categories. The total nun1ber of subjects was 75. They were categorised as either 
being with (n = 36) or without HID (n = 39). The total nmnber of post-menopausal 
fetnales was 10 (3 with and 7 without IHD). Inclusion and exclusion criteria for 
subjects involved in this study were explained in Chapter 2 (section 2.1). The study 
was approved by Research Ethics Cmntnittees in South West Surrey Local Research 
Ethics Committee (Guildford, UK); King Khalid National Guard Hospital (Jeddah, 
Saudi Arabia) and Mashhad University of Medical Sciences Ethics committee, 
(Mashhad, Iran). Subjects classification according to ethnicities; Caucasians (n = 31), 
Saudis (n = 22) and Iranians (n = 22) (Table 8.1). A standard 75g oral glucose 
tolerance test was carried out on all patticipating subjects. Subsequently subjects 
were classified according to World Health Organisation (WHO) criteria (Alberti and 
Zimtnet, 1998). More details about WHO criteria were discribed in Chapter 1 (Table 
1.4). Subjects were divided into four categories as follow: nonnal glucose tolerance 
(NGT, n = 42), impaired fasting glucose (IFG, n = 1 0), itnpaired glucose tolerance 
(IGT, n = 16) and type 2 diabetes (DM, n = 7). DM subjects were as described in 
section 2.1. Clinical characteristics of the subjects are shown in Table 8.1. The two 
groups were age and BMI tnatched. Established IHD was defined as described 
previously in section 2.1. 
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Table 8.1: Comparison between anthropometric and biochemical characteristics of 
study subjects without and with ischaemic heart disease (IHD) 
Biochemical characteristics Without IHD IHD 
All 
(n = 39) (n = 36) (n = 75) 
Caucasian (n) 16 15 31 
Iranaian (n) 10 12 22 
Saudi (n) 13 9 22 
Males(%) 67% 69% 68% 
Age (years) 49±2 54± 1 51± 1 
BMI (kg/m2) 28.1 ± 0.7 28.9 ± 0.7 28.5 ± 0.5 
Glucose (mmol/L) 5.5 ± 0.2 5.4 ± 0.2 5.4 ± 0.1 
Insulin (pmol/L) 81.1 ±7.0 87.8 ± 8.1 84.3 ± 5.3 
HOMA-IR 3.21 ± 0.34 3.47 ± 0.39 3.33 ± 0.26 
Total cholesterol (mmol/L) 4.57 ± 0.18 4.44 ± 0.19 4.51 ± 0.13 
HDL-C (mmol/L) 1.22 ± 0.05 1.14 ± 0.05 1.18 ± 0.03 
LDL-C (mmol/L) 2.73 ± 0.14 2.66 ± 0.13 2.7 ± 0.10 
HDL-C/LDL-C 0.52 ± 0.07 0.45 ± 0.03 0.49 ± 0.04 
Triglycerides (mmol/L) 1.37 ± 0.13 1.73 ± 0.20 1.55 ± 0.12 
IGF-I (nmol/L) 17.1 ± 1.1 17.5±1.1 17.3 ± 0.8 
lpiGFBP-1 (Jlg/L) 5.35 ± 0.51 2.68 ± 0.43*** 4.06 ± 0.37 
piGFBP-1 (Jlg/L) 33.3 ± 2.0 25.3 ± 2.2** 29.4 ± 1.5 
lpiGFBP-1/ piGFBP-1 0.16±0.01 0.11 ± 0.01 ** 0.13±0.01 
Data are mean± SE. Significant difference between subjects with and without IHD, 
**p < 0.01, ***p < 0.001. Key: BMI, body mass index; HDL-C, high density 
lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-IR, 
insulin resistance of homeostasis model assessment; IGF-1, insulin-like growth factor 
1; lpiGFBP-1, less-phosphorylated IGFBP-1; piGFBP-1, phosphorylated IGFBP-1. 
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8.2.2 Assays 
Insulin was ｴｮ･｡ｳｵｲｾ､＠ by solid phase two-site ELISA (Mercodia, Uppsala, Sweden 
cat. 10-1128-02). Glucose and lipids were assayed on a Sietnens Advia 1650 
analyser. Serum IGF-I was detennined by chemilmninescent hntnunoassay using 
IInmulite auto-analyser. These tnethods have been discussed in details in Chapter 2, 
section 2.4. Hmneostasis 1nodel assessment (HOMA-IR) was used as an index of 
insulin resistance in the study (Matthews et a!., 1985) (see section 1.5 .2.2). 
LpiGFBP-1 and npiGFBP-1 were tneasured as described in section 2.9.1. The 
capture antibody preferentially binds to the less- and non- phosphorylated forms of 
IGFBP-1. More details of R&D capture antibody criteria have been presented in 
section 2.8. The satne principle was followed to investigate antibodies involved in 
the development of piGFBP-1 ELISA. The following sections will describe this 
assay in detail. 
8.2.3 Antibodies characterisation ofpiGFBP-1 ELISA 
The two antibodies utilised in the piGFBP-1 in-house ELISA assay were Medix 
Biochen1ica 6303 as capture antibody and Becton Dickenson (BD) anti-
phosphoserine as labelled antibody. For tnore information on these two antibodies 
refer to Chapter 2, sections 2.7.2 and 2.7.3. By using electrophoresis and Western 
ligand blotting (WLB) techniques, both antibodies were investigated for binding to 
different forms of IGFBP-1. Other techniques such as alkaline phosphatase 
dephosphorylation and itn1nunopreci-pitations were essential for these investigations. 
Details of these techniques were given in Chapter 2, sections 2.8.3 and 2.8.4 
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8.2.3.1 Anti-IGFBP-1 antibody ofMedix Biocltemica 
In addition to the characterisation of 1nonoclonal antibody (Mab) 6303 described by 
Westwood et al.J (Westwood et al., 1994) the antibody was further characterised by 
our technique of electrophoresis followed by WLB. This antibody was applied to 
WLB to bind to rhiGFBP-1 and IGFBP-1 in a nonnal serum san1ple with and 
without dephosphorylation by alkaline phosphatase (Figure 8.1). A faint band of 
IGFBP-1 was observed for rhiGFBP-1 (npiGFBP-1). A shnilar faint band was 
observed after senun dephosphorylation indicating that Mab 6303 has the ability still 
to bind both to nonphosphorylated and less-phosphorylated IGFBP-1. After 
immunoprecipitation with antiphosphoserine antibody only a single band of 
phosphorylated IGFBP-1 was observed. This capture antibody showed no visible 
cross-reactivity with other IGFBPs when used to immunoprecipitate normal human 
serum. These outcomes supports the report of Westwood et al., about the same 
antibody (Westwood et al., 1994) . 
8.2.3.2 Antiphospbosel"ine antibody of Becton Dicl{enson 
The antiphosphoserine antibody was used in Western blotting with rhiGFBP-1 and 
human sermn sample before and after alkaline phosphatase pre-treatment. No bands 
were observed for rhiGFBP-1 (npiGFBP-1) or in the serum sample after 
dephosphorylation (Figure 8.2). No crossreactivity was observed with other proteins 
which co-1nigrate with IGFBP-1 (Mw 20, 30 and 40 Iilla) after satnple 
immunoprecipitation using antiphosphoserine antibody and ligand with anti-IGFBP-
1 antibody (Mab 6303, Medix) on WLB (Figure 8.3). 
Mw (kDa) 
30 ---+ 
20 ---+ 
ｾ＠ npiGFBP-1 
ｾ＠ piGFBP-1 
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Figure 8.1: Expression of IGFBP-1 in serum samples using Medix Biochemica 
(6303) capture antibody and LDS (Lithium Dodecyl Sulphate) as a sample buffer: I. 
Recombinant human IGFBP-1 (rhiGFBP-1) 2. Ladder of molecular weight (Mw) of 
20 and 30 k.Da 3. Normal serum sample immunoprecipitated with antiphosphoserine 
antibody 4. Normal serum sample 5. Normal serum sample after dephosphorylation. 
Key: npiGFBP-1 , nonphosphorylated IGFBP-1 ; plGFBP-1 , phosphorylated IGFBP-
I. 
Mw(kDa) 
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20 ---+ 
2 3 4 
+-- piGFBP-1 
Figure 8.2: Expression of piGFBP-1 in serum samples using Beckton Dickenson 
antiphosphoserine antibody and LDS (Lithium Dodecyl Sulphate) as a sample buffer: 
1. Ladder of molecular weight of 20 and 30 kDa 2. Recombinant human IGFBP-1 
(rhiGFBP-1) 3. Normal serum sample 4. Normal serum sample after 
dephosphorylation. Key: piGFBP-1 , phosphorylated IGFBP-1. 
Mw (kDa) 
40---+ 
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2 
.- piGFBP-1 
Figure 8.3: Crossreactivity of IGFBP-1 with other binding proteins using anti-
IGFBP-1 antibody (Mab 6303 Medix Biochemica) and LDS (Lithium Dodecyl 
Sulphate) as a sample buffer: I. Ladder of molecular weight of 20, 30 and 40 k.Da 2. 
Normal serum sample after immunoprecipitation with antiphosphoserine antibody. 
No visible cross-reactivity with any other binding proteins co-migrate with IGFBP-1. 
Key: piGFBP-1, phosphorylated IGFBP-1. 
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8.2.4 Biotin conjugation 
Biotin conjugation of antiphosphoserine antibody was achieved by using an lnnova 
Biosciences Lightening Link kit (catalogue number. 704-0010) with 100% recovery 
as indicated by the Innova Biosciences kit insert. Briefly 1 0 f.LL of a tnodifier 
solution was added to every 100 f.ll of antiphosphoserine antibody (250 f.Lg/mL). 
This was mixed and then dispensed into a vial containing a substance of Lightening-
Link lyophilised substrate. After a 1ninimum of 3 hours incubation at RT, 10 f.lL of 
quenching reagent was then added followed by at least 30 tninutes further incubation. 
The biotinylated (labelled) antibody was then ready to use or store in stnall aliquots 
at-80°C. 
8.2.5 piGFBP-1 ELISA protocol 
The piGFBP-1 ELISA technique is diagrammatically represented in Figure 8.4. 
Briefly, 96-well plates (Nunc, cat. 820848, Demnark) were coated with 100 f.LL 
capture antibody (10 ｾｴｧＯｴｮｌＩ＠ diluted in PBS at pH 7.4. This capture tnonoclonal 
antibody (Mab 6303, Medix Biochemica), recognizes the highly phosphorylated 
form of IGFBP-1 as previously discussed in section 2.7.2. After an overnight 
incubation at 4-8 °C, the plates were washed six times with 300 JlL of wash buffer 
(0.05% Tween-20 diluted in PBS at pH 7.4). Then 300 f.lL of freshly prepared assay 
buffer [50 tnM Na2HP04, 50 mM NaCl, 50 tnM NaSCN, 10 tnM EDTA tetrasodimn 
salt, 0.05% 3-[( chloroamidopropyl) dimethlamtnonio ]-1-propane sulphonate 
(CHAPS, Sigma), 1 %BSA, 0.03% Tween-20, 2 J.lllmL fetal calf sermn (Sign1a, 
catalogue nun1ber N463 7) and 0.1% Proclin 300, pH 8.5] was dispensed into each 
well for 1 hour blocking. After the washing step, 100 ｾｴｌ＠ of standard or serum (1 :2 
v/v in assay buffer) was dispensed into each well. The plate was then incubated for 
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two hours at room te1nperature (RT). Due to unavailability of plGFBP-1 standard 
primary n1aterials, the assay standard was prepared fr01n a pooled senun spechnens 
(I 0 smnples with high total IGFBP-1 ). Standards were serially diluted with the assay 
buffer. The standard assigned values were obtained by using a total IGFBP-1 DSL 
commercial kit. After washing the plate, 100 J..LL of biotinylated anti-phosphoserine 
antibody (250 }lg/mL, diluted 1 :300 in assay buffer) was then added into each well 
and incubated for a fmther 2 hours at RT with continuous shaking. After fmther 
washing, 100 J..LL of streptavidin horse-radish peroxidase (R&D cat. DY998) was 
then added to each well and incubated for 20 1ninutes. The substrate solution 
tetramethylbenzidine (TMB) stabilized with H202 (R&D cat. DY999) was then 
added to initiate the enzy1natic reaction followed by a further incubation for about 20 
Ininutes at RT. The reaction was stopped by addition of 1M sulphuric acid. The 
absorbance was read in a 1nicroplate reader (Multilabel Counter VICTOR model 
1420 fr01n PerkinElmer, UK) and corrected as described previousely in section 2.9.1. 
8.2.6 Characteristics of antibody binding using ELISA 
The binding of anti-phosphoserine antibody to piGFBP-1 using the ELISA was 
evaluated by the following two techniques: 
The 1nean concentration (± SE) of IGFBP-1 in 8 senun before (94.2 ± 14.1 f!g/L) 
and after (6.6 ± 2.4 ｾｴｧＯｌＩ＠ alkaline phosphatase treatment was significantly decreased 
(p < 0.001). 
Another technique was carried out by using a com1nercial kit which can estimate the 
total IGFBP-1 concentration (Diagnostic Systetn Laboratories, cat. DSL-10-7800). 
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Eight serum samples were analysed to confinn these findings. The mean value (± 
SE) of IGFBP-1 tneasured by our established in-house piGFBP-1 assay was not 
significantly different in concentration (27.4 ± 6.4 f..lg/L) than total IGFBP-1 (24.0 ± 
6.4 ｾｴｧＯｌＩＮ＠ Significant positive association between the obtained values from the two 
immunoassays was observed (r = 0.82, p < 0.05). 
8.2.7 Performance characteristics ofpiGFBP-1 ELISA 
The lower limit of detection of the assay was 0.6 ｾｴｧＡｌ＠ as detennined by tnean plus 
2SD of the blank smnple consisting of sample buffer only run ten times. Within-run 
hnprecision was estimated by five times repeating analysis of two satnples with 
different concentrations (tnean ± SD; 2.6 ± 0.1 and 21.3 ± 1.7). The coefficient of 
variation (CV) ranged from 2.0 to 7.7% respectively. Between-run imprecision was 
calculated by observing data for 2 satnples in duplicate wells in 5 separate assays 
(1nean ± SD; 2.6 ± 0.2 and 21.1 ± 2.1) and ranged frmn 6.0 to 10.0% respectively. 
The range of recovery was 103-123% (Table 8.2). Linearity was tested by analyzing 
serially diluted standard (pooled serum samples) in assay buffer (Figure 8.5). 
Biotinylated Antiphosphoserine Ab (BD) 
174 
TMB substrate 
+ 
Streptavidin-HRP 
0 
Colour 
(product) 
IGFBP-1 Capture Ab (Medix) 
Figure 8.4: The piGFBP-1 two step sandwich ELISA using anti-human IGFBP-1 
(Mab 6303 Medix Biochemica) as a capture antibody and anti-phosphoserine (BD) 
as biotin labelled antibody. 
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Table 8.2: Percentage recovery of piGFBP-1. 
Endogenous Added Expected Observed Recovery Sample piGFBP-1 piGFBP-1 piGFBP-1 plGFBP-1 (%) ＨｾｧｩｌＩ＠ ＨｾｧｩｌＩ＠ ＨｾｧｩｌＩ＠ ＨｾｧｩｌＩ＠
44.1 40.4 84.5 86.9 103 
20.7 64.7 74 114 
10.6 54.6 67.3 123 
II 22.2 40.4 62.6 69.9 112 
20.7 42.8 46.4 108 
10.6 32.7 33.8 103 
III 3.7 40.4 44.1 49.5 112 
20.7 24.4 28 I 15 
10.6 14.3 14.9 104 
Three serum samples with different levels of piGFBP-1 were added with known 
amount of piGFBP-1 standard. Recovery (%) was calculated as a ratio between 
observed and expected levels. 
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i 
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y = O.OM2x + 0.0451 
R2 = 0.9991 
ＰＮＰＰＫＭＭＭｾＭＭＭＭＭＭＭＭｾＭＭＭＭｾＭＭｾｾＭＭｾＭＭｾｾＭＭｾＭＭｾ＠
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 
piGfBP-1 (Jigll} 
Figure 8.5: Phosphorylated IGFBP-1 (piGFBP1) ELISA linearity validation study. 
The curve shows the absorbances of serially diluted standard (pooled serum) against 
different levels of piGFBP-1. 
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8.3 Results 
8.3.1 Biochemical characteristics 
Difference in the biochemical characteristics of subjects with and without IHD are 
smntnarized in Table 8.1. There were a total of 75 subjects in the entite group with 
28.5 ± 0.5 kg/tn2 as a tnean of BMI ± SE. The two groups of subjects with and 
without IHD were evenly distributed in BMI and age as there were no significant 
differences in these two parmneters. Levels of lpiGFBP-1, piGFBP-1 (Figure 8.6) 
and the ratio were significantly higher in individuals without IHD compared to those 
with IHD (p < 0.001, p < 0.01 and p < 0.01 respectively). There were no significant 
differences in all cardiovascular risk factors including age·, BMI, cholesterol and 
insulin resistance, but they were higher in individuals with IHD compared to those 
without. The unit ratios between lpiGFBP-1 to piGFBP-1 in subjects without and 
with IHD were 1 :6 and 1 :9 respectively. 
8.3.2 Associations with cardiovascular risl<. factors and IGF-1 
Spearman's correlation analysis of the two different forn1s of I GFBP-1 with various 
cardiovascular risk factors are sumtnarised in Table 8.3. The correlation coefficients 
were tnore strongly associated between piGFBP-1 and cardiovascular risk factors 
(BMI, insulin, glucose, HOMA-IR and HDL-C) than lplGFBP-1 or the ratio. Levels 
of IGF-I were weakly negatively associated with piGFBP-1 but were more strongly 
negatively associated with lpiGFBP-1 (r =- 0.33, p < 0.01) and highly significantly 
with the ratio (r =- 0.45, p < 0.0001). 
40.0 • lpiGFBP-1 
0 piGFBP-1 
0.0 
WlthoutiHD 
Status of IHD 
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IHD 
Figure 8.6: Less-phosphorylated IGFBP-1 (lpiGFBP-1) and phosphorylated 
IGFBP-1 (plGFBP-1) in subjects with and without ischaemic heart disease (IHD). 
Results are means (95% Confidence interval)· significance of differences compared 
with the subjects without IHD is indicated above the columns of subjects with IHD; 
**p < 0.01 , ***p < 0.001. 
Table 8.3: Spearman s correlations for lpiGFBP-1 , piGFBP-1 and their ratio in 
relation to cardiovascular risk factors 
lpiGFBP-1 piGFBP-1 lpiGFBP-1: piGFBP-1 
BMI -0.16 -0.31 ** 0.01 
Insulin -0.18 -0.31 ** -0.04 
Glucose 0.01 -0.13 0.11 
HOMA-IR -0.14 -0.28* -0.01 
Cholesterol 0.20 0.10 0.19 
HDL-C 0.21 0.29* 0.06 
LDL-C 0.20 0.10 0.19 
Triglycerides -0.18 -0.18 -0.13 
IGF-I -0.33** -0.10 -0.45**** 
lpiGFBP-1 0.71 **** 0.83**** 
piGFBP-1 0.71 **** 0.23* 
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****p< 0.0001 , ***p< 0.001 **p< 0.01 , *p< 0.05. Key: BMI, body mass index; HOMA-IR, 
insulin resistance by homeostasis model assessment: HDL-C, high density lipoprotein 
cholesterol; LDL-C, low density lipoprotein cholesterol; IGF-1, insulin-like growth 
factor I; lplGFBP-1, less-phosphorylated IGFBP-1; piGFBP-1 , phosphorylated IGFBP-
1. 
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8.3.3 Association betweenlpiGFBP-1 and piGFBP-1 
A significant association between lpiGFBP-1 and piGFBP-1 was found in the pooled 
group of subjects (r = 0.71, p < 0.0001). After subjects were subclassified according 
to the presence or absence of IHD, it was found that this association was stronger in 
subjects without IHD (r = 0.72, p < 0.0001) than in those with IHD (r = 0.54, p < 
0.001) (Figure 8.7). If subjects were reclassified according to their glucose tolerance 
status, then the maximmn of association would be obtained (r = 0.80, p < 0.0001) in 
NGT subjects (n = 42). In the same subjects (NOT) and after reclassification 
according to the IHD status; (n = 21 without IHD; n = 21 with IHD) the tnean 
differences between the two groups retnained significant for lplGFBP-1 (5.24 ± 0.76 
vs. 2.60 ± 0.54, p < 0.05), piGFBP-1 (33.5 ± 2.9 vs. 24.3 ± 3.1, p < 0.05), and the 
ratio (0.15 ± 0.02 vs. 0.10 ± 0.02, p < 0.05). 
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Figure 8.7: Correlation coefficient between lpiGFBP-1 and piGFBP-1 parameters 
represented by scatter plots diagram in 75 subjects without ( o, n = 39) and with IHD 
(A, n = 36). 
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8.3.4 Receiver operating characteristic (ROC) curve analysis 
The diagnostic perfonnance of a test to discrilninate between diseased and non-
diseased can be evaluated using Receiver Operating Characteristic (ROC) curve 
analysis (Metz, 1978). In addition to this, the ROC curve can be used to cotnpare the 
diagnostic performance of different tests. Observation of the results distribution for 
each test allows true positive and true negative rates to be determined. Therefore, 
cut-off values which discriininate between subjects with and without disease with 
maxhnum sensitivity and specificity can be estimated using ROC curves. Therefore 
ROC was used to analyse data obtained on lpiGFBP-1, piGFBP-1 and the ratio in 
subjects with IHD and without IHD in order to determine which forn1 of IGFBP-1 
could best discriminate between subjects with and without IHD. 
Analyse-it v2.12 software was used to study receiver operating characteristic (ROC) 
curves for estin1ating the optimal cut-off points as advised by Stephan et a!., 
(Stephan et a!., 2003). They were defined as points with maxiinum sensitivity and 
specificity. The area under the curve (AUCs) were also estitnated and cmnpared 
using the same software. For detennining the opthnum cut-off values for subjects 
with and without IHD ROC plot is shown in Figure 8.8. The optimum cut-off value 
for lpiGFBP-1 was 2.83 ｾｴｧＯｌ＠ with tnaxhnmn sensitivity and specificity of 75% and 
74% respectively. For piGFBP-1 the cut-off was at 29.9 flg/L with 67% sensitivity 
and 67% specificity. Regarding the ratio (lpiGFBP-1: piGFBP-1) the cut-off value 
was 0.14 with 64% sensitivity and 62% specificity. AUCs of sermnlpiGFBP-1 was 
0.75 [95% CI, 0.63- 0.86], piGFBP-1 0.68 [0.56- 0.80] and the ratio 0.71 [0.59-
0.83]. With a AUC 0.75 [95% CI, 0.63 - 0.86] and using the cut-off value of 2.83 
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ｾｧＯｌ＠ the lpiGFBP-1 showed higher diagnostic sensitivity (75%) and specificity 
(74%) than the piGFBP-1 or the ratio (Figure 8.8). 
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Figure 8.8: ROC for determining the optimum cut-off values for distinguishing 
between subjects with and without IHD using lpiGFBP-1 piGFBP-1 and their ratio. 
The optimum cut-off values for (a) lpiGFBP-1 , (b) plGFBP-1 and (c) the ratio 
(lpiGFBP-1: piGFBP-1 ). 
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8.4 Discussion 
8.4.1 piGFBP-1 estintation 
The piGFBP-1 has been estimated quantitatively using ELISA or radioimmunoassay 
(RIA) (Khosravi et al., 2007; Nuutila et al., 1999; Westwood et al., 1994). The RIA 
used previously (Rutan en and Pekonen, 1991) was a competitive displacement assay 
using radiolabelled IGFBP-1 which cmnpetes with serum or standard IGFBP-1 for 
binding to Medix 6303 antibody as a capture antibody. In 2002 Heald and his 
colleagues investigated different forms of IGFBP-1 in subjects with type 2 diabetes 
with macrovascular disease (Heald et al., 2002) but the piGFBP-1 level was 
estitnated indirectly by calculation as lpiGFBP-1 was subtracted from the total 
IGFBP-1. The assay established in this study was different in that the absolute levels 
ofpiGFBP-1 were esthnated directly using a novel ELISA immunoassay. 
The ELISA established recently by Khosravi et al., was based on a polyclonal 
antibody which can bind to the total IGFBP-1 and the secondary antibody was 
directly labelled with alkaline phosphatase (Khosravi et al., 2007). The assay 
established in this study was different in that the capture antibody binds 
predmninantly to piGFBP-1 instead of total IGFBP-1 and the secondary antibody 
was labelled with biotin rather than alkaline phosphatase as this procedure was safe, 
shnple, specific and keeps the integrity of the antibody (Diatnandis and 
Christopoulos, 1991 ). 
8.4.2 Association with cardiovascular risl{ factors and IGF-1 levels 
The correlation between known cardiovascular risk factors, natnely BMI, insulin, 
HOMA-IR and HDL-C with piGFBP-1 was stronger than with lpiGFBP-1. Due to 
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the degree of strength of association between different IGFBP-1 forms, it was 
expected that the strength of association between cardiovascular risk factors and 
these different forn1s should be the same. At present there is no explanation for this 
different strength of association. Until purified piGFBP-1 standard primary 1naterial 
becmnes available such an association cannot be investigated. 
The mean values of IGF-I between the two groups of subjects (with and without 
IHD) were not significantly different. Previous studies showed that the levels ofiGF-
1 were higher in individuals with IHD (Botker et al., 1997; Lee et al., 1999) but 
others have failed to confirm this (Janssen et al., 1998; van den Beld et al., 2003). An 
explanation for this discrepancy could be due to differences in characteristics of the 
investigated groups; as the two groups involved in this study were sitnilar in terms of 
their BMI and age. 
8.4.3 Association with IGF -1 
Low IGFBP-1 levels have been reported to be independently associated with 
increased risk ofiHD 1nortality (Laughlin et al., 2004). However, to investigate such 
association using different forms of IGFBP-1 requires a larger number of subjects. 
IGF-I was tnore strongly inversely associated to lpiGFBP-1 than piGFBP-1 but 
association with the ratio (lpiGFBP-1: piGFBP-1) was found to be stronger and 
highly significant. Frotn such an association it could be inferred that the 
bioavailability ofiGF-1 is more likely to be highly related to the ratio than with each 
individual fonn ofiGFBP-1. This can possibly be explained by IGFBP-1 acting as a 
shuttle for IGF-1 from the intravascular to extravascular space. In a situation where a 
low ratio between lpiGFBP-1 and piGFBP-1 (1 to 9) was observed, as in subjects 
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with IHD, this would be expected to be associated with n1ore IGF-I being bound with 
higher affinity to plGFBP-1 and consequently decreased biological effect (Figure 
8.9). If this were reflected within the atherosclerotic plaque, a lower biological 
impact of IGF-I activity contributing to plaque smooth tnuscle cell proliferation tnay 
lead to a greater likelihood of plaque instability. The higher ratio between lpiGFBP-1 
and piGFBP-1, as in subjects without IHD (1 to 6), would be expected to result in 
more IGF-I being released due to lower binding affinity which would allow IGF-I to 
bind to its receptors on cellular surface (Figure 8.9). 
8.4.4 Association betweenlpiGFBP-1 and piGFBP-1 
In this study we showed that the two fonns of IGFBP-1 are highly associated. In 
previous work by Khosravi eta!., the authors reported a siinilar association between 
lpiGFBP-1 and piGFBP-1 in serum satnples from non-pregnant subjects (Khosravi 
et al., 2007). Due to the pathological status of subjects included in this study 
association was found to be weaker in subjects with IHD compared to nonnal 
subjects. The explanation for this weaker association is not entirely clear but it could 
be due to interference effects from other factors responsible for phosphorylating or 
dephosphorylating IGFBP-1 i.e. levels of casein kinase, proteolytic enzymes or 
inflammatory cytokines (Ankrapp et a!., 1996; Gibson and Cohen, 1999; Lang et al., 
1999). In addition to this, insulin stitnulation has been found to induce protein 
dephosphorylation (Hunter, 1995) and thus it could be one of the reasons for low 
piGFBP-1levels as observed in subjects with IHD. 
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Figure 8.9: The same number of IGFBP-1 molecules represented by a ratio between 
less-phosphorylated (lp-) and phosphorylated (p-) forms in subjects with and without 
ischaemic heart disease (IHD). Lower IGF-1 is released due to strong binding affinity 
with plGFBP-1 in status ofiHD. 
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8.4.5 Specificity, sensitivity and area under the curve (AUC) 
ROC analysis was used in our study to predict levels of two different forms of 
IGFBP-1 and their ratio in fasting senun, which could potentially be used in clinical 
practice. Atnongst the three parameters, lpiGFBP-1 proved to be the best marker for 
distinguishing between patients with and without IHD, detnonstrating the highest 
sensitivity, specificity and AUC. Furthennore, the output data in this study showed 
the optitnum cut-off values with the tnaxitnum sensitivity and specificity for 
lpiGFBP-1, piGFBP-1 and the ratio but when cmnpared to other studies 
investigating sitnilar subjects, these output data could be different as they will be 
method dependent. 
8.5 Limitations of this study 
One of the main limitations of this study was the small satnple size, though it was 
considered a pilot study. It remains inconclusive whether these findings are specific 
to IHD. Clearly larger nmnbers of subjects need to be investigated who have a 
variety of other conditions. Another limitation of the study was that possible effects 
of concomitant drug therapy were not taken into consideration e.g. antihypertensive 
and anticoagulant drugs. Moreover, the subjects included in this study were from 
three different ethnic populations. It would be appropriate to perfonn extensive 
studies focussing on individual populations. 
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8.6 Conclusions 
This study detnonstrates that noveltnarkers tnay help identify subjects at high risk of 
developing IHD or even with previously undiagnosed established IHD. A new 
paratneter natnely the ratio of lpiGFBP-1 vs. piGFBP-1 tnay provide a tneasure of 
the biological activity of IGF-I. This was achieved by establishing a novel 
hnmunoassay to estimate absolute levels of piGFBP-1. More investigations are 
required to explain the role of different IGFBP-1 forms in the developtnent of other 
metabolic disorders. 
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Chapter 9 
General discussion and conclusions 
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9. General discussion and conclusions 
Insulin resistance is recognised to be a central feature of the tnetabolic syndrome and 
strongly associated with an increased risk to the individual of developing diabetes 
and cardiovascular disease. The etnerging importance has led to its assessment in 
research studies that have examined its pathogenesis, aetiology and consequences. 
The reference standard technique used to quantitate insulin resistance is the 
euglycaetnic hyperinsulinaemic clatnp technique. It is difficult and expensive to 
undetiake. The frequently satnpled intravenous glucose tolerance test (FSIVGTT) is 
a surrogate alternative technique. Other sitnple indices estimating insulin resistance 
can also be derived fr01n the oral glucose tolerance test and fr01n one-off fasting 
samples e.g. homeostasis tnodel assesstnent (HOMA). 
The fasting level of a biomarker that reflects the status of insulin resistance would be 
a more convenient means of assessing insulin resistance. Initial studies have 
indicated that insulin-like growth factor binding protein 1 (IGFBP-1), an emerging 
tnarker of insulin resistance could fulfill this role (Maddux et al., 2006). Low sermn 
IGFBP-1 concentrations have been shown to be associated with a variety of 
cardiovascular risk factors viz body mass index (BMI) and plasn1a insulin. Its senun 
level has been shown to be regulated by insulin. IGFBP-1 level is considered as a 
predictor of cardiovascular risk and to increase during appropriate lifestyle 
interventions. As such in the context of other laboratory tests and clinical evaluation 
IGFBP-1 may have a place both in the assesstnent of cardiovascular risk and 
monitoring of treatment. 
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In this series of studies, vve have used FSIVGTT as an alternative technique to the 
reference procedure. In addition to this other sitnple indices of insulin resistance 
including fasting IGFBP-1 were included. 
The principle ain1s of these studies were to cmnpare FSIVGTT with IGFBP-1 and 
other simple indices of insulin resistance. Thereafter the satne indices were used to 
compare insulin resistance between two different populations. Other aitns were to 
establish and validate appropriate ELISA techniques for the 1neasure1nent of serum 
IGFBP-1 and to assess its reproducibility as well as opthnising the FSIVGTT 
protocol used to assess insulin sensitivity (Si). At the end of these series of studies 
the established and validated ELISA techniques of different phosphorylated forms of 
IGFBP-1 were used to compare individuals with and without ischaetnic heart disease 
(IHD). 
In the first study the Si of standard FSIVGTT technique was assessed in lean and 
overweight individuals in addition to assessing intra-individual reproducibility using 
two different protocols and software packages. The 1nost recent reproducibility study 
of standard FSIVGTT technique was perfonned by Duysinx in 1994 (Duysinx et al., 
1994) using an earlier version of Minn1od. Given the availability of the updated 
version of the software (Mimnod Millnemimn) it was therefore considered timely 
and appropriate to reassess reproducibility of Si using the new software prior to 
carrying out the other studies. The results obtained have shown that Mimnod 
Millennium is more consistent than other software. In addition to this, as expected Si 
results were significantly inversely associated with body tnass index. Our data have 
shown that a short satnpling protocol of the standard FSIVGTT in lean subjects was 
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tnore reliable than in obese ones. Using this short protocol in lean subjects is 
therefore an alternative to the standard protocol and this tnay offer advantages in 
expenses and labour intensity. The small nmnber of subjects in the study of 
reproducibility was one of the litnitations of this study but this was due to the 
difficult nature of the applied technique and its repetition on the satne human 
subjects. 
The study which followed sought to evaluate reproducibility (variation) of the simple 
indices of insulin resistance. Assesstnent of variation of these indices is important 
especially if they are to becotne available for clinical use as their precision of the 
results is a key feature governing their utility. Although those indices have been 
con1pared with reference tnethods in tnany studies, data on their precision are limited 
especially in subjects with varying degrees of glucose tolerance. Therefore, we have 
evaluated seven con11nonly used indices of sitnple insulin resistance and ｾＭ｣･ｬｬ＠
function in subjects across the glycaetnic spectrum. Our evaluation was based on 
short-term (4 fasting samples in 20 tninutes) and long-tenn (2 fasting samples in 
average of 10 days) intervals. Our proposal was that the values of intra-individual 
variation of those indices tnay be largely affected by the method of mathetnatical 
calculation but the actual variation was by the glycaen1ic status of the subjects. As 
discussed in section 4.4, previous studies had sotne limitations with the evaluation of 
intra-individual variation of sitnple indices of insulin resistance. Our outcomes 
showed that over the long-tenn interval the CV s for all fasting indices including ｾﾭ
cell function were lower in subjects with NGT cmnpared to other glycaetnic 
categories where the reproducibility of indices decreased progressively with the 
deteriorated status of glucose tolerance. This is an important observation of which 
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those carrying out epidemiological studies using any of those surrogate indices need 
to be aware. For the ｳｨｯｲｴｾｴ･ｮｮ＠ interval our outc01nes were different. Reproducibility 
was poorest in individuals with nonnal glucose tolerance but it improved in subjects 
with deteriorating glucose tolerance. We considered therefore that other factors tnay 
be involved in determining variation over the short-term interval variation e.g. 
pulsatility of insulin secretion in different status of glucose tolerance. Further studies 
are required to investigate this. 
Our results of the long-tenn reproducibility ofn QUICK! agree with those previously 
reported by Sarafidis et a!., (Sarafidis et al., 2007) in that it was the most 
reproducible index of insulin sensitivity. It is well known that log and reciprocal 
correlation between paratneters (as in QUICKI) are successful in tnaintaining a 
relatively low CV. Does this tnean that the QUICKI index is tnore precise than other 
indices? It seems that the calculated CV of each index of insulin resistance depends 
firstly on the variability of each individual c01nponent (insulin and glucose) involved 
in the tnathematical formulae of that index. Secondly any clinical condition affecting 
glucose and insulin levels is an itnportant factor in determining reproducibility of any 
index. 
We used the satne principle design of the previous study to investigate the variation 
of serum IGFBP-1 in individuals with different degrees of glucose tolerance. We 
observed that IGFBP-1 values were least variable in NOT individuals over both 
long-term and short-tenn intervals and variability increased with deteriorating 
glucose tolerance. It appears that variation of IGFBP-1 over the long-term was 
related to variability in fasting insulin levels while over short-tenn intervals other 
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factors may override insulin variability. In type 2 diabetes levels ofiGFBP-ltnust be 
interpreted carefully because defects in beta cell insulin secretion will have an 
influence on IGFBP-1 levels which can then not be purely taken as reflecting the 
degree of insulin resistance. 
Analytical variation tnay have a crucial effect on the total reproducibility of the 
siinple indices of insulin sensitivity and IGFBP-1 tests. However after we had taken 
account of the analytical variation, no significant effect was observed on the trend of 
variation for both shnple indices of insulin resistance and IGFBP-1. It is widely 
accepted that the desirable target for analytical variation is less than or equal to 50% 
of the biological variation. This tneans that if this target is achieved, analytical 
variation should contribute less than 12% to the total variation of the result (Marchall 
and Bangert, 2008). In our study, this contribution was found to be less than 12% of 
the total variation for each sin1ple fasting index of insulin resistance or ｾＭ｣･ｬｬ＠ activity 
which we have investigated. The same finding was observed with the IGFBP-1. 
In another study of evaluating indices of insulin resistance we investigated how 
FSIVGTT (Si) correlates with other simple indices of insulin resistance. Therefore, 
HOMA-IR, QUICK!, Raynaud index, ISI-gly, insulin and IGFBP-1 were subjected 
to correlation analysis with Si (FSIVGTT). Due to the negative regulation of insulin 
on IGFBP-1 transcription and strong correlation with insulin sensitivity parameter of 
hyperinsulinaemic euglycaetnic clmnp in fasting non-diabetic subjects (Maddux et 
al., 2006) IGFBP-1 had to be further validated to be used as a marker of insulin 
resistance by using standard FSIVGTT as an alternative technique to the gold 
standard procedure. FSIVGTT was applied to subjects with nonnal glucose tolerance 
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(NGT) and impaired fasting glucose (IFG). In this study it was observed that fasting 
serum IGFBP-1 correlated tnm·e strongly with the insulin sensitivity parameter (Si) 
derived from standard FSIVGTT than did other simple indices in NGT subjects but 
not the case with subjects of IFG. Another interesting finding in this study was that 
itnprovetnent in correlation coefficients following logarithtnic or Ln-transfonnation 
was observed for all indices but to different degrees. 
We have shown in two different groups frmn two nonnal populations shnilar in 
adiposity that Si and IGFBP-1 were significantly lower in Saudis compared to 
Caucasians. Further evidence for a difference in insulin resistance between the two 
populations was the raised levels of HbA1c and diastolic BP in Saudis cmnpared to 
Caucasians. Kinetic changes of glucose and insulin after dextrose infusion in both 
populations were also investigated. Glucose and insulin levels were significantly 
higher in Saudis cmnpared to Caucasians, at a few thne points, a finding in line with 
lower insulin sensitivity in the Saudis. As discussed previously in the first Chapter, 
these outcotnes were not unexpected given that the prevalence of metabolic 
syndrmne is relatively high in the Saudi population cmnpared to other populations. 
Saudi Arabia has gone through significant changes over the last 20-30 years 
including econmny, life style, food habits, education etc. A dramatic shift towards a 
Western diet and lifestyle have led to physical inactivity, weight gain and ultimately 
to the metabolic syndrmne. In the smne study we observed that levels ofiGFBP-1 in 
nonnal glucose tolerant individuals at 2 hours decreased to about half the baseline 
level regardless of the route of glucose administration. Additionally the study 
provided evidence that HbA 1 c could be used as a shnple marker of insulin resistance 
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due to its high significant negative association with Si in addition to other features of 
HbA1c as discussed in section 7.4.7. 
Different phosphorylated forms of IGFBP-1 have a major regulatory role on the 
tnetabolic and tnitogenic effects of IGF-I (Gibson et al., 1999). In Chapter 8 we 
identified the status of different phosphorylated forms of IGFBP-1 in subjects with 
and without ischaemic heart disease. In the same Chapter we utilised the two in-
house immunological assays using different antibodies to recognise different IGFBP-
1 forms (lpiGFBP-1 and piGFBP-1). By using different techniques we have verified 
the cross-reactivity of each utilised capture antibody. We then estitnated the 
lpiGFBP-1 form using the first assay. By using the novel second assay absolute 
levels of piGFBP-1 fonns were tneasured directly. This was a tnore satisfactory 
approach than using estimated values based on subtraction frmn total IGFBP-1 as 
described in a previous study in subjects with type 2 diabetes and tnacrovascular 
disease (Heald et al., 2002). 
We found that the ratio between different IGFBP-1 forms (lpiGFBP-1 vs. piGFBP-1) 
was strongly associated with the level of IGF-1. This new index tnight therefore 
reflect IGF-I biological activity. It would be of interest to substantiate this by 
correlating the ratio with direct tneasuretnents of free IGF-1 assays which have 
recently become available. Levels of lpiGFBP-1, piGFBP-1 and their ratio were 
significantly higher in individuals without than with IHD. It is unclear at present 
whether these findings are directly related to the pathogenesis of cardiovascular 
disease itself or whether they are sitnply tnarkers of the disease process of diagnostic 
interest. To clarify this will require further investigation to study the involvement of 
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other factors such as drugs, physical activities, and ethnicity between the study 
subjects. 
Most of our aims which have been listed in the first chapter (section 1.9) were 
achieved. The novel outcmnes of our aims can be smntnarised as follows: the 
variability of shnple indices of insulin resistance and IGFBP-1 levels can be affected 
by the glycaemic status of the investigated subjects. IGFBP-1 can be used as a 
tnat·ker of insulin resistance at least in individuals with NOT. This is due to the 
strong association between IGFBP-1 and Si derived frmn FSIVGTT. The level of 
this marker was not reliable in individuals with type 2 diabetes, who were not taking 
any antidiabetic tnedications. Norn1al Saudis were found to be tnore insulin resistant 
than nonnal Caucasians. This observation is in accord with evidence frmn previous 
studies which have shown a high prevalence of metabolic syndrmne and type 2 
diabetes in the Saudi population. Finaly regarding the question of whether IGFBP-1 
or its phosporylated fonns can be used as a marker for cardiovascular risk or not. Our 
preliminary data suggest that they tnay be, although there are a numbei: of limitations 
to this. 
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Limitations 
There are smne limitations with respect to this work that need to be considered: 
1. One of the tnost hnportant limitations was the number of subjects involved in 
the work described in this thesis. In view of the relatively small nmnber of 
subjects involved in this project smne outcmnes should be verified using 
larger samples. For exatnple the cmnparison of individuals frmn two different 
popuations ideally needs larger nmnbers of subjects. Nevertheless we 
considered it appropriate to carry out what was a pilot study cotnparing 
Saudis with Caucasians as no such had previously been carried out. 
2. The total nmnber of subjects investigated within each chapter did differ, and 
ideally the smne subjects should have been investigated using the different 
assays. However these investigations were undertaken sequentially with 
lhnited atnounts of stored serum. 
3. The standard FSIVGTT technique has some lhnitations. The assumptions of 
the tnodel can be violated and it tnay not be possible to fit the insulin curve 
by the systetn due to unexpected insulin kinetics. This probletn is comn1on 
for FSIVGTT (standard or tnodified) and it can occur not only with NGT but 
also across all other glycaetnic categories (Boston et al., 2003). Therefore in 
7 out of our total 48 subjects the curve could not be fitted and consequently 
the Si could not be estitnated. Another limitation of using the standard 
FSIVGTT rather than the insulin- tnodified technique was that it cannot be 
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applied to subjects with insufficient insulin secretion (e.g. type 2 diabetes) as 
this may cause the Si to be falsely elevated. Therefore subjects with type 2 
diabetes could not be recruited into our study for the standard technique of 
FSIVGTT. These lhnitations were not clear to us at the outset. 
4. Using the total instead of biological variation for fasting simple indices of 
insulin resistance and IGFBP-1 was not considered in the beginning of this 
study. Calculation of the total variation would not exclude analytical variation 
which might be cruicial for determining biological variation. Therefore in 
appendix 2 and 3 tables were added to clarify this point and to calculate the 
biological variation. 
5. Investigation of different fonns of phosphorylated and non-phosphorylated 
IGFBP-1 in subjects with and without ischaetnic heart disease using 
dedicated ELISA assays was one of the novelities of this study. Possible 
effects of concomitant tnedications (e.g. antihypertensives, anticoagulant and 
lipid lowering drugs) were not taken into consideration. Moreover, the 
subjects included in this study were frmn three different ethnicities rather 
than one population. However, we consider that tnore investigations of 
IGFBP-1 and its phosphorylation status are necessary. 
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Future work 
Our observations on insulin resistance along with the outcomes of other previous 
studies indicate that the Saudi population in particular faces a high future prevalence 
of tnetabolic syndrmne and its related risk factors. It would therefore be interesting to 
investigate insulin sensitivity in a tnuch larger sample of normal glucose tolerant 
subjects frmn the Saudi population. As an alternative reference technique and 
appropriate investigative tool, the short protocol FSIVGTT would lend itself well to 
such a study as it has advantages in tenns of expense and labour intensity. As 
previously tnentioned, a wide ｶ｡ｾﾷｩ･ｴｹ＠ of other risk factors and biochemical markers 
are relevant to metabolic syndrome and the developtnent of vascular disease (viz 
markers of antioxidant status, cytokines, heat shock proteins and CRP). Whilst these 
are all worthy of study their investigation was beyond the scope of this thesis but 
some or all should be incorporated into future, tnore ambitious studies. 
Our findings regarding levels of different fonns of IGFBP-1 in IHD are interesting 
and also worthy of further investigation. For future similar studies it would be 
advisable to focus on subjects from a single ethnic group of sufficiently large sample 
size and to exclude subjects on anti-hypertensive and anticoagulant drugs or with 
extensive physical activities as these factors might have direct effects upon IGFBP-1 
level or its phosphorylation status and so tnay confound interpretation of the data. 
Appendices 
Appendix 1: 
1 
30 kDa---+ 
20 kDa---+ 
2 3 4 
+-- npiGFBP-1 
+-- piGFBP-1 
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Different bands IGFBP-1 of a single serum sample using Western ligand blotting and 
after applying the same capture antibody (R&D, cat. MAB 675) but two different 
sample buffers: 1. Recombinant human insulin like growth factor binding protein-1 
(rhiGFBP-1 ). 2. Ladder (molecular weight 20 and 30 kDa) 3. Serum sample (1 :8 
dilution) mixed with 2-mercaptoethanol (10%) 2. Same serum sample (1 :8 dilution) 
mixed with LOS (Lithium Dodecyl Sulphate) sample buffer. Key: npiGFBP-1 
nonphosphorylated IGFBP-1; piGFBP-1 , phosphorylated IGFBP-1. 
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Appendix 2: Biological variation (%CVb) for techniques used to assess ｾＭ｣･ｬｬ＠
function and insulin sensitivity in different glycaemic categories. 
Simple index Long-term variation Short-term variation 
%CVb %CVb 
NGT 16.7 14.6 
ＥｈｏｍａＭｾ＠ lFG 28.8 11.0 
IGT 30.5 8.3 
DM 68.5 9.4 
NGT 11.3 7.4 
ＥｈｏｍａＲＭｾ＠ IFG 15.9 6.7 
IGT 22.2 3.1 
DM 44.6 5.8 
NGT 25.2 14.3 
HOMA-IR IFG 29.7 11.4 
IGT 33.0 7.9 
DM 51.9 11.2 
NGT 19.4 11.8 
%HOMA2-S IFG 25.8 10.2 
IGT 29.4 5.5 
DM 31.5 11.0 
NGT <0.1 <0.1 
IFG <0.1 <0.1 QUICKI 
IGT 1.0 <0.1 
DM 3.1 <0.1 
NGT 18.6 15.3 
FGIR IFG 19.9 10.6 
IGT 29.6 8.8 
DM 25.4 10.7 
NGT 19.7 15.4 
Raynaud IFG 24.5 10.6 
IGT 29.2 8.7 
DM 30.9 11.4 
Key: NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired 
glucose tolerance; DM, type 2 diabetes; ｈｏｍａＭｾ Ｌ＠ homeostasis model ｡ｳｳ･ｳｳｭ･ｮｴｾＭ
cell activity; HOMA-IR, homeostasis model assessment insulin resistance· QUICKI, 
quantitative insulin check index; FGIR, fasting glucose insulin ratio. 
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Appendix 3: Biological variation (%CVb) for fasting plasma insulin and IGFBP-1 
in different glycaemic categories. 
Long-term Short-term 
Simple index variation variation 
%CVb %CVb 
NGT 24.2 14.2 
Insulint 
IFG 28.1 10.8 
IGT 33.3 9.1 
DM 39.8 11.7 
NGT 18.9 5.2 
IFG 28.1 14.8 IGFBP-1 A 
IGT 31.9 28.5 
DM 47.1 12.3 
tThe value for the control sera of 4.9% was utilised as the analytical variation for the 
insulin assay. /\The average value for the control sera of 9.0% and 6.3% for the long 
and short-term variations respectively was utilised as the analytical variation for the 
IGFBP-1 assay. Key: NGT, normal glucose tolerance; IFG impaired fasting glucose; 
IGT, impaired glucose tolerance· DM, type 2 diabetes; IGFBP-1 , insulin-like growth 
factor binding protein- I. 
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